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Abstract 
 
A series of monodentate (N-) and chelating bidentate (N,N-, N,O-), monomeric and 
dendritic ligands based on a poly(propyleneimine) dendrimer scaffold were 
synthesized via Schiff base condensation reactions of the relevant amine and 
appropriate aldehydes. These reactions yielded air- and moisture-stable oils or 
solids. These ligands contained pyridyl-imine moieties and salicylaldimine moieties. 
These compounds were isolated in good yields and characterized using standard 
spectroscopic and spectrometric, analytical techniques. 
 
The monomeric and dendritic ligands were reacted with dimeric precursors of the 
type [Ru(η6-arene)Cl2]2 generating new ruthenium(II) arene complexes, consisting of 
neutral monodentate (N-), neutral chelating bidentate (N,O-) and cationic chelating 
bidentate (N,N-) compounds. These ruthenium(II) arene complexes were also 
isolated as air- and moisture-stable solids, in moderate to good yields, and were fully 
characterized using NMR and IR spectroscopies, as well as by elemental analysis 
and mass spectrometry. The molecular structures of the mononuclear ruthenium(II) 
arene complexes were determined using single crystal X-ray crystallography. 
 
The cytotoxicities of the mononuclear and dendritic ruthenium(II) arene complexes 
were evaluated against the cisplatin sensitive (A2780) and cisplatin resistant 
(A2780cisR) human ovarian cancer cells. The chelating bidentate ruthenium(II) arene 
metallodendrimers showed superior biological activity over the monodentate 
ruthenium(II) arene analogues. The octanuclear cationic ruthenium(II) 
hexamethylbenzene complex was found to be the most active.  
 
DNA interactions of the two most highly cytotoxic chelating bidentate ruthenium(II) 
arene complexes along with their mononuclear analogues were also investigated. 
This study showed a clear correlation between the size of the metallodendrimer, DNA 
damage and cytotoxicity. 
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Chapter 1 
Review of Ruthenium(II) Arene Multinuclear Dendritic Compounds, 
and their Applications in Medicinal Chemistry  
 
1.1 Background 
 
Cancer is a type of disease where cells within the body undergo cell division beyond 
the normal limits, invading adjacent tissues, and sometimes spreading to other 
locations of the body via blood or lymph.1 These three malignant properties of 
cancers differentiate them from benign tumors, which are self-limited, and do not 
invade or metastasize.  
Metastases takes place in many ways: through the lymphatic system, through the 
bloodstream, by spreading through spaces within the body, such as the bronchi or 
abdominal cavity, or through implantation. The most common way for cancer to 
spread is through the lymphatic system. The lymph system has its own channels that 
circulate throughout the body. These channels are very small and carry a tissue fluid 
called lymph throughout the body, an ideal pathway for the spread and growth of 
cancer.1 
Most cancers form a tumor but some, like leukemia, do not. The branch of medicine 
concerned with the study, diagnosis, treatment, and prevention of cancer is oncology.  
 
Cancer is one of the leading causes of death world wide, responsible for about 13 % 
of all human deaths in 2004.2 According to the American Cancer Society, 7.6 million 
people died from cancer in the world during 2007.3 The main types of cancer leading 
to overall cancer mortality each year are: 
• lung (1.3 million deaths per year) 
• stomach (803 000 deaths per year) 
• colorectal (639 000 deaths per year) 
• liver (610 000 deaths per year)  
• breast (519 000 deaths per year)  
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The WHO (World Health Organization) has also reported that by 2030, deaths 
related to cancer may rise to 12 million per year.2 Cancer may affect people of all 
ages, even foetuses, but the risk for most varieties increases with age (Fig. 1.1).4 
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Figure 1.1: Number of new cases and rates, by age and sex, all malignant 
neoplasms, United Kingdom, 2006.4 
 
The increase in survival rates is due to better cancer treatment, thanks to the 
introduction of efficient anticancer drugs. Cancer treatment aims to cure, prolong and 
improve the quality of life for patients. Some of the most common cancer types, such 
as breast cancer, cervical cancer and colorectal cancer, have high cure rates when 
detected early and treated according to best practice. Currently, principal treatment 
methods are surgery, radiotherapy and chemotherapy. Fundamental for adequate 
treatment is an accurate diagnosis through imaging technology (ultrasound, 
endoscopy or radiography) and laboratory (pathology) investigations.2 
 
1.2 Platinum based anticancer drugs 
 
Reports on the earliest therapeutic use of metals or metal-containing drugs in cancer 
treatment were first reported in the 16th century. Hundreds of years of experience 
with inorganic anticancer agents was nearly forgotten until the mid to late 1960’s, 
when the anticancer properties of cis-[PtCl2(NH3)2] (cis-diamminedichloro-
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platinum(II)) was discovered by Barnett Rosenberg.5 The various activities of metal 
ions in biology have stimulated the development of metal-based therapeutics, and 
thus the field of metal-based compounds in medicine has become very appealing to 
inorganic chemistry researchers.6-8 
Metal complexes that fragment when introduced into the cell and retain their carrier 
ligands are important, as these non-leaving ligands can mediate the interaction with 
the target molecule (i.e. DNA) and provide selectivity and/or controlled activity. 
Examples of such complexes are the platinum(II) anticancer compounds (Fig. 1.2), 
which lose anionic ligands and form coordinate bonds with their targets.9 
 
cis-[PtCl2(NH3)2] (Fig. 1.2) was first synthesized by Michele Peyrone in 1844 and was 
known as Peyrone’s chloride. More than a century later it became the first metal-
containing anticancer drug. Cisplatin is one of the leading metal-based drugs, used in 
treatment of a variety of cancers,10 in particular, testicular11,12 and ovarian 
cancers.13,14 It is especially effective against squamous cell carcinoma and small cell 
lung carcinoma.15 
 
Analogues of cisplatin, carboplatin and oxaliplatin (Fig. 1.2), have shown 
effectiveness as other second-generation chemotherapeutic agents for cancer.15 
 
 
 
 
 
 
Figure 1.2: Selected platinum compounds that are currently in clinical use. 
 
More recently, Farrell’s group have had successes in synthesizing multiplatinum 
drugs.16 The platinum-based trinuclear complex [trans, trans, trans- 
(NH3)2Pt(Cl)NH2(CH2)6NH2Pt(NH3)2NH2(CH2)6NH2Pt-(NH3)2(Cl)][NO3]4 (BBR3464) 
showed to have higher in vitro cytotoxicity than its mononuclear analogue and 
cisplatin, and has been claimed to be the first platinum based compound with a DNA 
binding mode different to that of cisplatin.16,17 Though phase II trials of BBR3464 
   cisplatin carboplatin oxaliplatin 
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were not pursued further,17 the concept of multinuclearity assisting in the 
improvement of the potency of potential anticancer drugs was established. 
 
Figure 1.3: An example of Farrell’s multinuclear cationic trans-platinum(II) 
compound, BBR3464.17 
 
The clinical successes of cisplatin therapy are limited by severe toxic side effects and 
drug resistance, in particular nausea and vomiting, neuropathy, ototoxicity and 
nephrotoxicity.18,19 To overcome limitations associated with platinum-based drugs, 
researchers have focused their attentions on compounds containing other metals.20-22 
 
1.3 Ruthenium(III) compounds in cancer therapy 
 
Ruthenium metal has proved to possess favourable properties, thus having the ability 
to replace platinum and form the basis for anticancer drug design.15 Ruthenium is 
less toxic than platinum and its activity as an anticancer agent may reside in its ability 
to mimic the behaviour of iron, and bind to several biomolecules, such as human 
serum albumin and transferrin.24 A variety of ruthenium complexes with 2+ or 3+ 
oxidation states have shown activity against metastatic cancers.25,26 Two 
ruthenium(III) complexes, NAMI-A (imidazolium [trans-tetrachloro(dimethylsulfoxide)-
imidazoleruthenate(III)])27 and KP1019 (indazolium [trans-tetrachlorobis 
(1H-indazole)ruthenate(III)])28,29 (Fig. 1.4) have successfully completed phase I 
clinical trials and are currently undergoing phase II clinical trials.30 
4+ 
BBR3464 
4- 
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Figure 1.4: Ruthenium(III) drugs which have completed phase I clinical trials, 
KP1019 and NAMI-A.30 
 
NAMI-A was the first ruthenium anticancer agent to undergo clinical trials. The drug 
was developed by Sava et al. and is a negatively charged complex containing an 
octahedral ruthenium(III) centre bound to a single imidazole ligand, with a trans 
positioned dimethyl sulfoxide (DMSO) ligand and four chloride ligands.31 They 
showed that the drug was not very active against cancer cell lines, which is usually 
the initial screen for potential activity as antitumor agents. However, the drug showed 
enhanced activity against metastases and appears to inhibit cancer growth as a 
result of a delayed process of metastasis, but has little impact on primary tumours in 
animal models.32,33  
 
KP1019 was the second ruthenium anticancer agent to undergo clinical trials. The 
drug was synthesized by the Keppler group in 1989.28 Both cisplatin and KP1019 are 
administered intravenously and therefore, proteins are the first binding partners in the 
blood stream. It is thought that the binding of platinum complexes to serum proteins 
leads to the side effects, while KP1019 binds to transferrin, and seems to be an 
important step in the mode of action.34 Despite the similarities between NAMI-A and 
KP1019, the drug was found to be a cytotoxin, active against primary tumours and 
being investigated for activity against colorectal cancers. 
 
In recent years interest has shifted from ruthenium(III) compounds to ruthenium(II) 
complexes, in particular ruthenium(II) arene anticancer agents, some of which show 
KP1019 NAMI-A 
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antimetastatic activity similar to that of NAMI-A. It has been suggested that 
ruthenium(III) complexes are ‘activated’ by undergoing reduction in vivo to 
ruthenium(II), which coordinates more rapidly to biomolecules.25,26 There is a lower 
oxygen content and more acidic pH within tumours than in normal tissue and so the 
production of ruthenium(II) relative to ruthenium(III) should be favoured in tumours.25 
 
1.4 Ruthenium(II) anticancer complexes  
 
The majority of ruthenium compounds which have been evaluated for anticancer 
activity are coordination compounds with the ruthenium in the 3+ oxidation state. It 
has been proposed that in this oxidation state ruthenium is less biologically active 
and is reduced in vivo to more biologically active ruthenium(II) complexes, a process 
less favoured in the hypoxic environment of a tumour.35 However, it should be noted 
that ruthenium(II) compounds exhibit a low general toxicity and since cancer cells 
can also become oxidized at certain stages of their growth cycle, oxidation of the 
ruthenium cannot be excluded.36 
 
1.4.1 Ruthenium(II) arenes: An alternative to classic ruthenium anticancer 
agents 
Similar to ruthenium(III) complexes, organometallic ruthenium(II) arene complexes of 
the type [(η6-arene)Ru(ZY)X] (ZY = chelating ligand and/or two monodentate ligands, 
X typically a halide), where ZY are nitrogen or oxygen donor ligands (NN-, NO-, OO-) 
have also been studied extensively (Scheme 1.1), as potential anticancer agents. 
 
Ru
ZX
Y
Ru
ZH2O
Y
Ru
ZHO
Y
H2O pKa
n n+1 n
 
Scheme 1.1: Aquation of a ruthenium(II) arene compound. 
 
These complexes all have the η6-arene ring occupying one coordination site, and 
depending on the nature of the chelating ligand, the complexes can either be neutral 
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or cationic (isolated as salts). The presence of the η6-arene ring stabilises and 
protects the metal centre, preventing rapid oxidation to ruthenium(III).36 
The structural and electronic features of metal-arene bonding have been thoroughly 
reviewed.37,38 The η6-arene is considered as a pi-acid/pi-acceptor ligand towards 
ruthenium. Evidence comes from the 1H-NMR spectrum, upon arene coordination to 
the ruthenium centre, the proton-resonance shifts to a lower frequency due to 
increased electron density.39,40 
Generally ruthenium-arene bonds are stable towards hydrolysis although recently 
there have been reports that photochemical displacement of the arene can occur in 
aqueous solution for dinuclear complexes such as {(η6-indan)RuCl}2 
(µ-2,3-dpp)](PF6)2 (where indan = arene and µ-2,3-dpp = 2,3-bis(2-
pyridyl)pyrazine).41 Arene lability can be induced by the presence of strong  
pi-acceptor ligands bonded elsewhere in the complex. 
 
There are presently two types of ruthenium(II) arene anticancer classes which are 
widely developed, one class developed by Sadler and the other by Dyson  
(Fig. 1.5).42,43 
 
 
Figure 1.5: Two classes of ruthenium(II) arene anticancer agents, ruthenium(II) 
agents of Sadler (left)42 and RAPTA agents of Dyson (right).43 
 
The first class was synthesized by Sadler’s group, a three-legged ‘piano-stool’ 
conformation, consisting of an aryl group coordinated to the ruthenium metal, which 
is coordinated to a bidentate ethylenediamine and a chloride ligand. Sadler’s group 
showed that this type of arene ruthenium complex is as potent as cisplatin and 
carboplatin in primary cell lines, and was also active against some cell lines which 
have formed a resistance to cisplatin.42 They also showed that by replacing the 
simple aryl group to more extended aryl systems (e.g. biphenyls, 
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tetrahydroanthracene) the anticancer activity was increased. On the other hand, 
changing the N-donor ligands to a more bulky ligand (e.g. N, N, N’, N’-
tetramethylethylenediamine) reduced the anticancer activity.44 
The second class of ruthenium(II) arene anticancer agents was synthesized by 
Dyson’s group. These were termed RAPTA (Ruthenium-Arene PTA) anticancer 
agents, similar in structure to the first class synthesized by Sadler’s group, but 
instead the three remaining coordination sites are occupied by two chloride ligands 
and a mono-dentate PTA (1,3,5-triaza-7-phosphaadamantane) ligand. Similar to that 
of NAMI-A, these agents were found to be inactive against primary tumours, but were 
found to be very active in vivo against lung metastases in CBA mice.45 RAPTA 
compounds were found to be less toxic (in mice) than NAMI-A and thus could be 
administrated in high doses.43 
 
1.4.2 Proposed mechanism of cytotoxic action of Ru(II) arene complexes 
The mechanism of action of ruthenium(II) arenes is generally thought to involve 
hydrolysis of the Ru-X bond resulting in an active Ru-OH2 species (aquation), while 
the arene-Ru bond is robust. This species can exist over a range of pH values, but 
above the pH = pKa value (the pH at which 50 % of the species exists as Ru-OH2 
and Ru-OH through deprotonation of the H2O ligand) the hydroxo Ru-OH species 
formed by deprotonation will be predominant (Scheme 1.1). This complex is usually 
considered to be a less reactive species as hydroxide is a less labile ligand than 
water and will not be easily displaced by biomolecule targets. Thus, ideally pKa 
values of ca. pH > 7 for aqua adducts should ensure that the active species 
predominates at physiological pH (7.2 - 7.4). The rate of hydrolysis is therefore 
important. If the complexes hydrolyze too fast, they may not reach the target site.46 
 
Hydrolysis can be suppressed extracellularly due to high chloride concentration  
(ca. 0.1 M) but this becomes impossible after the complex enters the cells due to 
lower chloride concentrations (ca. 4 - 25 mM) typically found intracellularly, thus 
obtaining selective attraction inside the cell. The primary cellular target for 
ruthenium(II) arenes, as with many metal-based drugs, is thought to be DNA.47 
Therefore, factors affecting DNA binding such as rate, extent of binding and non-
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covalent interactions such as hydrogen bonding and DNA intercalation become 
important.46 
 
1.4.3 Ruthenium(II) arene anticancer complexes: Structure versus activity  
One of the earliest examples of a ruthenium(II) arene complexes investigated as an 
anticancer drug candidate was [(η6-C6H6)Ru(DMSO)Cl2].48 It has been suggested by 
the authors that the DMSO derivative strongly inhibits topoisomerase (II) activity by 
cleavage complex formation via interaction with DNA and crosslink formation with 
topoisomerase (II). 
 
Morris and co-workers synthesized a series of ruthenium(II) arene complexes with 
three mono-dentate ligands [(p-cymene)Ru(X)(Y)(Z)], where X, Y or Z = halide, 
acetonitrile or isonicotinamide.49 The ruthenium(II) arene complexes proved inactive 
(IC50, the dose which inhibits cell growth by 50 % of the cells, 
 
> 50 µM) towards the human ovarian cells (A2780) in vitro. The authors suggested 
that the complexes may be too reactive with components of the cell culture medium 
and/or the cells, and are deactivated by biomolecules before reaching their target 
sites.  
 
To avoid this problem, the authors decided to keep the ligand constant and vary the 
arene ring.50 They obtained reproducible cytotoxicity against the A2780 cell line, for 
chelated diamine complexes of the type [(η6-arene)Ru(N,N)(X)]+ where N,N- is 
typically ethylenediamine, and X is chloride (Fig. 1.6).  
NH2
H2N Ru
Cl
+
R
benzene p-cymene
biphenyl
tetrahydroanthracenediahydroanthracene
 
Figure 1.6: Five [(η6-arene)Ru(en)Cl]+ complexes (arenes shown separately) which  
show activity against the A2780 cell lined.50  
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Cells were incubated with the particular ruthenium(II) arene complex for 24 hours, 
washed, and then cell numbers determined after growth on fresh medium for a 
further three days. Activity was found to increase with the size of the coordinated 
arene (Table 1.1): benzene < p-cymene < biphenyl < dihydroanthracene < 
tetrahydroanthracene, such that, the biphenyl complex has similar cytotoxicity to the 
anticancer drug carboplatin (IC50 = 6 µM) and while the tetrahydroanthracene 
complex is as active as cisplatin (IC50 = 0.6 µM). 
 
Table 1.1: IC50 values for ruthenium(II) arene complexes [(η6-arene)Ru(X)(Y)(Cl)]A 
(A= PF6- for positively-charged complexes) in the A2780 cell line after  
24 hour  drug exposure, and comparison with carboplatin and cisplatin.50 
 
Arene/Pt complex X Y IC50 (µM) 
p-cymene CH3CN CH3CN > 100 
p-cymene Cl isonicotinamide > 100 
C6H5CO2CH3 H2NCH2CH2NH2 56 
benzene H2NCH2CH2NH2 17 
p-cymene H2NCH2CH2NH2 10 
carboplatin - 6 
C6H5C6H5 H2NCH2CH2NH(Et) 6 
C6H5C6H5 H2NCH2CH2NH2 5 
dihydroanthracene H2NCH2CH2NH2 2 
cisplatin - 0.6 
tetrahydroanthracene H2NCH2CH2NH2 0.5 
 
On the other hand, it appears that extended ligand groups, such as biphenyl and 
tetrahydroanthracene, improve the cytotoxicity of the drug, whilst the introduction of 
an electron withdrawing group at the arene moiety (such as CO2CH3) results in 
complexes with poor cytotoxicity. Compared to (p-cymene)RuCl(en)]PF6 (where en = 
ethylenediamine) (IC50 = 9 µM) (Fig. 1.7), the cationic complex [(η6-
C6H5CO2CH3)RuCl(en)]PF6  
(IC50 = 55 µM) (Fig. 1.7), showed a moderate activity on the A2780 cell line, due to 
the presence of an electron-withdrawing group on the arene ligand, reducing the 
activity of the complex.49  
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Figure 1.7: Two ruthenium(II) arene complexes, (p-cymene)RuCl(en)]PF6 (left) and 
[(η6-C6H5CO2CH3)RuCl(en)]PF6 (right), complexes of  which biological 
activity against A2780 cells vary with particular arene moiety.49 
 
Recently, a new series of organometallic ruthenium(II) arene complexes with 
potential hydrogen-bonding groups attached to the pendant arm of the arene ligand 
have been prepared and studied for their cytotoxicity as potential anticancer 
agents.51 The pta (1,3,5-triaza-7-phosphaadamantane) and dapta (3,7-diacetyl-1,3,5-
triaza-5-phosphabicyclo[3.3.1]nonane) ligands were used to obtain the neutral and 
cationic mononuclear ruthenium(II) arene complexes shown (Fig. 1.8). The 
cytotoxicity of these functionalized ruthenium(II) arene complexes showed no 
enhancement of biological activity towards the cancer cells screened, as compared 
to the analogous ruthenium(II) arene complexes without hydrogen-bonding 
substituents, namely toluene, p-cymene, hexamethylbenzene.51 
 
Whilst the presence of hydrogen bonding substituents can potentially hydrogen bond 
to DNA, in a similar manner titanocene-type drugs containing hydrogen bonding 
groups, showed an increase in cytotoxicity.52 In the case of these ruthenium(II) arene 
complexes the effect of the hydrogen-bonding function is actually the opposite. The 
origin of this unexpected effect was not clearly identified. 
 
IC50 = 9 µM IC50 = 55 µM 
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Figure 1.8: Seven [(η6-arene)Ru(X)Cl2]+ complexes, where X = pta or dapta, with 
potential hydrogen bonding groups.51 
 
Ruthenium(II) arene complexes appear to have a wide spectrum of cytotoxicity 
towards cancer cells. For example, the complexes [(η6-biphenyl)Ru(en)Cl]PF6 and 
[(η6-dihydroantracene)Ru(en)Cl]PF6 are not only active against A2780 human ovarian 
cancer cells, but also HT29 colon, Panc-1 pancreatic and NX02 lung cancer cells 
with IC50 values in the range 1 - 13 µM.53 
 
1.4.4 Multinuclear ruthenium(II) arene complexes as anticancer agents 
In contrast to multinuclear platinum complexes, analogous multinuclear 
organometallic ruthenium compounds have been rarely studied for their anticancer 
properties, with just a few examples to be found in the literature.23,54-58 
 
Keppler and co-workers have reported on the development of dinuclear ruthenium 
arene compounds (Scheme 1.2)59,60 with high in vitro anticancer activity (Table 1.2), 
whereas the mononuclear maltolato complex ([(η6-p-cymene)Ru(mal)Cl], were  
mal = 3-oxy-2-methyl-4-pyrone)
 
was found to be inactive.61,62 
      i ii     iii 
iv v vi vii 
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Scheme 1.2: Synthesis of the dinuclear ruthenium complexes (a, n=3; b, n=6;  
c, n=12).59 
 
Table 1.2: IC50 values of the complexes a - c in A2780 and SW480 cells, comparing 
cisplatin, oxaliplatin, carboplatin, BBR3464, the ruthenium(III) compound 
KP1019 and the mononuclear maltolato complex.59 
 
 IC50 (µM) 
Compound A2780 SW480 
a 25 ± 2 62 ± 14 
b 30 ±  6 26 ±  8 
c 1.5 ± 0.3 0.29 ± 0.05 
Mononuclear maltolato > 100 > 100 
Cisplatin 0.33 ± 0.04 4.5 ± 1.7 
Carboplatin - 61 ± 10 
Oxaliplatin 0.40 ± 0.12 0.30 ± 0.08 
BBR3464 0.01 - 
KP1019 - 49 ± 11 
 
In addition, they have synthesized a series of mono-, di- and tri-nuclear ruthenium(II) 
arene complexes, and investigated their anticancer activity.63 The in vitro anticancer 
activity of the dinuclear, its closest mononuclear analogue, and the trinuclear 
complex (Fig. 1.9) was compared.  
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Figure 1.9: Dinuclear, mononuclear and trinuclear ruthenium(II) arene anticancer 
compounds.63 
 
In both SW480 and A2780 cells, the dinuclear complex was identified as the most 
active species, while there is no meaningful difference between the mono- and the 
tri-nuclear complex (Table 1.3). When comparing the hydrophilicity of the three 
complexes (i.e. their solubility in water), the mononuclear complex is the most 
soluble, followed by the tri- and di-nuclear derivatives (Table 1.3). 
 
Table 1.3: Water solubility and IC50 values of ruthenium(II) arene complexes in 
human SW480 and A2780 cells.63 
 
  IC50 (µM) 
Compound Solubility (mM) SW480 A2780 
Dinuclear 3.9 26 ± 8 30 ± 6 
Mononuclear 10.3 42 ± 1 88 ± 12 
Trinuclear 7.4 59 ± 18 80 ± 7 
 
Keppler and co-workers also showed that the dinuclear compound represents a good 
balance between solubility and hydrophilicity necessary for cellular uptake. They 
concluded that the modification of the compound to link a higher number of 
ruthenium moieties improved the water solubility; but, showed a decrease in 
biological activity. 
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In contrast, Therrien and co-workers showed that an increase in nuclearity results in 
an increase in biological activity. They reported the synthesis of water-soluble 
metallaprisms which are capable of encapsulating planar aromatic molecules  
(e.g. pyrene, coronene),64 or metal complexes (e.g. [Pd(acac)2], [Pt(acac)2]).58 These 
“complex-in-a-complex” systems showed high cytotoxicity toward the human ovarian 
cancer cell line, A2780.58 More recently, this group synthesized tetranuclear 
metallarectangles (Fig. 1.10)65 of the general formula 
[Ru4(arene)4(N∩N)2(OO∩OO)2]4+ (arene = p-cymene or hexamethylbenzene; 
OO∩OO = 2,5-dihydroxy-1,4-benzoquinonato, 2,5-dichloro-1,4-benzoquinonato; 
N∩N = pyrazine, 4,4’-bipyridine or 1,2-bis(4-pyridyl)ethylene), prepared from a 
particular dinuclear ruthenium(II) arene complex (Fig. 1.11).58,64  
 
 
Figure 1.10: ORTEP representation of ruthenium(II) hexamethylbenzene 
tetranuclear metallarectangle.65 (Permission obtained from authors to 
reproduce structure). 
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Figure 1.11: Capped stick representations of ruthenium(II) hexamethylbenzene 
tetranuclear metallarectangle (left) and diethyl ether encapsulated by 
ruthenium(II) hexamethylbenzene tetranuclear metallarectangle 
(right).65 (Permission obtained from authors to reproduce structure). 
 
The authors evaluated the activity of the water-soluble complexes against the A2780 
ovarian cancer cell line. All the complexes showed moderate to excellent activity with 
IC50 values in the range 4 - 66 µM. It is likely that these large rectangular complexes 
would be taken up more efficiently by tumor cells,66 which are permeable to large, 
non-natural molecules, whereas healthy cells are less able to take up such 
structures, which should provide a degree of selectivity and ultimately lead to 
reduced drug side effects. 
 
There is a clear enhancement in biological activity between mononuclear and 
multinuclear ruthenium(II) arene compounds, hence functionalizing the ruthenium-
arene moiety on the periphery of a dendritic scaffold might be a viable option. 
 
1.5. Metallodendrimers 
 
Dendrimers are complex molecules, built around a central core, having a well defined 
molecular structure.67 The term ‘dendrimer’ is built from two Greek words “dendros” 
meaning “tree” or “branch”, and “meros” meaning “part”. These compounds can be 
obtained by a series of reaction steps. Both regular and highly branched types exist 
(Fig. 1.12).68 They are represented in a symmetrical fashion with all tiers pointing 
outwards. These macromolecules can have a wide range of functionalities located on 
the periphery. Functionalization of the periphery with transition metals, gives the 
complex several advantages in the field of catalysis, such as enhanced catalytic 
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activity when compared to other mononuclear analogues.69,70 These metal containing 
branched macromolecules are known as metallodendrimers.  
 
1.5.1 Synthesis, characterization and properties 
The divergent route and convergent route are two synthetic strategies used for the 
formation of various dendrimers. Both approaches involve a repetition of steps, with 
each yielding an additional generation. Each route has its own characteristics and 
therefore, to obtain the desired dendritic product, care has to be taken when 
choosing the synthetic approach.   
 
 
 
 
Figure 1.12: Regular dendrimer (top) and a highly branched dendrimer (bottom).68 
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The divergent route involves starting the synthesis with a multifunctional core 
molecule and extending it to the periphery in a stepwise manner.68 In such a manner, 
the poly(propyleneimine) dendrimers are synthesized with the polyalkylamine core 
(Fig. 1.13). The nitrogen atoms serve as branch points which are reacted with 
acrylonitrile via a “Michael addition” to give a branched alkyl chain structure. The 
end-group is reduced yielding a new set of primary amines. The process can be 
repeated for further branching.71 This approach is sometimes troublesome because 
as the generations increase, so do the number of structural defects, making 
purification difficult. 
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Figure 1.13: Poly(propylene imine) dendrimer synthesis via the divergent 
approach.71 
 
Hence, a second approach is required. The convergent approach (sometimes known 
as the “defect-free” method) entails making dendrons (a dendritic wedge without a 
core) and reacting them to a core molecule in the last step of a synthesis. The large 
“molecular difference” between the reactant and the product facilitates ease of 
purification. 
 
Early dendritic structures were synthesized using the divergent route, which have 
been thoroughly investigated by Tomalia72 and Newkome,73 for poly(amidoamine) 
(PAMAM) dendrimers and arboral systems respectively. In 1978, Buhleier reported 
the first synthesis of the poly(propylene imine) dendrimers, which were also prepared 
by the divergent route.74 The convergent approach was introduced by Hawker and 
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Fréchet, where synthesis started at the periphery and extended towards the core 
(Fig. 1.14).75  
 
Figure 1.14: Convergent approach, making use of wedges that can be connected to 
a core in the last step of a reaction by Hawker and Fréchet.75 
 
The last type of dendrimer is a convergently produced phenylacetylene dendrimer 
synthesized by Xu and Moore (Fig. 1.15).76 
SiMe3
 
Figure 1.15: Convergently synthesized phenylacytylene dendrimer by Xu and 
Moore.76 
 
Characterisation of dendrimers is complex, due to the shear size and symmetry of 
the macromolecules. A number of techniques can be used to fully characterise the 
dendritic complexes, such as NMR spectroscopy (1H, 13C{1H}, 15N, 31P), elemental 
analysis and chromatography techniques (HPLC and SEC).77 Softer analytical 
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methods such as ESI (electrospray ionization) and MALDI-TOF  
(matrix-assisted laser desorption ionization-time of flight) mass spectrometry allow for 
in-depth analysis of macromolecules by giving the molecular ion of the dendrimer.78 
 
1.5.2 General applications of metallodendrimers 
Early work of Tomalia and Newkome mainly focused on the synthesis and 
characterisation of dendrimers.72,73 More recently, the focus has shifted, to areas of 
functionality and applications of dendrimers. Such areas include medicinal 
chemistry,79 host-guest chemistry80 and catalysis.81 
 
A high density of functional groups on the periphery attracted researchers to the area 
of medicinal chemistry. Functionalization of the periphery with identical biologically 
active groups showed enhanced activities.82 Roy and co-workers investigated the 
activity of glycodendrimers, having an L-lysine core with various carbohydrates 
substituted on the periphery, compared to the monofunctional residue (Fig. 1.16).83 
As a biological catalyst, the glycodendrimer showed enhanced binding properties 
compared to the monofunctional residue.83 
 
 
Figure 1.16: A glycodendrimer with an L-lysine core and various carbohydrates on 
the periphery, synthesized by Roy and co-workers.83 
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It has been shown that dendrimers can possess cavities within their macromolecular 
structure that can be used to accommodate guest molecules.84 Therefore, research 
is focusing on this property for the development of sophisticated drug-delivery 
systems (Fig. 1.17). 
 
Figure 1.17: Dendritic box synthesized by Jansen and co-workers, used as a drug 
delivery agent.84 
 
Functionalization of the dendrimer arms with various transition-metals showed 
promise in medicine and catalysis. Metallodendrimers used in medicine and catalysis 
can have the active metal centre located at the core or on the periphery (Fig. 1.18).  
 
 
 
Figure 1.18: Catalytically active transition-metal complexes can be attached to the 
periphery (a), the core (b), at the focal point of a wedge (c), and at the 
periphery of a wedge (d).67 
= Transition Metal 
a b c d 
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An example of a multinuclear metallodendrimer synthesized by Smith and co-workers 
is the poly(propyleneimine)pyridyliminepalladium dendrimer (Fig. 1.19), which was 
used in ethylene polymerisation studies.85  The dendritic palladium complex also 
shows high activity and efficiency in Heck cross-coupling reactions in the coupling of 
an aryl halide with electron-deficient or electron-rich olefins.85 
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Figure 1.19: Poly(propylene imine)pyridyliminepalladium metallodendrimer.85 
 
1.5.3 Enhanced permeability and retention (EPR) effect 
The EPR effect is a phenomenon in which macromolecules (such as polymers and 
dendrimers) can accumulate at the tumour site due to an increase in blood vessel 
permeability within the cancerous tissues over normal tissues (Fig. 1.20).86 The 
normal endothelial layer surrounding the blood vessels feeding healthy tissues, 
restricts the size of molecules that can diffuse from the blood stream. In contrast, the 
endothelial layer of blood vessels in cancerous tissues is more porous, providing 
access to the surrounding tissue. Furthermore, diseased tissues do not usually have 
a lymphatic drainage system. Therefore, once macromolecules have entered the 
tissue they are retained and show increased bio-availability. A tetraruthenium cluster 
was found to be highly active against the polio virus without damaging the host cells, 
thereby offering the potential of developing highly selective drugs.87 
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Figure 1.20: Diagram representing the enhanced permeability and retention (EPR) 
effect.86 
 
1.5.4 Metallodendrimers used as anticancer agents 
More recently it has been shown that polynuclear platinum complexes are a very 
important group of antitumor active compounds. A different toxicity profile and slight 
different mode of action was observed compared to cisplatin. They cross-link the 
DNA differently, in a 1→4 base pair pattern rather than the 1→2 base pair pattern of 
cisplatin.88 
 
It was shown that synthesis of polymeric platinates is another means to increase 
platinum solubility, reduce toxicity and localise more drug in the tumour via the 
enhanced permeability and retention effect, to partially overcome mechanisms of 
resistance.89,90 
 
The study done by Kapp and co-workers focused their attention to the design of 
drugs with increased selectivity for breast tumors.91 They coupled the DAB  
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(1,4-diaminobutane poly(propyleneimine)) polyamine dendrimer with the well-known 
[1,2-bis(4-flurophenyl)ethylenediamine]platinum(II) complex (Fig. 1.21).92 It was 
concluded that the platinum functionalized dendrimer operates as a carrier for the 
shuttling of platinum into the cell nuclei of the cancerous cell, with no cytotoxic effects 
seen. 
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Figure 1.21: A platinum functionalized metallodendrimer synthesized by Kapp and 
co-workers.91 
 
To overcome cisplatin resistance Jansen and co-workers coupled the DAB(PA)4 
polyamine dendrimer with cisplatin to render the tetranuclear platinum  
(DAB(PA-tPt-Cl)4) compound (Fig. 1.22).93 The compound was designed to 
overcome two problems associated with cisplatin, deactivation of cisplatin by 
intracellular thiolates and improved repair of crosslinks with DNA. The tetranuclear 
platinum compound showed moderate cytotoxicity (IC50 = 12.4 µM) against L1210 
mouse leukemia cells and less cytotoxicity in resistant cell lines. The low cytotoxicity 
of the tetranuclear platinum complex was attributed to the high charge of the species 
at physiological pH. The high charge makes diffusion through the cell membrane 
(apolar) unlikely. 
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Figure 1.22: The first generation tetranuclear platinum complex DAB(PA-tPt-Cl)4. 93 
 
Malik and co-workers synthesized a dendrimer-platinate with a sodium carboxylate 
surface (Fig. 1.23), by conjugating the polyamidoamine (PAMAM) dendrimer 
(generation 3.5) with cisplatin, which was highly water soluble and released platinum 
slowly in vivo.94 Whilst in vivo, the dendrimer-Pt complex and cisplatin were  
equi-active against L1210 (mouse lymphocytic leukemia) cell line. At high 
concentration of the dendrimer-Pt, the dendrimer killed B16F10 (mouse melanoma) 
cells whilst cisplatin did not. Additionally, the dendrimer-Pt was used to treat a 
palpable B16F10 melanoma and showed antitumour activity whereas cisplatin was 
inactive. Thus, this approach showed potential as a novel antitumor approach. 
 
 
Figure 1.23: Proposed structure of generation 3.5 PAMAM dendrimer-Pt with the 
three possible binding sites: monodentate, bidentate and cross-linked.94 
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In 2009 Zhao et al. reported synthesis of a multinuclear chloropyridyliminecopper(II) 
complex. The dendritic complex contained seven copper(II) centers (Fig. 1.24).95 
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Figure 1.24: A multinuclear (top) and mononuclear copper complex (bottom) 
synthesized by Zhao and co-workers.95 
 
They investigated the biological activity of these complexes as potential anticancer 
agents, which to their surprise showed enhanced in vitro cytotoxicity. The copper(II) 
complexes were studied against leukemia cells (MOLT-4), breast cancer cells  
(MCF-7), and Chang Liver cells (Table 1.4).  
 
Table 1.4: IC50 values of multinuclear and mononuclear Cu-complexes versus 
cisplatin.95 
 
 IC50 (µM) 
Compound MOLT-4 MCF-7 Chang liver 
Cisplatin 15.5 ± 4.2 - 73.5 ± 3.7 
Multinuclear Cu-complex 11.1 ± 0.6 10.2 ± 1.5 8.7 ± 0.7 
Mononuclear Cu-complex 24.7 ± 2.4 73.1 ± 4.9 - 
 
In comparison with the mononuclear copper derivative, the authors showed an 
enhanced improvement in cytotoxicity. Furthermore, the multinuclear copper complex 
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demonstrated enhanced cytotoxicity compared to cisplatin, against MOLT-4 and 
cisplatin-resistance MCF-7. 
 
1.5.5 Ruthenium(II) arene metallodendrimers 
Functionalized metallodendrimers with ruthenium arene moieties on the periphery 
are rare in the literature. A ruthenium arene functionalized metallodendrimer was 
recently synthesized by Pettirossi and co-workers.96 They synthesized the 
multicationic ruthenium arene metallodendrimer (Fig. 1.25) by coupling of  
[(η6-p-cymene)Ru(κ3-dpk-OCH2CH2OH)]X (dpk = 2,2’-dipyridyl ketone, X=PF6) with 
the DAB(PA)4 polyamine dendrimer mediated by 1,1’-carbonyldiimidazole (CDI). The 
metallodendrimers were characterised with multidimensional and multinuclear NMR 
techniques (1H, 13C, 1H-COSY, 1H-NOESY, 1H,13C-HSQC NMR, and 1H,13C-HMBC 
NMR spectroscopy). The authors showed that the attachment of an organometallic 
moiety to a dendritic structure neither alters the relative anion–cation orientation nor 
does it cause a significant spatial proximity of two metal centers. The solvophobicity 
of the metallodendrimers is much higher than that of neutral dendrimers and 
increases with the generation. 
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Figure 1.25: First ruthenium arene metallodendrimer synthesized by Pettirossi and 
co-workers.96 
 
The use of functionalized metallodendrimers combined with ruthenium arene 
moieties on the periphery as anticancer agents are few and rare, which further gives 
motivation for the present study. 
 
1.6 General conclusions 
 
Severe side effects, high toxicity and drug resistance of platinum-based therapies 
have over shadowed the clinical successes of these compounds. Thus, researchers 
have focused their attention on compounds incorporating ruthenium metal. Arene 
ruthenium chemistry has shown to be an attractive alternate to platinum-based 
therapies. These compounds are stable and have shown high antiproliferative activity 
to a variety of carcinomas. However, whilst the field of ruthenium arene chemistry is 
growing, exploration into functionalized ruthenium arene metallodendrimers is in its 
infancy. 
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As a result, the development of ruthenium arene metallodendrimers and their uses as 
biological agents have not been studied. Coupling the stability and cytotoxicity of the 
ruthenium arene moiety with the ‘enhanced permeability and retention’ (EPR) effect 
of dendrimers prompts further investigation into this field. 
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1.7 Aims and objectives of the dissertation 
 
1.7.1 General aims 
In light of the past and recent developments in the field of ruthenium-arene 
chemistry, interest towards the use of these types of compounds as potential 
biological agents is rife. Therefore, the aim of this project is to synthesize and 
characterize a range of highly functionalized multinuclear monodentate and chelating 
bidentate ruthenium(II) arene metallodendrimers, and to evaluate their biological 
activity as potential anticancer agents.  
 
1.7.2 Specific objectives 
The specific objectives of the Dissertation are to: 
• Synthesize and characterize a range of Schiff-Base end-group modified first 
and second generation poly(propyleneimine) dendrimers (Fig. 1.26). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.26: 1st and 2nd generation Schiff-Base end group modified 
poly(propyleneimine) dendrimers. 
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• Complex ruthenium-arene precursors such as [Ru(η6-p-PriC6H4Me)Cl2] 97 and 
[Ru(η6-C6Me6)Cl2]2 98 (Fig. 1.27) with the appropriate poly(propyleneimine) 
dendritic ligands. 
Ru Cl
Cl
Ru
Cl
Cl
Ru Cl
Cl
Ru
Cl
Cl
 
Figure 1.27: Ruthenium arene dimers, [Ru(η6-p-PriC6H4Me)Cl2]2 (left),97 and 
[Ru(η6-C6Me6)Cl2]2 (right).98 
 
• Synthesize ruthenium(II) arene mononuclear analogues to compare their 
biological activities with those of the multinuclear derivatives.  
 
• Evaluate the antiproliferative activity of the mononuclear and dendritic 
ruthenium(II) arene complexes, against the A2780 and A2780cisR human 
ovarian cell lines. 
 
• Conduct DNA binding experiments on the most biologically active 
ruthenium(II) arene dendritic complexes 
 
All compounds are characterized by a variety of analytical and spectroscopic 
techniques, which include NMR and IR spectroscopy, elemental analysis and mass 
spectrometry.  
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Chapter 2 
Synthesis and Characterisation of Dendritic and Monomeric  
Pyridyl-imine and Salicylaldimine Ligands 
 
2.1 Introduction 
 
In order to exploit size selective uptake of drugs into tumour cells effectively, large 
compounds are required. In recent years, dendrimers have found potential as 
molecular tools in biological applications,1-3 especially as nano-carriers,4,5 diagnostic 
agents6 and as chemotherapeutics.7-9 Moreover, another advantage of dendrimers is 
their multivalency, which leads to increased interaction between a dendrimer-drug 
conjugate and target bearing multiple receptors, further improving selectivity to 
cancer cells. 
 
As part of a study towards the synthesis of ruthenium(II) arene complexes, a series of 
pyridylimine- and salicylaldimine-functionalised ligands were prepared. The dendritic 
scaffolds of interest are based on the poly(propyleneimine) dendrimer, the 1,4-
diaminobutane poly(propyleneimine) tetraamine (DAB-dendr-(NH2)4-G1) and  
1,4-diaminobutane poly(propyleneimine) octaamine (DAB-dendr-(NH2)8-G2)  
(Fig. 2.1).  
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Figure 2.1: Diagram of dendritic scaffolds chosen, DAB-dendr-(NH2)4-G1 (left) and 
DAB-dendr-(NH2)8-G2 (right). 
 
The periphery of the dendritic scaffolds has been modified with iminopyridyl and 
salicylaldimine moieties via a condensation reaction, by reacting the dendritic 
Chapter 2  Results and Discussion: Ligands 
 
 39 
scaffold (amine) with the appropriate aldehyde, with aims to synthesize mono- and 
bidentate dendritic ligands (Scheme 2.1). 
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Scheme 2.1: Mechanistic outline of a Schiff-base condensation reaction. 
 
This chapter describes the synthesis and characterisation of a series of monodentate 
and chelating bidentate ligands containing pyridyl-imine and salicylaldimine moieties. 
These compounds were characterized using a range of spectroscopic and analytical 
techniques, which include 1H-NMR, 13C{1H}-NMR and infrared (IR) spectroscopy, 
mass spectrometry and elemental analysis. 
 
2.2 Synthesis of 4-pyridyl-imine and 2-pyridyl-imine monomeric ligands (L1, L2) 
 
Monomeric pyridylimine-functionalised ligands L1 and L2 were synthesized by 
reacting either the commercially available 4-pyridinecarboxaldehyde or the  
2-pyridinecarboxaldehyde with n-propylamine (Scheme 2.2). The reactions were 
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stirred for 24 hours in the presence of anhydrous magnesium sulfate in dry diethyl 
ether. Isolation of the air stable organic products afforded pale-yellow (L1) and yellow 
(L2) oils, with yields of 71 % and 35 % respectively. The oils were soluble in most 
organic solvents such as dichloromethane, chloroform, methanol, toluene, diethyl 
ether, tetrahydrofuran, acetonitrile and dimethylsulfoxide. 
 
Scheme 2.2 Outline for the synthesis of monomeric ligands (L1 and L2). 
 
2.2.1 1H-NMR and 13C{1H}-NMR spectroscopy 
The two monomeric ligands L1 and L2 were characterized by 1H- and 13C{1H}-NMR 
spectroscopy and detailed chemical shifts were listed in Chapter 5. Evidence of the 
condensation reaction is clearly reflected by the 1H-NMR spectrum (Fig. 2.2) of both 
L1 and L2, which shows the disappearance of the NH2 singlet around 0.90 ppm and 
the appearance of the (CH)imine singlet around 8.09 ppm for L1 and around 8.36 ppm 
for L2. Further evidence is the shift of the triplet assigned to the CH2 group adjacent 
to the nitrogen atom from 2.52 ppm (n-propylamine) to 3.73 ppm for L1 and to 3.63 
ppm for L2. The downfield shift of this signal is due to the electron withdrawing 
effects of the imine bond. Aromatic protons for the 4- and 2-pyridyl rings are seen in 
the 1H-NMR spectra (Fig. 2.2) and showed typical chemical shifts for aromatic 
protons between 7 ppm and 9 ppm. 
 
The 13C{1H}-NMR spectra for ligands L1 and L2 showed similar shifts for the aliphatic 
carbons in the region of 12-63 ppm with differences only observed in the shifts of the 
aromatic carbon signals. The 4-pyridyl-imine and 2-pyridyl-imine ligands showed 
aromatic signals between 121-159 ppm. The characteristic singlet observed for the 
N
R
N
R
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O
H2O
NH2 N R
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imine carbon at ~160 ppm confirms the Schiff-base condensation reaction, and the 
presence of the imine bond, for both ligands L1 and L2. 
1
2
3
NH2
 
n-propylamine 
 
1
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N
8
9
 
L1 
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Figure 2.2: 1H-NMR spectra of n-propylamine (top), ligand L1 (middle) and ligand L2 
(bottom). 
 
2.2.2 Infrared (IR) spectroscopy 
Infrared spectroscopy was also used as a diagnostic tool to show the formation of the 
imine bond of the iminopyridyl ligands L1 and L2. The IR spectra of the two ligands 
L1 and L2 were recorded in dichloromethane using NaCl solution cells. In both 
cases, two strong absorption bands are observed around 1650 and 1590 cm-1. These 
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which were assigned to the (C=N)imine stretching vibration and (C=N)pyridyl stretching 
vibration respectively. 
 
2.2.3 Elemental analysis and mass spectrometry 
Elemental analyses of the monomeric oils (L1, L2) were found to correlate with 
calculated results. The 1H- , 13C{1H}-NMR and IR spectral data was supported by 
ESI-MS data, which showed a molecular ion peak in the spectrum of each ligand at 
m/z 149 [M+H]+ and 130 [M-CH3H2]+ for ligand L1 and L2, respectively. 
 
2.3 Synthesis of 4-pyridyl-imine dendritic ligands (L3, L4) 
 
The new 4-pyridyl-imine-functionalised dendritic ligands L3 and L4 were first 
synthesized in 2009.10 In the formation of N- donor, monodentate ligands, dendritic 
ligands L3 and L4 were synthesized by reacting  
4-pyridinecarboxaldehyde with DAB-dendr-(NH2)n (n = 4, 8 for L3, L4 respectively) 
(Scheme 2.3). The starting materials were stirred with anhydrous magnesium sulfate 
in toluene for 24 hours. The crude product was isolated and washed with copious 
amounts of distilled water to remove any unreacted aldehyde. With higher 
generations of dendrimers, the ‘arms’ of the dendrimer have the ability to fold-in 
towards the core, trapping unreacted aldehyde. Thus, washings were increased from 
6 to 8 times with distilled water. This occurrence has also been observed with other 
poly(propyleneimine) dendrimers functionalised at the periphery with organic 
groups.15 The organic products were isolated as a dark-orange oil for L3 and an 
orange-yellow oil for L4, with yields ranging between 68-84 %. The dendrimers are 
soluble in most organic solvents such as dichloromethane, chloroform, methanol, 
diethyl ether and tetrahydrofuran. 
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Scheme 2.3 Outline for the synthesis of dendritic ligands (L3 and L4). 
 
2.3.1 1H-NMR and 13C{1H}-NMR spectroscopy 
The dendritic ligands L3 and L4 were characterized in deuterated chloroform
 
using  
1H- and 13C{1H}-NMR spectroscopy. The chemical shifts are listed in Chapter 5 for 
both ligands L3 and L4. The condensation reaction can be confirmed with the shift in 
the CH2 signal, adjacent to the NH2 of the starting 1st generation dendrimer, to around 
3.63 ppm, in the 1H-NMR spectrum of L3 (Fig. 2.3). Two distinct doublets, typical of a 
para substituted aromatic ring, are seen with coupling constants (3J~ 6.0 Hz) typical 
of vicinal protons, and assigned to the aromatic protons on the pyridyl rings. Further 
verification of the reaction is the appearance of a singlet at 8.23 ppm assigned to the 
imine proton. For the higher generation dendritic ligand L4, the 1H-NMR spectrum 
shows a singlet assigned to the imine proton at around 8.17 ppm. 
 
Both ligands L3 and L4 show complex 1H-NMR spectra upon increasing dendrimer 
generation. The reason for this is the dendritic framework has a distinct set of 
aliphatic segments separated by nitrogen atoms. Confirmations of the higher 
generation aliphatic systems were made using 2D 1H-NMR, by performing 2D-COSY 
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experiments on the ligands. Thus with the use of these experiments and other related 
publications,11-14 spectra were assigned appropriately. 
 
13C{1H}-NMR spectra for both ligands L3 and L4 showed similar spectra. Signals 
assigned to the aliphatic carbons were seen in the region of 25-60 ppm and aromatic 
carbons in the region of 121-150 ppm for both generations. As expected for both 
ligands, the imine-carbon was the most deshielded signal at 159 ppm. 
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Figure 2.3: 1H-NMR spectra of DAB-dendr-(NH2)4 (top) and dendritic ligand L3 
(bottom). 
 
2.3.2 Infrared (IR) spectroscopy 
Infrared spectroscopy was used to give a qualitative description of the end-group 
moiety, illustrating the presence of the imine bond in ligands L3 and L4. The dendritic 
ligands (L3, L4) were recorded in dichloromethane utilising NaCl solution cells. 
Similar to the monomeric ligand L1, two strong absorption bands appeared at ~1647 
cm-1 and 1599 cm-1 and were assigned the (C=N)imine vibration and (C=N)pyridyl 
vibrations. 
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2.3.3 Elemental analysis and mass spectrometry 
Elemental analysis results showed percentages of which were outside acceptable 
limits. As mentioned before, dendrimers have the ability to trap solvent molecules or 
excess aldehyde within the dendritic framework. Evidence of this can be seen in the 
1H-NMR spectra of L3, where a strong dichloromethane peak can be noted at 5.25 
ppm and a small peak at around 10 ppm for the aldehyde moiety. Thus, with the 
inclusion of solvent molecules, the recalculated values were found to be in 
acceptable limits to the values found by elemental analysis. This is also the case for 
the higher generation L4. 
 
The 1H-NMR, 13C{1H}-NMR and IR spectral data were supported by FAB-MS data, 
which showed the molecular ion peak in the spectrum of each ligand at m/z 673 [M]+ 
and 1485 [M]+ for ligand L3 and L4 respectively.  
 
2.4 Synthesis of 2-pyridyl-imine dendritic ligands (L5, L6) 
 
A series of N,N- chelating, bidentate, dendritic ligands L5 and L6 were synthesized 
via a condensation reaction, by a route similarly used by Smith and co-workers 
(Scheme 2.4).12,13 The dendritic starting material was stirred with  
2-pyridinecaboxaldehyde and anhydrous magnesium sulfate in toluene for 24 hours. 
The crude products were isolated by filtration and rotatory evaporation of the reaction 
solution. The purification method used was similar to that of dendritic ligands L3 and 
L4. Drying of the products under reduced pressure yielded a yellow-brown oil and an 
orange-yellow oil for ligands L5 and L6 respectively, in relatively good yields of 61 % 
and 74 % respectively. The oils were found to be soluble in most organic solvents 
such as dichloromethane, chloroform, methanol, toluene, diethyl ether, 
tetrahydrofuran, acetonitrile and dimethylsulfoxide.  
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Scheme 2.4 Outline for the synthesis of dendritic ligands (L5 and L6). 
 
2.4.1 1H- NMR and 13C{1H}-NMR spectroscopy 
The successful reaction of the aldehyde with the DAB dendrimers (DAB-dendr-
(NH2)4 or DAB-dendr-(NH2)8) was confirmed from the 1H- and 13C{1H}-NMR spectra 
(Chapter 6) of oils L5 and L6 (Fig. 2.4). Evidence for the formation of 2-pyridylimine 
dendrimers L5 and L6 (similar to L3 and L4), is supported by the downfield shift of 
the triplet assigned for the CH2 moiety adjacent to the imine bond. Other evidence is 
the singlet corresponding to the imine proton at 8.35 ppm for L5 and 8.33 ppm for L6. 
The aromatic protons of the pyridyl rings for both the first and second generations 
showed similar resonance to their monomeric analogue L2. As mentioned earlier, the 
higher generations of dendrimer showed slightly more complex 1H-NMR spectra, 
resulting in the overlap of signals for the aliphatic protons.  
 
13C{1H}-NMR spectra for both ligands L5 and L6 were similar. Signals for the 
aliphatic carbons were observed in the region of 22-60 ppm and aromatic carbons in 
the region of 121-155 ppm for both generations (L5 and L6). As seen for the  
4-pyridylimine-functionalised ligands, the imine-carbon was the most deshielded 
signal at 159 ppm and 162 ppm for L5 and L6 respectively. 
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Figure 2.4: 1H-NMR spectra of DAB-dendr-(NH2)4 (top) and dendritic ligand L5 
(bottom). 
 
2.4.2 Infrared (IR) spectroscopy 
To confirm that the Schiff-base condensation and the formation of the imine bond 
had occurred, the infrared spectra of ligands L5 and L6 were recorded on NaCl 
solution cells in dichloromethane. Similar to the monomeric equivalent L2, strong 
absorption bands are seen in the regions of 1649 cm-1 and 1588 cm-1 and were 
assigned to the (C=N)imine and (C=N)pyridyl vibrations. 
 
2.4.3 Elemental analysis and mass spectrometry 
Elemental analysis was obtained on both the 1st and 2nd generation dendritic ligands  
(L5, L6). The purification procedures were similar to that of the 4-pyridylimine-
functionalised ligands, using dichloromethane. The higher generations showed 
percentages outside acceptable limits, this can ascribed to possible solvent inclusion, 
and also seen in the 1H-NMR spectrum of L5 and L6. Recalculation of the 
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percentages with the inclusion of half a molecule of dichloromethane gave 
percentages within acceptable limits. The phenomenon is also observed in other 
poly(propyleneimine) dendrimers functionalised at the periphery with organic 
groups.15 The 1H-, 13C{1H}-NMR and IR spectral data was supported by FAB-MS 
data, which showed the molecular ion peak in the spectrum of each ligand at m/z 673 
[M]+ and 1485 [M]+ for ligand L5 and L6 respectively.  
 
2.5 Synthesis of salicylaldimine monomeric ligand (L7) 
 
Prior to the synthesis of the dendritic N,O- chelating , bidentate ligands, the 
monomeric salicylaldimine ligand L7 was synthesized using a similar method to that 
of the monomeric ligands L1 and L2, via a Schiff-base condensation reaction. The 
commercially available starting materials, salicyldehyde and n-propylamine, were 
reacted in the presence of anhydrous magnesium sulfate, and stirred at room 
temperature in ethanol for 5 hours (Scheme 2.5). The crude product was isolated and 
purified by washing with copious amounts of distilled water. The purified ligand was 
isolated as an orange-yellow oil in 72 % yield. The oil was soluble in most organic 
solvents such as dichloromethane, chloroform, methanol, toluene, diethyl ether, 
tetrahydrofuran, acetonitrile and dimethylsulfoxide. 
Scheme 2.5 Outline for the  synthesis of monomeric ligand (L7). 
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2.5.1 1H-NMR and 13C{1H}-NMR spectroscopy 
The reaction between n-propylamine and salicyldehyde resulted in the formation of 
monomeric ligand L7, and can be confirmed from 1H- and 13C{1H}-NMR 
spectroscopy. 1H- and 13C{1H}-NMR spectra were recorded in deuterated chloroform. 
In the 1H-NMR spectrum of the ligand L7, the characteristic shift of the CH2 group 
(adjacent to the newly formed imine bond) was observed from 2.52 ppm to 3.56 ppm 
(Fig. 2.5). This is an expected shift due to the electron withdrawing effect of the imine 
group. The peaks assigned to the aromatic protons appear between 6.00 ppm and 
8.00 ppm. Further confirmation can be seen in the appearance of the singlet 
assigned to the imine proton at 8.32 ppm. A broad signal was observed at 13.66 
ppm, which was assigned to the proton on the hydroxyl group. 
 
The 13C{1H}-NMR spectrum of the monomeric ligand L7 showed 3 signals upfield, 
assigned to the aliphatic carbons in the aliphatic region. Signals assigned to the 
carbons of the aromatic ring were seen between 117 ppm and 132 ppm. The signal 
assigned to the carbon of the imine group appeared at 164 ppm. 
 
2.5.2 Infrared (IR) spectroscopy 
The infra-red spectrum of the monomeric ligand L7 was recorded using a NaCl 
solution cell in dichloromethane, to assist in confirming the formation of the imine 
bond. A strong sharp absorption band was seen at 1635 cm-1 which was assigned to 
the (C=N)imine stretching frequency. 
 
2.5.3 Elemental analysis and mass spectrometry 
The microanalysis of L7 was found to be within acceptable limits, confirming the 
integrity of the proposed structure. Further complementing our proposed structure 
was the ESI-MS data, which showed a molecular ion peak at m/z 164 [M+H]+. 
 
 
 
 
 
Chapter 2  Results and Discussion: Ligands 
 
 50 
1
2
3
NH2
 
n-propylamine 
 
1
2
3
N
4
5
6
7
8
9
10HO
 
L7 
 
 
Figure 2.5: 1H-NMR spectra of n-propylamine (top) and ligand L7 (bottom). 
 
2.6 Synthesis of salicylaldimine dendritic ligands (L8, L9) 
 
The salicylaldimine dendritic ligands L8 and L9 were formed using the method 
reported by Malgas and co-workers.16 Salicyldehyde was added to a solution of the 
DAB-dendr-(NH2)n (n = 4, 8 for L8, L9 respectively) in toluene (Scheme 2.6). The 
reaction was stirred at 40 oC overnight. A crude oil was isolated. Once purified the 1st 
generation ligand L8 was isolated as a bright yellow solid in 51 % yield. The 2nd 
generation ligand L9 was isolated as an orange oil in 92 % yield. The dendritic 
ligands L8 and L9 are soluble in most organic solvents such as dichloromethane, 
chloroform, methanol, diethyl ether and tetrahydrofuran. 
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Scheme 2.6: Outline for the synthesis of dendritic ligands (L8 and L9). 
 
2.6.1 1H-NMR and 13C{1H}-NMR spectroscopy 
The 1H- NMR and 13C{1H}-NMR spectra of ligands L8 and L9 was recorded in 
deuterated chloroform. The 1H-NMR spectra of the dendritic ligands showed a 
distinct shift in the signal assigned to CH2 group adjacent to the imine nitrogen from 
2.52 ppm to 3.60 ppm for L8 and 3.58 ppm for L9 (Fig. 2.6). The shift in the signal is 
expected due to the electron withdrawing effects experienced by the imine group. 
The aliphatic protons of the core and of the branches of the dendritic ligand L8 
appear between 1.40 ppm and 3.60 ppm. The higher generation dendritic ligand L9 
showed a more complex 1H-NMR spectrum, resulting in the overlap of signals for the 
aliphatic protons. The aromatic protons resonate in a similar range to the monomeric 
ligand L7, between 6.82 ppm and 7.27 ppm for both dendritic ligands L8 and L9. The 
imine and hydroxyl protons were observed around 8.30 ppm and 13.50 ppm 
respectively for both dendritic ligands. 
 
13C{1H}-NMR spectra for both dendritic ligands L8 and L9 showed similar pattern. 
Signals for the aliphatic carbons were seen in the region of 24-57 ppm and aromatic 
carbons in the region of 117-132 ppm for both generations. Similar to the 
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pyridylimine-functionalised ligands the signal assigned to the imine-carbon was the 
most deshielded signal at 165 ppm for both dendritic ligands L8 and L9.  
 
Figure 2.6: 1H-NMR spectra of DAB-dendr-(NH2)4 (top) and dendritic ligand L8 
(bottom). 
 
2.6.2 Infrared (IR) spectroscopy 
Infrared spectra were used to give a qualitative characterisation of the end group 
functionalized moiety. The dendritic ligands L8 and L9 were recorded in 
dichloromethane in NaCl solution cells. Similar to the monomeric ligand L7, a strong 
sharp absorption band appears at ~1631 cm-1 for ligand L8 and 1635 cm-1 for ligand 
L9, assigned to the (C=N)imine vibration. 
 
2.6.3 Elemental analysis and mass spectrometry 
The elemental analysis data was found to be within acceptable limits and confirms 
the proposed structures for both dendritic ligands L8 and L9, without the presence of 
solvent inclusions. 
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Formation of L7 and L8 was further supported by FAB-MS data, which showed 
molecular ion peak in the spectrum of each ligand at m/z 733 [M]+ and 1607 [M]+ for 
dendritic ligands L8 and L9 respectively.  
 
2.7 Conclusions 
 
A range of N- (L1, L3, L4), N,N- (L2, L5, L6) and N,O- (L7, L8, L9) donor 
monodentate and chelating bidentate ligands were prepared. The synthesized 
compounds were characterized using a range of spectroscopic and analytical 
techniques, namely 1H-, 13C{1H}- NMR and IR spectroscopy; and mass spectrometry 
and elemental analysis. 
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Chapter 3 
Synthesis and Characterization of Multinuclear Ruthenium(II) Arene  
Complexes of Pyridyl-imine and Salicylaldimine Ligands 
 
3.1 Introduction 
 
Ruthenium(II) arene complexes are reported to have a wide range of applications in 
the fields of catalysis,1 supramolecular self assemblies2 and in the field of medicinal 
chemistry, displaying antiviral,3 antibiotic4,5 and anticancer activities.6 The 
ruthenium(II) arene complexes have the typical half-sandwich geometry known as 
the “three-legged piano stool” complexes (Fig. 3.1), with a pseudo-tetrahedral 
geometry around the ruthenium centre. The arene ring occupies one coordination 
site (the seat) and the ligands occupy the remaining three sites (the legs). The arene 
π system stabilizes the +2 oxidation state and prevents rapid oxidation into the +3 
oxidation state. 
 
Ru
L
L
R
LL = Ligand
R
= arene
                  
Figure 3.1: Line drawing of a ruthenium(II) arene compound, illustrating the ‘three-
legged piano stool” structure. 
 
In synthesizing ruthenium(II) arene complexes, ruthenium-arene dimers are 
synthesized by reacting the ruthenium(III) salt (RuCl3.nH2O) with a diene to give rise 
to a ruthenium-arene dimer. The ruthenium-arene dimers or precursors  
([Ru(η6-p-PriC6H4Me)Cl2]2 and [Ru(η6-C6Me6)Cl2]2) were synthesized via two routes. 
The most common route involves reacting the ruthenium salt (RuCl3.nH2O) with a 
cyclohexadiene ligand in methanol or ethanol (Scheme 3.1-Route A).7 The second 
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route involves the exchange of the π ligand at elevated temperatures (Scheme 3.2-
Route B).8 
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Scheme 3.1: General synthesis of ruthenium(II) arene precursors. 
 
Reactions involving the chloro-bridged dimers with a range of ligands, generally 
afford half sandwich ruthenium(II) arene complexes. This chapter describes the 
synthesis and characterisation of a series of half sandwich ruthenium(II) arene 
monodentate and chelating bidentate, neutral and cationic, mononuclear and 
multinuclear complexes. These dendritic compounds were characterized using a 
range of spectroscopic and analytical techniques, including 1H-NMR, 13C{1H}-NMR 
and infrared (IR) spectroscopy, mass spectrometry, and elemental analysis. 
 
3.2 Synthesis of neutral 4-pyridyl-imine mononuclear and dendritic 
ruthenium(II) arene complexes (1 - 6) 
   
The general method of complexation involved stirring a solution of the ligand  
(L1, L3, L4) and the dimer ([Ru(η6-p-PriC6H4Me)Cl2] or [Ru(η6-C6Me6)Cl2]2) in 
dichloromethane at room temperature. The reactions were generally allowed to 
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proceed for 24 hours with the mononuclear reaction proceeding for a shorter period. 
The complexation reactions yielded two new mononuclear complexes (1, 2) and four 
new dendritic complexes (3 - 6). 
The 4-pyridyl-imine ligands L1, L3 and L4 yield neutral monodentate complexes, 
such that coordination of the ruthenium metal occurs only at the pyridyl nitrogen 
atom. The rationale for the synthesis of the mononuclear complexes (1, 2), was to 
help investigate properties, assist in characterisation and optimize methodology 
before synthesising the larger more complex metallodendrimers (3 - 6). 
In the synthesis of complexes 1 - 6, m equivalents (where m = 2 for 1 and 2; m = 0.5 
for 3 and 4; m = 0.25 for 5 and 6) of the ligand (L1 for 1 and 2, L3 for 3 and 4, L4 for 
5 and 6) were added to a solution of the ruthenium dimer ([Ru(η6-p-PriC6H4Me)Cl2] 
for 1, 3, 5; [Ru(η6-C6Me6)Cl2]2 for 2, 4, 6) in dichloromethane (Scheme 3.2). 
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Scheme 3.2: Outline synthesis of neutral ruthenium(II) arene complexes (1 - 6). 
 
The reaction was stirred overnight and the solvent reduced. The product was 
precipitated from solution with petroleum ether and further washed with the same 
solvent.  
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3.2.1 Physical properties 
The complexes were dried under vacuum and were isolated as yellow solids in 
moderate to high yields, and were found to be thermally stable (Table 3.1). 
 
Table 3.1:  Physical appearance, percentage yield and melting points for complexes  
1 - 6. 
Complex Physical  Appearance 
Yield 
(%) 
Melting Point 
(oC) 
1 Mustard- yellow solid 46 163 - 166 
2 Yellow-orange solid 50 139a  
3 Mustard- yellow solid 79 165a 
4 Yellow solid 87 188a 
5 Mustard- yellow solid 98 214a 
6 Yellow solid 92 194a 
aDecompose without melting into a black solid 
 
Ruthenium(II) arene complexes 1 - 6 are non-hygroscopic, air-stable and soluble in 
most organic solvents, such as dichloromethane, chloroform, ethanol, 
dimethylsulfoxide, acetone and acetonitrile, and insoluble in diethyl ether, petroleum 
ether and tetrahydrofuran. 
 
3.2.2 1H-NMR and 13C{1H}-NMR spectroscopy 
Coordination of the ruthenium-arene moiety to the pyridyl nitrogen was confirmed by 
1H-NMR spectroscopy in chloroform-d. The 1H-NMR spectrum (Fig. 3.2) of complex 1 
and 2 showed the presence of peaks associated with the complexation of ligand L1 
and the ruthenium dimer ([Ru(η6-p-PriC6H4Me)Cl2]  or [Ru(η6-C6Me6)Cl2]2).  
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Figure 3.2: 1H-NMR spectra of 4-pyridyl-imine ligand L1 (top) and mononuclear 
complexes 1 (middle) and 2 (bottom). 
 
A similar pattern was observed in the 1H-NMR spectra of the tetranuclear complexes 
(3, 4) (Fig. 3.3) and the octanuclear complexes (5, 6). The coordination of the 
ruthenium metal centre to the pyridyl nitrogen atom (and not the imine nitrogen atom) 
was evidenced by a downfield shift of the doublet (assigned the protons ortho-
substituted to the pyridyl nitrogen atom) from ~8.7 ppm (in the ligand) to ~8.9 ppm 
(Table 3.2). This is due to the electron-withdrawing effects of the coordinated metal. 
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Table 3.2: Selected 1H-NMR data for complexes 1 - 6. 
Complex Imine Proton(s) (ppm) 
Pyridyl Protons 
(ppm) 
Arene Ring  
(ppm) 
1 8.27 7.60; 9.10 1.32; 2.11; 3.00 5.2-5.5 
2 8.23 7.54; 8.78 1.99 
3 8.20 7.49; 9.06 1.30; 2.09; 2.97 5.3-5.7 
4 8.23 7.51; 8.78 1.97 
5 8.19 7.49; 9.05 1.32; 2.09; 2.97 5.3-5.5 
6 8.26 7.57; 8.86 2.03 
 
This is the characteristic splitting pattern seen for aromatic rings with different groups 
para-positioned on the ring. A single doublet, integrating for two protons, was 
observed downfield and another doublet (integrating for two protons) is observed 
upfield (Fig. 3.4). The aliphatic protons of the dendritic core and side arms of the 
dendritic complexes (3 - 6) occur at similar shifts to those of the dendritic ligands L3 
and L4. The imine proton remains constant at ~8.2 ppm further confirming 
coordination at the pyridyl nitrogen only.  
 
p-Cymene complexes (1, 3, 5) 
The methyl protons of the isopropyl group appear as a doublet in the 1H-NMR 
spectra for all the p-cymene complexes (1, 3, 5) and the multiplet at ~ 3 ppm was 
assigned to the single proton of the isopropyl groups. Two doublets in the range 
between 5.2 - 5.7 ppm were assigned to the aromatic protons of the p-cymene ring 
and the singlet at ~ 3 ppm assigned to the single methyl group for the p-cymene 
complexes (1, 3, 5). 
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Figure 3.3: 1H-NMR spectra of 4-pyridyl-imine dendritic ligand L3 (top) and dendritic  
complexes 3 (middle) and 4 (bottom). 
 
Hexamethylbenzene (2, 4, 6) 
The appearance of the singlet (~ 2 ppm), which was assigned to the protons of the 
CH3 groups on the arene ring, showed the presence of the arene ring for the 
mononuclear complex (2). Similarly a singlet at the same chemical shift confirmed the 
presence of the desired dendritic complex (4, 6), and was assigned to the methyl 
protons of the arene ring. 
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Figure 3.4: 1H-NMR spectrum of a mononuclear complex, illustrating the 
characteristic splitting pattern observed for para-substituted aromatic 
rings. 
 
The 1H-NMR spectra of the 1st generation dendritic complexes (3, 4) show 
broadened peaks (Fig. 3.3). After extensive washing with a non-polar solvent 
(petroleum ether), peaks of small intensity could still be seen on the baseline, which 
are assigned to solvent inclusions or other inorganic material. This is attributed to a 
phenomenon, where the fluxional arms of the dendrimer can trap solvent molecules 
and/or molecules of starting material.10 The 1H-NMR spectrum of the second 
generation complexes (5, 6) showed similar shifts to the first generation complexes 3 
and 4 respectively. Once again, broad overlaps of signals are seen, these were 
assigned to the aliphatic protons of the side arms of the dendrimer.  
 
13C{1H}-NMR spectra of the mononuclear complexes (1, 2) were similar to that of the 
monomeric ligand L1 with differences only in the chemical shifts of the pyridyl 
carbons (Table 3.3), due to coordination of the ruthenium metal centre. 13C{1H}-NMR 
spectra for dendritic complexes (3 - 6) were similar with only extra signals seen in the 
13C{1H}-NMR spectrum of the second generation complexes (5, 6) (Table 3.3). These 
were assigned to the carbons of the aliphatic side arms of the dendrimers. 
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ClCl
R
N
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Chapter 3  Results and Discussion: Complexes 
 63 
Table 3.3: Selected 13C{1H}-NMR data for complexes 1 - 6. 
Complex Imine Carbon(s) (ppm) 
Pyridyl Carbons 
(ppm) 
Arene Ring  
(ppm) 
1 157 123-145 18-22; 31-104 
2 158 123-144 15; 91 
3 158 123-140 18-22; 31-103 
4 159 123-144 15; 91 
5 158 123-144 18-22; 31-103 
6 159 123-144 15; 91 
 
13C{1H}-NMR spectra of  the neutral monodentate complexes 1 - 6 show chemical 
shifts of its pyridyl carbons in the range of 123-144 ppm. The p-cymene derivatives 
(1, 3, 4) showed signals in two ranges (18-22 ppm and 31-104 ppm), which are 
assigned to the carbons of the arene ring. The hexamethylbenzene ring of 
complexes 2, 5 and 6, show two signals, one at 15 ppm and another at 91 ppm, and 
were assigned to the methyl carbons and the aromatic carbons respectively.  
A singlet ~159 ppm was assigned to the imine carbons of complexes 1 - 6. 
 
3.2.3 Infrared (IR) spectroscopy 
Infrared studies were employed on all neutral monodentate complexes (1 - 6) using a 
NaCl solution cell in dichloromethane, to qualitatively show coordination of the 
ruthenium metal centre to the aromatic nitrogen. Shifts in the (C=N)imine and the 
(C=N)pyridyl bands verified the mode of coordination of the metal to one or both 
nitrogen sites. The dendritic complexes (3 - 6) showed a similar pattern as their 
mononuclear analogues (1, 2) (Table 3.4).  
 
A shift in the (C=N)pyridyl band, for all monodentate complexes (1 - 6), was observed 
from a lower frequency around 1599 cm-1 (in the ligand) to a higher frequency around 
1614 cm-1 in the IR spectrum. This confirms coordination of the ruthenium metal to 
the pyridyl nitrogen atom only. The characteristic free (C=N)imine band around 1647 
cm-1 remains unchanged and confirms no coordination occurred at this site.  
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Table 3.4: Selected IR absorption bands for complexes 1 - 6. 
Complex (C=N)imine  (cm-1) 
(C=N)pyridyl 
(cm-1) 
1 1647 1615 
2 1646 1614 
3 1646 1615 
4 1646 1614 
5 1646 1614 
6 1646 1613 
 
3.2.4 Elemental analysis and mass spectrometry 
Elemental analysis results of the new mononuclear complexes (1, 2) were found to 
correlate with the calculated values. However, the ruthenium(II) arene functionalised 
metallodendrimers (3, 6) were precipitated as solids, with the inclusion of solvent 
trapped between the dendritic arms. The dendritic arms often tend to fold back on 
one-another which results in the entrapment of solvent molecules. The elemental 
analysis data correlates with the inclusion of 2 and 4 molecules of dichloromethane 
for the p-cymene dendritic complexes 3 and 5 respectively. The calculations correlate 
well with the inclusion of 1 molecule (4) and 2 molecules (6) of dichloromethane for 
the hexamethylbenzene dendritic complexes. 
Along with elemental analysis the ESI-mass spectrometry results further confirmed 
the proposed structures for complexes 1 - 6 (Table 3.5). 
 
Table 3.5: Mass spectrometry data for complexes 1 - 6. 
Complex 
Calculated 
Molecular Mass 
(g/mol) 
Molecular 
Fragment 
(m/z) 
Assignment 
1 454.1 419 [M-Cl]+ 
2 482.5 447 [M-Cl]+ 
3 1897.7 565 [M+4H+4CH2Cl2+H2O]4+ 
4 2009.9 635 [M-3Cl]3+ 
5 3935.7 569 [M-7Cl+3CH2Cl2+CH3CN]7+ 
6 4160.0 631 [M-7Cl+5CH2Cl2+2CH3CN]7+ 
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3.2.5 X-ray crystallography 
The molecular structures were established of the neutral mononuclear complexes 1 
and 2 were confirmed by single crystal X-ray diffraction. The crystals were grown by 
slow diffusion of hexane into a concentrated dichloromethane solution of the 
complexes. Complexes 1 and 2 both crystallize in the monoclinic space groups P21/c 
and P21. The structure analysis shows the ruthenium atom possessing the well 
documented “three-leg piano-stool”, pseudo-tetrahedral geometry.11 The arene ring 
represents the “seat” and, the ligand bound by the pyridyl-nitrogen and chlorido 
ligand, are the “legs”. ORTEP drawings of the mononuclear complexes 1 and 2 are 
shown (Fig. 3.5), with the crystallographic data listed in Table 3.6 and selected bond 
lengths and angles tabulated in Table 3.7. 
 
 
Figure 3.5: The ORTEP structures of the neutral mononuclear complexes 1 (left) and 
2 (right). 
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Table 3.6: Crystallographic and structure refinement parameters for neutral 
complexes 1 and 2. 
 
Complex 1 2 
Chemical formula C19H26Cl2N2Ru C21H30Cl2N2Ru 
Formula weight (g /mol) 454.39 482.44 
Crystal system Monoclinic Monoclinic 
Space group P 21/c P21 
a (Å) 18.246(3) 15.005(3) 
b (Å) 15.057(2) 8.100(2) 
c (Å) 7.3464(11) 19.185(4) 
α (o) 90.00 90.00 
β (o) 101.360(14) 112.03(3) 
γ (o) 90.00 90.00 
V (Å3) 1978.7(5) 2161.5(8) 
Z 4 4 
T (K) 293(2) 293(2) 
Wavelength λ (Å) 0.71073 0.71073 
Density Dχ (g /cm3) 1.525 1.483 
Absorption coefficient µ (mm-1) 1.065 0.980 
F(000) 928 992 
Scan range (o) 1.14 < θ < 25.26 2.17 < θ < 26.04 
Unique reflections 12695 12997 
Reflections used [l > 2σ(l)] 3530 7781 
Rint 0.2154 0.1150 
Final R indices [l > 2σ(l)]a 0.0650, wR2 0.1515 0.1037, wR2 0.2687 
R indices (all data) 0.1632, wR2 0.1830 0.1442, wR2 0.2839 
Goodness-of-fit (GOF) 0.755 1.031 
Maximum, Minimum ∆ρ (e Å-3) 0.504, -0.991 4.646, -1.864 
a
 Structures were refined on F02: wR2 = [Σ[w(F02 - Fc2)2] / Σ w(F02)2]1/2,  
where w-1 = [Σ (F02) + (aP)2 + bP] and P = [max(F02, 0) + 2Fc2]/3. 
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Table 3.7: Selected bond lengths (Å) and angles (o) for neutral complexes 1 and 2. 
1 2 
Distances (Å) Distances (Å) 
Ru(1)-C(1) 2.216(12) Ru(2)-C(26) 2.180(2) 
Ru(1)-C(2) 2.171(12) Ru(2)-C(27) 2.250(2) 
Ru(1)-C(3) 2.188(13) Ru(2)-C(28) 2.150(2) 
Ru(1)-C(4) 2.206(13) Ru(2)-C(29) 2.221(16) 
Ru(1)-C(5) 2.181(10) Ru(2)-C(30) 2.213(14) 
Ru(1)-C(6) 2.151(11) Ru(2)-C(31) 2.202(17) 
Ru(1)-Cl(1) 2.406(3) Ru(2)-Cl(3) 2.423(5) 
Ru(1)-Cl(2) 2.405(3) Ru(2)-Cl(4) 2.427(5) 
Ru(1)-N(1) 2.128(9) Ru(2)-N(2) 2.123(15) 
N(2)-C(16) 1.340(3) N(4)-C(16) 1.220(3) 
N(2)-C(17) 1.490(3) N(4)-C(17) 1.650(3) 
C(13)-C(16) 1.540(2) C(13)-C(16) 1.490(3) 
    
Angles (o) Angles (o) 
N(1)-Ru(1)-Cl(1) 87.0(2) N(2)-Ru(2)-Cl(3) 87.90(5) 
N(1)-Ru(1)-Cl(2) 84.8(2) N(2)-Ru(2)-Cl(4) 84.40(4) 
Cl(1)-Ru(1)-Cl(2) 87.65(12) Cl(3)-Ru(2)-Cl(4) 87.33(19) 
 
The bond distance of the Ru-Npyr of complexes 1 (2.128(9) Å) and 2 (2.123(15) Å) are 
comparable to the bond distances of the Ru-Npyr of the p-cymene derivative recently 
published (2.130(2) Å) by Keppler and co-workers.9 Similarly, the bond angles of 
Npyr-Ru-Cl and Cl-Ru-Cl of complexes 1 (84.8(2) o and 87.65(12) o) and 2 (84.40(4) o 
and 87.33(19) o)
 
are also comparable to the bond angles of the p-cymene derivative 
Npyr-Ru-Cl and Cl-Ru-Cl (84.50(6) o and 87.00(2) o) synthesized by Keppler.9 The 
crystal analysis thus further confirms mode of coordination at the pyridyl nitrogen 
atom. 
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3.3 Synthesis of cationic 2-pyridyl-imine mononuclear and dendritic 
ruthenium(II) arene salts (7 - 12) 
 
The N,N- donor ligands (L2, L5, L6) were complexed with two ruthenium precursors 
([Ru(η6-p-PriC6H4Me)Cl2]) and ([Ru(η6-C6Me6)Cl2]2). For complexes 7 - 12, m 
equivalents (where m = 2 for 7 and 8; m = 0.5 for 9 and 10; m = 0.25 for 11 and 12) 
of the ligand (L2 for 7 and 8; L5 for 9 and 10; L6 for 11 and 12) were added to a 
solution of the ruthenium dimer ([Ru(η6-p-PriC6H4Me)Cl2] for 7, 9, 11; [Ru(η6-
C6Me6)Cl2]2  for 8, 10, 12) in ethanol or methanol (Scheme 3.3). As seen for similar 
chelating systems,12-14 2-pyridyl-imine ligands have the ability to coordinate to the 
metal centre in a cationic bidentate fashion via the imine and pyridyl nitrogen atoms. 
Coordination of the ligand (L2, L5, L6) to the ruthenium metal centre splits the dimer, 
displacing a chloride ion (as the counter-ion), and generate a cationic metal complex.  
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Scheme 3.3: Outline synthesis of cationic ruthenium(II) arene complexes (7  - 12). 
 
However, isolation and purification of the complexes (7 - 12) as chloride salts proved 
to be a major challenge, as these compounds were found to be very hygroscopic. 
Due to the large nature of the complexes the chlorido anion was not a suitable 
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counter-ion for the complex, which could have aided in difficulty in isolating the 
complexes. A metathesis reaction was preformed, using the sodium 
hexafluorophosphate salt to assist in the exchange (Scheme 3.3). The bulky nature 
of this anion is said to stabilise the overall complex. The products precipitated out of 
solution and were isolated by filtration, and dried under vacuum. The complexation 
reactions yielded two new mononuclear salts 7 and 8, and four new dendritic 
ruthenium(II) arene salts 9 - 12.  
 
3.3.1 Physical properties  
The complexes (7 - 12) were dried and isolated as dark yellow-red solids in moderate 
yields, and were found to be thermally stable (Table 3.8). 
 
Table 3.8: Physical appearance, percentage yield and melting points for complexes  
7 - 12. 
 
Complex Physical  Appearance 
Yield  
(%) 
Melting Point 
(oC) 
7 Yellow solid 38 186-187 
8 Orange solid 51 239-241 
9 Yellow-brown solid 48 169-172 
10 Red-brown solid 66 232-236 
11 Yellow-brown solid 40 175-179 
12 Red-brown solid 48 210-212 
 
The cationic salts 7 - 12 were non-hygroscopic, air-stable and soluble in 
dimethylsulfoxide, acetone, acetonitrile and insoluble in methanol, diethyl ether, 
hexane and tetrahydrofuran. 
 
3.3.2 1H-NMR and 13C{1H}-NMR spectroscopy 
1H-NMR spectroscopy was used to assist in providing evidence for the coordination 
of the ruthenium-arene moiety to both the imine and pyridyl nitrogen atoms. The  
1H-NMR spectra (Fig. 3.6) of complexes 7 and 8 were run in acetone-d6 and showed 
all the relevant peaks for a combination of the ligand L2 and the ruthenium dimer 
([Ru(η6-p-PriC6H4Me)Cl2] or [Ru(η6-C6Me6)Cl2]2). 
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A similar pattern is seen in the 1H-NMR spectra (Fig. 3.7) of the dendritic complexes 
9 - 12. The 1H-NMR spectra for the dendritic salts showed broadened peaks, with 
many of the peaks overlapping and/or coalescing, due to the multinuclear nature of 
these complexes. 
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Figure 3.6: 1H-NMR spectra of 2-pyridyl-imine ligand L2 (top), mononuclear salts 7 
(middle) and 8 (bottom) recorded in acetone-d6. 
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Figure 3.7: 1H-NMR spectra of 2-pyridyl-imine dendritic ligand L5 (top), dendritic 
salts 9 (middle) and 10 (bottom) recorded in acetone-d6. 
 
As a result of the ruthenium-arene moiety coordinating to both the imine and pyridyl 
nitrogen atom, there is a shift in both the imine proton and protons on the pyridyl ring, 
for all complexes 7 - 12. All cationic salts showed a general shift of signals downfield 
due to the cationic nature of the complex. Upon coordination of the ruthenium-arene 
moiety to the ligand, the ruthenium metal centre becomes chiral. The newly formed 
chiral centre is due to the coordination of four different groups on the ruthenium metal 
centre. The diastereotopic nature of the protons on carbon 3 of the mononuclear 
complexes 7 and 8 further confirm the formation of the chiral centre. Both sets of 
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diastereotopic protons, on each carbon, show two sets of multiplets in the ranges of 
2.0 - 2.1 ppm and 4.4 - 4.7 ppm for complexes 7 and 8. The diastereotopic protons 
on the dendritic arms of complexes (9 - 12), adjacent to the imine nitrogen, show the 
same effect as to their mononuclear counterparts. Two broad multiplets for the first 
generation complexes (9 and 10), between 4.6 - 4.7 ppm are seen and a very broad 
multiplet for the second generation complexes (11 and 12) between 4.6 - 4.8 ppm is 
also noted. 
 
p-Cymene salts (7, 9, 11) 
There is a lack of rotation around the p-cymene ring due to the bulky nature of the 
isopropyl group. This in turn results in the methyl protons of the isopropyl group 
exhibiting two sets of doublets (~1.1 ppm) in the 1H-NMR spectrum of the 
mononuclear complex 7. Two broad multiplets were observed for the dendritic 
complexes at ~1.1 ppm (9 and 11) and were assigned to the methyl protons of the 
isopropyl group. A septet (7) and a broad multiplet (9 and 11) were observed at 2.5 
ppm and were assigned to the single proton of the isopropyl group (Table 3.9). The 
triplet and the doublet-of-doublets observed at 5.9 ppm and 6.2 ppm respectively (7), 
correspond to the aromatic protons of the p-cymene ring. The dendritic salts (9 and 
11) show two multiplets assigned to the aromatic protons of the p-cymene ring. The 
splitting pattern can be explained as a result of the long range coupling with the 
isopropyl protons (Table 3.9).  
 
Hexamethylbenzene salts (8, 10, 12) 
A strong singlet is seen in the 1H-NMR spectrum of complex 8 at 2.2 ppm, and was 
assigned the methyl protons of the hexamethylbenzene ring (Table 3.9). Similarly the 
dendritic salts (10 and 12) show a singlet at 2.2 ppm assigned to the methyl protons 
of the hexamethylbenzene ring (Table 3.9). 
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Table 3.9: Selected 1H-NMR data for cationic salts 7 - 12. 
 
Complex Imine Proton(s) (ppm) 
Pyridyl Protons 
(ppm) 
Arene Ring  
(ppm) 
7 8.79 7.8-8.3; 9.57 1.11; 2.3-2.8;  5.9-6.2 
8 8.70 7.8-8.2; 9.07 2.24 
9 8.98 7.8-8.2; 9.57 1.11; 2.3-2.8;  6.0-6.3 
10 8.76 7.8-8.2; 9.08 2.21 
11 9.13 7.8-8.3; 9.58 1.09; 2.3-2.8; 6.0-6.3 
12 8.70 7.8-8.2; 9.07 2.20 
 
The aromatic protons of the arene ring (p-cymene or hexamethylbenzene) are 
observed more downfield compared to the starting ruthenium precursors  
([Ru(η6-p-PriC6H4Me)Cl2]2 or [Ru(η6-C6Me6)Cl2]2) due to the cationic nature of the 
complex. 
 
13C{1H}-NMR spectra of the mononuclear complexes 7 and 8 were run in acetone-d6 
and were found to be similar to that of the monomeric ligand L2, with a downfield 
shift seen in the signals assigned to the imine and pyridyl carbons as a result of 
coordination to the ruthenium metal centre (Table 3.10). 13C{1H}-NMR spectra of the 
dendritic complexes 9 and 10 were similar to the second generation complexes 11 
and 12, with only extra signals seen in the 13C{1H}-NMR spectra, assigned to the 
carbons of the aliphatic side arms (Table 3.10). 
 
Table 3.10: Selected 13C{1H}-NMR data for cationic salts 7 - 12.
 
 
Complex Imine Carbon(s) (ppm) 
Pyridyl Carbons 
(ppm) 
Arene Ring  
(ppm) 
7 167 129-155 21-23; 31-106 
8 167 128-155 15; 97 
9 166 129-155 19-22; 31-106 
10 167 128-155 15; 97 
11 169 129-155 19-22; 31-106 
12 167 128-155 15; 97 
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13C{1H}-NMR spectra of  the cationic salts (7 - 12) showed chemical shifts of signals 
assigned to its pyridyl carbons in the range of 128 - 155 ppm, and peaks for the imine 
carbons at ~168 ppm. The 13C{1H}-NMR spectra of the p-cymene complexes  
(7, 9, 11) showed a range of signals between 19 - 22 ppm and between 31 - 106 
ppm. The 13C{1H}-NMR spectra of the hexamethylbenzene complexes (8, 10, 12) 
showed signals at 15 and 97 ppm, assigned to the sp3 and sp2 hybridized carbons of 
the arene ring. 
 
3.3.3 Infrared (IR) spectroscopy 
The IR spectrum for the mononuclear complexes (7 and 8) showed shifts of the two 
bands assigned to the (C=N)pyridyl and (C=N)imine stretching frequencies, which 
suggests coordination of the ruthenium metal to these systems. Similarly, shifts in the 
(C=N)pyridyl and (C=N)imine stretching frequencies for the dendritic salts (9 - 12) were 
also seen. The (C=N)pyridyl stretching frequency shifted from around ~1590 cm-1 to a 
higher frequency of ~1600 cm-1 for all of the cationic salts 7 - 12 (Table 3.11), whilst 
the (C=N)imine stretching frequency shifted from around ~1650 cm-1 to a lower 
frequency of ~1623 cm-1 for the same complexes (Table 3.11).  
 
Table 3.11: Selected IR absorption bands for cationic salts 7 - 12.
 
 
Complex (C=N)imine  (cm-1) 
(C=N)pyridyl  
(cm-1) 
7 1623 1599 
8 1625 1600 
9 1625 1599 
10 1624 1598 
11 1623 1598 
12 1621 1597 
 
These shifts can be explained by the synergic effect.15 The (C=N)imine experiences 
electron-withdrawing effects from the coordinated metal and the pyridyl ring, which 
in-turn weakens the (C=N)imine bond and pushes the stretching frequency to a lower 
frequency. The shift of the (C=N)pyridyl is brought about by the synergic effect (Fig. 
3.8). Back-donation of electron density from the electron rich metal centre into the 
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empty anti-bonding (π*) orbitals, strengthening the (C=N)pyridyl bond, thus pushing the 
stretching-frequency to a higher frequency.   
M  =  Ru
N C
H
R
pi
σ
pi
imine / pyridyl
bond
M
pi pi∗
 
Figure 3.8: Molecular orbital diagram illustrating the synergic effect. 
 
3.3.4 Elemental analysis and mass spectrometry 
The values for cationic salt 7, correlated with the calculated values. When comparing 
the observed values for cationic salt 8 with the calculated values, they were found to 
be outside acceptable limits. With the possibility of solvent inclusions, calculated 
values were recalculated to include half a molecule of methanol. This brought the 
observed values in direct correlation with calculated values. Elemental analysis for 
the cationic dendritic complexes 9 - 12 were found to correlate with calculated 
values. 
Further complementing spectroscopic and analytical data, were the MALDI-TOF 
mass spectrometry data for the cationic salts 9, 10 and 12, which showed the 
molecular ion base peak with one-less a PF6 molecule as the highest molecular 
weight fragment, but, cationic salt 11 gave the molecular ion base peak as the 
highest molecular weight fragment (Table 3.12). 
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Table 3.12: Mass spectrometry data for 7 - 12.
 
Complex Calculated Molecular Mass (g/mol) 
Molecular 
Fragment (m/z) Assignment 
7 563.9 419 [M-PF6]+ 
8 592.0 447 [M-PF6]+ 
9 2335.8 2192 [M-PF6]+ 
10 2448.0 2304 [M-PF6]+ 
11 4811.8 4811 [M]+ 
12 5036.2 4891 [M-PF6]+ 
 
3.3.5 X-ray crystallography 
The proposed structures of the mononuclear cationic salts 7 and 8 were confirmed by 
single crystal X-ray diffraction. The crystals were grown by slow diffusion of hexane 
into a concentrated acetone solution of the salts. The complexes 7 and 8
 
crystallize in 
the triclinic and orthorhombic space groups P -1 and P 212121 respectively. The 
crystal analysis shows the ruthenium atom possess the “three-leg piano-stool”, 
pseudo-tetrahedral geometry in both structures.11 Similar to the neutral mononuclear 
complexes (1, 2), the arene ring (p-cymene or hexamethylbenzene) represents the 
“seat” and, coordinated to the metal centre are the pyridyl-nitrogen, imine- nitrogen 
atoms and single chlorido atom, which are the “legs”. ORTEP drawings of the 
mononuclear cationic salts 7 and 8 are shown (Fig. 3.9), with the crystallographic 
data listed (Table 3.13) and selected bond lengths and angles tabulated (Table 3.14). 
 
Figure 3.9: The ORTEP structures of the cationic salts 7 (left) and 8 (right), counter-
ions (PF6) have been omitted for clarity. 
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Table 3.13: Crystallographic and structure refinement parameters for mononuclear 
cationic salts 7 and 8. 
 
Complex 7 8 
Chemical formula C19H26ClF6N2PRu C21H30ClF6N2PRu 
Formula weight (g /mol) 563.91 591.96 
Crystal colour and shape Orange block Orange block 
Crystal size (mm) 0.26 x 0.23 x 0.18 0.24 x 0.21 x 0.16 
Crystal system Triclinic Orthorhombic 
Space group P -1 P 212121 
a (Å) 9.1490(9) 12.4312(10) 
b (Å) 9.8468(9) 13.1480(12) 
c (Å) 12.2766(12) 14.1942(10) 
α (o) 81.583(11) 90.00 
β (o) 79.178(11) 90.00 
γ (o) 83.705(11) 90.00 
V (Å3) 1070.76(18) 2320.0(3) 
Z 2 4 
T (K) 293(2) 293(2) 
Wavelength λ (Å) 0.71073 0.71073 
Density Dχ (g /cm3) 1.749 1.695 
Absorption coefficient µ (mm-1) 0.992 0.920 
F(000) 568 1200 
Scan range (o) 2.27 < θ < 26.05 2.11 < θ < 26.18 
Unique reflections 7931 12015 
Reflections used [l > 2σ(l)] 3927 4563 
Rint 0.0244 0.0501 
Final R indices [l > 2σ(l)]a 0.0238, wR2 0.0589 0.0335, wR2 0.0617 
R indices (all data) 0.0305, wR2 0.0725 0.0525, wR2 0.0671 
Goodness-of-fit (GOF) 1.152 0.929 
Maximum, Minimum ∆ρ (e Å-3) 0.641, -0.673 0.710, -1.485 
a
 Structures were refined on F02: wR2 = [Σ[w(F02 - Fc2)2] / Σ w(F02)2]1/2,  
where w-1 = [Σ (F02) + (aP)2 + bP] and P = [max(F02, 0) + 2Fc2]/3. 
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Table 3.14: Selected bond lengths (Å) and angles (o) for cationic complexes 7 and 8. 
 
Complex 7 8 
 Distances (Å) 
Ru(1)-C(10) 2.228(3) 2.260(4) 
Ru(1)-C(11) 2.209(3) 2.230(4) 
Ru(1)-C(12) 2.176(3) 2.208(4) 
Ru(1)-C(13) 2.197(3) 2.255(4) 
Ru(1)-C(14) 2.212(3) 2.198(4) 
Ru(1)-C(15) 2.193(3) 2.206(4) 
Ru(1)-Cl(1) 2.3910(7) 2.3979(10) 
Ru(1)-N(1) 2.079(2) 2.097(4) 
Ru(1)-N(2) 2.076(2) 2.089(4) 
N(2)-C(7) 1.464(4) 1.465(6) 
N(2)-C(6) 1.283(4) 1.277(6) 
C(6)-C(5) 1.444(4) 1.433(6) 
   
 Angles (o) 
N(1)-Ru(1)-N(2) 76.50(14) 77.00(9) 
N(1)-Ru(1)-Cl(1) 82.76(10) 86.42(6) 
N(2)-Ru(1)-Cl(1) 88.00(10) 85.67(6) 
 
The bond distances of the Ru-Npyr and Ru-Nimine of complex 7 (2.079(2) Å and 
2.076(2) Å) are comparable to the bond distances of the Ru-Npyr and Ru-Nimine of the 
hexamethylbenzene derivative of complex 8
 
(2.097(4) Å and 2.089(4) Å). Similarly 
the bond angles of Npyr-Ru-Nimine, Npyr-Ru-Cl and Nimine-Ru-Cl of complex 7  
(76.50(14) o, 82.76(10) o and 88.00(10) o) are comparable to the bond angles of Npyr-
Ru-Nimine, Npyr-Ru-Cl and Nimine-Ru-Cl of complex 8 (71.09(9) o, 86.42(6) o and 
85.67(6) o). The bond distance and angles of both complexes 7 and 8
 
are 
comparable to similar known cationic complexes synthesized by the Kollipara 
group.12-14 The crystal analysis thus confirms mode of coordination of the ruthenium 
metal centre. 
A hydrogen bond is observed in the crystal packing of the cationic salt 8, between the 
CHimine group and the chloride atom of an adjacent molecule (Fig. 3.10). The 
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hydrogen bonding gives rise to infinite one-dimensional chains in the crystal. In the 
cationic salt 8 the C···Cl distance is 3.697(5) Å and the C-H···Cl angle 153.6 °. 
However, this was not observed in the crystal packing of cationic salt 7, with the 
CHimine group slightly protected by the propyl chain. The chloride atom (cationic salt 
7) interacts weakly with a CH group of the arene ring (adjacent molecule), whilst the 
CHimine group interacts with two fluorine atoms of the PF6 counter-ion. 
 
Figure 3.10: Crystal packing of cationic salt 8 illustrating the infinite one-dimensional 
chains. 
 
3.4 Synthesis of neutral salicylaldimine mononuclear and dendritic 
ruthenium(II) arene complexes (13 -18) 
 
In synthesizing new neutral chelating bidentate ruthenium(II) arene complexes, 
salicylaldimine N,O- ligands L7, L8 and L9 were complexed with the particular 
ruthenium dimer ([Ru(η6-p-PriC6H4Me)Cl2]2 or [Ru(η6-C6Me6)Cl2]2). The method of 
complexation involved the stirring of a solution of the ligand (L7, L8, L9), with a weak 
base (Et3N), to assist in deprotonation of the ligand. Deprotonation of the ligand was 
followed by the addition of the ruthenium dimer in ethanol at room temperature. The 
reactions involving the dendrimers were generally allowed to proceed for 15 hours 
(with second generations proceeding overnight) and the mononuclear reactions 
proceeding for a shorter period (Scheme 3.4). In the synthesis of complexes 13 - 18, 
m equivalents (where m = 2 for 13 and 14; m = 0.5 for 15 and 16; m = 0.25 for 17 
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and 18) of the ligand (L2 for 13 and 14; L5 for 15 and 16; L6 for 17 and 18) were 
added to a solution of the ruthenium dimer ([Ru(η6-p-PriC6H4Me)Cl2] for 13, 15, 17;  
[Ru(η6-C6Me6)Cl2]2  for 14, 16, 18) in ethanol or tetrahydrofuran (Scheme 3.4). 
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Scheme 3.4: Outline synthesis of neutral ruthenium(II) arene complexes (13  - 18). 
 
This complexation was first carried out without the addition of the base. The starting 
material was stirred in ethanol at room temperature and then in a separate reaction, 
at an elevated temperature, with both reactions yielding no product. A weak base 
(Et3N) was then added to promote the reaction, with the base removing the phenolic 
proton from the aromatic ring (Scheme 3.5). 
 
O
H
Et3N
O-
Et3N+
H
Deprotonation Reaction
 
Scheme 3.5: Mechanism of the deprotonation of a phenolic proton. 
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The complexation reactions yielded two new mononuclear (13, 14) and four new 
multinuclear (15 - 18) ruthenium(II) arene complexes. The salicylaldimine ligands  
(L7 - L8) chelate to the ruthenium metal centre, via the N- and O- donor atoms, 
yielding a neutral 6-membered ring complex. 
 
3.4.1 Physical properties 
The complexes were dried and isolated as dark orange solids in moderate yields, 
and were found to be thermally stable (Table 3.15). 
 
Table 3.15: Physical appearance, percentage yield and melting points for complexes 
10 - 15. 
 
Complex Physical  Appearance 
Yield  
(%) 
Melting Point  
(oC) 
10 Red-brown solid 43 150-152 
11 Red-orange 74 205-208 
12 Orange-brown solid 88 161-164 
13 Dark orange solid 87 186-188 
14 Red-orange solid 60 172a 
15 Mustard-yellow solid 66 177a 
aDecompose without melting into a black solid 
 
The chelating N,O- ruthenium(II) arene complexes 13 - 18 are non-hygroscopic,  
air-stable and soluble in dimethylsulfoxide, acetone, acetonitrile, tetrahydrofuran, 
dichloromethane, chloroform, toluene, ethanol, methanol and insoluble in diethyl 
ether and hexane. 
 
3.4.2 1H-NMR and 13C{1H}-NMR spectroscopy 
The proposed chelation of the ruthenium metal centre to the N- and O- atoms were 
confirmed by 1H-NMR spectroscopy.  The 1H-NMR spectra (Fig. 3.11) of 
mononuclear complexes 13 and 14 were run in chloroform-d and showed 
characteristic peaks for the coordination of the ligand L7 and the ruthenium precursor 
([Ru(η6-p-PriC6H4Me)Cl2] or [Ru(η6-C6Me6)Cl2]2). 
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Figure 3.11: 1H-NMR spectra of salicylaldimine ligand L7 (top), mononuclear 
complexes 13 (middle) and 14 (bottom). 
 
A similar pattern is seen in the 1H-NMR spectra (Fig. 3.12) of the dendritic complexes 
15 - 18. The 1H-NMR spectra of the dendritic complexes showed broadened peaks 
(similar to that of the previously mentioned dendritic complexes), with many of the 
peaks overlapping and/or coalescing, due to the multinuclear nature of these 
complexes. 
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Figure 3.12: 1H-NMR spectra of salicylaldimine dendritic ligand L8 (top), dendritic 
complexes 15 (middle) and 16 (bottom). 
 
As a result of the ruthenium-arene moiety coordinating to both the imine and oxygen 
atom, there is a shift in both the imine proton and protons on the aromatic ring for all 
complexes 13 - 18. Similar to the cationic salts, upon coordination of the ruthenium-
arene moiety to the ligand, the ruthenium metal centre becomes chiral. The newly 
formed chiral centre is due to the coordination of four different groups on the 
ruthenium metal centre. The diastereotopic nature of the protons on the aliphatic 
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chain of the mononuclear complexes 13 and 14 further confirms the presence of the 
chiral centre. Both sets of diastereotopic protons, on each carbon (carbon 2 and 3), 
show two sets of multiplets in the ranges 1.6 - 2.1 ppm and 3.7 - 4.2 ppm for 
complexes 13 and 14. The diastereotopic protons on the dendritic arms of complexes 
(15 - 18), adjacent to the imine nitrogen, show the same effect as their mononuclear 
counterparts. Two broad multiplets for the first generation complexes (15 and 16), 
between 4.0 - 4.5 ppm are seen and a very broad multiplet for the second generation 
complexes (17 and 18) between 4.0 - 4.5 ppm is also noted. 
 
p-Cymene complexes (13, 15, 17) 
In the 1H-NMR spectrum of complex 13, the methyl protons on the isopropyl group 
(on the p-cymene ring), exhibit one doublet per methyl group, each of the doublets 
integrated for three protons. This could be due to the lack of rotation of the  
p-cymene ring, similar to that of the cationic salts previously mentioned. Two broad 
multiplets were observed for the dendritic complexes (15 and 17) at ~1.0 ppm and 
~1.1 ppm and were assigned the diastereotopic methyl protons of the isopropyl 
group.  
A multiplet for complex (13) and a broader multiplet for complexes (15 and 17) were 
observed between 3.0 - 3.3 ppm and were assigned to the single proton of the 
isopropyl group (Table 3.16).  
The doublet and the multiplet observed at 5.0 ppm and 5.4 ppm respectively (10), 
correspond to the aromatic protons of the p-cymene ring. The dendritic complexes 
(15 and 17) show two doublets assigned to the aromatic protons of the p-cymene 
ring. Similar to the cationic salts, the splitting pattern can be explained due to the 
long range coupling with the isopropyl protons (Table 3.16).  
 
Hexamethylbenzene complexes (14, 16, 18) 
A singlet, integrating for 18 protons, is seen in the 1H-NMR spectrum of complex 14 
at 2.0 ppm, and was assigned to the methyl protons of the hexamethylbenzene ring 
(Table 3.16). Similarly, the dendritic complexes (16 and 18) show a singlet peak at 
1.7 ppm and 1.9 ppm respectively, and were assigned to the methyl protons of the 
hexamethylbenzene ring (Table 3.16). 
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Table 3.16: Selected 1H-NMR data for complexes 13 - 18. 
 
Complex Imine Proton(s) (ppm) 
Aromatic 
Protons (ppm) 
Arene Ring 
(ppm) 
13 7.7 6.4-7.1 1.17; 1.9-2.8; 5.0-5.4 
14 7.7 6.4-7.1 1.96 
15 8.0 6.4-7.1 1.12; 2.2-3.2; 5.2-5.4 
16 8.1 6.4-7.1 1.71 
17 8.1 6.4-7.2 1.10; 2.2-3.3; 5.3-5.5 
18 8.1 6.4-7.2 1.94 
 
The 1H-NMR spectrum showed upfield shifts of the imine and aromatic protons, due 
to coordination of the ruthenium metal. The disappearance of the broad peak  
(~ 13.5 ppm) assigned to the hydroxyl proton of the free ligand (L7, L8, L9), confirms 
coordination of the ruthenium metal to both imine nitrogen and the phenolic oxygen. 
 
13C{1H}-NMR spectra of the neutral chelating complexes (13 - 18) were run in 
chloroform-d
 
and were found to be very similar, with extra signals seen in the  
13C{1H}-NMR spectra, these were assigned to the carbons of the aliphatic side arms 
(Table 3.17). The 13C{1H}-NMR spectrum of the mononuclear complexes (13 and 14) 
is similar to the 13C{1H}-NMR spectrum of the monomeric ligand L2, with shifts seen 
in the signals that were assigned to the imine and pyridyl carbons, as a result of 
coordination to the ruthenium metal centre (Table 3.17).  
 
Table 3.17: Selected 13C{1H}-NMR data for complexes 13 - 18. 
 
Complex Imine Carbon(s) (ppm) 
Aromatic 
Carbons (ppm) 
Arene Ring 
(ppm) 
13 164 114-165 19-23; 31-102 
14 165 114-166 16; 91 
15 165 114-165 19-23; 31-100 
16 165 114-166 16; 91 
17 165 114-165 19-23; 31-100 
18 165 114-166 16; 91 
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13C{1H}-NMR spectra of  the neutral chelating complexes (13 - 18) showed chemical 
shifts of its aromatic carbons in the range of 114 - 165 ppm. The 13C{1H}-NMR 
spectra of the p-cymene complexes (13, 15, 17) showed a range of signals between 
19 - 23 ppm and 31 - 102 ppm. The 13C{1H}-NMR spectra of the hexamethylbenzene 
complexes (14, 16, 18) showed signals at 16 and 91 ppm. 
 
3.4.3 Infrared (IR) spectroscopy 
Further confirmation for the coordination of the ruthenium metal centre can be seen 
from the IR spectra of the complexes (13 - 18). A distinct shift in the imine stretching 
frequency from ~1635 cm-1 (for the ligand) to ~1620 cm-1 for the complexes (13 - 18) 
is seen (Table 3.18). 
 
Table 3.18: Selected IR absorption bands for complexes 13 - 18. 
 
Complex (C=N)imine  (cm-1) 
13 1624 
14 1624 
15 1621 
16 1618 
17 1621 
18 1618 
 
3.4.4 Elemental analysis and mass spectrometry 
Elemental analysis data of the new mononuclear neutral chelating complexes 13 and 
14 were found to correlate with the calculated values. The dendritic complexes were 
found to be inconsistent with theoretical values. Thus, calculated values were 
recalculated with the inclusion of solvent molecules (dichloromethane). This brought 
the found values in direct correlation with calculated values. 
Due to the various sizes of the complexes, mononuclear complexes were sent for 
electron spray mass spectrometry, whilst the larger dendritic complexes were sent for 
MALDI-TOF mass spectrometry. Mass spectrometry data further supported 
elemental analysis data for the neutral chelating complexes (14 - 18), which showed 
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[M-Cl]+ as the highest molecular weight fragment but mononuclear complex 13 gave 
[C20H23NRuClO]+ as the highest molecular weight fragment (Table 3.19). 
 
Table 3.19: Mass spectrometry data for 13 - 18. 
 
Complex 
Calculated 
Molecular Mass 
(g/mol) 
Molecular 
Fragment (m/z) Assignment 
13 433.0 430 [C20H23NRuClO]+ 
14 461.0 426 [M-Cl]+ 
15 1812.5 1777 [M-Cl]+ 
16 1923.5 1888 [M-Cl]+ 
17 3800.5 3765 [M-Cl]+ 
18 3990.5 3955 [M-Cl]+ 
 
3.4.5 X-ray crystallography 
The neutral mononuclear chelating complex 14 was structurally characterized by 
single crystal X-ray crystallography. The crystals were grown by slow diffusion of 
diethyl ether into a concentrated dichloromethane/methanol (5:1) solution of complex 
14. Crystals of complex 14 were isolated as orange crystalline plates, in the 
monoclinic space group P 21/c. The ruthenium centre of the mononuclear structure 
shows the typical “three-leg piano-stool”, pseudo-tetrahedral geometry.11 Similar to 
the cationic mononuclear complexes 7 and 8, the arene ring (hexamethylbenzene) 
represent the “seat” and, bound by the oxygen and imine- nitrogen are the bidentate 
and single chlorido ligands, which are the “legs”. The ORTEP drawing of the neutral 
mononuclear complex 14 is shown (Fig. 3.13), with the crystallographic data listed 
(Table 3.20) and selected bond lengths and angles tabulated in Table 3.21. 
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Figure 3.13: The ORTEP structure of the mononuclear salicylaldimine complex 14. 
 
The salicylaldimine mononuclear complex 14 is essentially a planar molecule, with 
the arene moiety being the only substituent out of the plane. Complex 14 has bond 
distances of the Ru-Nimine and Ru-O being 2.078(15) and 2.085(10) Å respectively. 
The ruthenium atom is π bonded to the hexamethylbenzene ligand with Ru-C 
distances ranging from 2.160(14) to 2.236(13) Å. The Ru-Cl distance in complex 14 
(2.429(5) Å) is slightly longer than the cationic salts 7 (2.3910(7)) and 8 (2.3979(1) 
Å). The bond distances and angles of complex 14
 
are comparable to similar known 
N,O- complexes.16,17 The crystal analysis confirmed the mode of coordination of the 
ruthenium metal centre. 
 
As seen for the cationic salt 8, the mononuclear complex 14 showed a hydrogen 
bond between the CHimine group and the chloride atom of a neighbouring molecule; 
giving rise to infinite one-dimensional chains (Fig. 3.14). In complex 14, the hydrogen 
bond C-H···Cl distance is 3.557(17) Å with a C-H···Cl angle of 135.5°. 
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Table 3.20: Crystallographic and structure refinement parameters for mononuclear 
salicylaldimine complex 14. 
 
Complex 14 
Chemical formula C22H30ClNORu 
Formula weight (g /mol) 460.99 
Crystal colour and shape Orange plate 
Crystal size (mm) 0.18 x 0.15 x 0.07 
Crystal system Monoclinic 
Space group P 21/c 
a (Å) 7.620(2) 
b (Å) 21.340(4) 
c (Å) 12.830(3) 
α (o) - 
β (o) 99.67(3) 
γ (o) - 
V (Å3) 2056.7(8) 
Z 4 
T (K) 173(2) 
Wavelength λ (Å) 0.71073 
Density Dχ (g /cm3) 1.489 
Absorption coefficient µ (mm-1) 0.903 
F(000) 952 
Scan range (o) 1.37 < θ < 26.63 
Unique reflections 5350 
Reflections used [l > 2σ(l)] 1814 
Rint 0.3647 
Final R indices [l > 2σ(l)]a 0.1373, wR2 0.3016 
R indices (all data) 0.2884, wR2 0.3898 
Goodness-of-fit (GOF) 0.937 
Maximum, Minimum ∆ρ (e Å-3) 1.620, -1.563 
a
 Structures were refined on F02: wR2 = [Σ[w(F02 - Fc2)2] / Σ w(F02)2]1/2,  
where w-1 = [Σ (F02) + (aP)2 + bP] and P = [max(F02, 0) + 2Fc2]/3. 
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Table 3.21: Selected bond lengths (Å) and angles (o) for mononuclear salicylaldimine 
complex 14. 
 
Complex 14 
Distances (Å) 
Ru(1)-C(11) 2.160(14) 
Ru(1)-C(12) 2.236(13) 
Ru(1)-C(13) 2.225(13) 
Ru(1)-C(14) 2.175(12) 
Ru(1)-C(15) 2.195(13) 
Ru(1)-C(16) 2.192(13) 
Ru(1)-Cl(1) 2.429(5) 
Ru(1)-N(1) 2.078(15) 
Ru(1)-O(1) 2.085(10) 
N(1)-C(4) 1.295(16) 
C(4)-C(5) 1.410(19) 
  
Angles (o) 
N(1)-Ru(1)-Cl(1) 86.4(5) 
O(1)-Ru(1)-Cl(1) 85.2(4) 
O(1)-Ru(1)-N(1) 84.5(5) 
 
 
 
Figure 3.14: Crystal packing of mononuclear complex 14 illustrating the infinite one-
dimensional chains. The hydrogen atoms are omitted for clarity. 
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3.5 Conclusions 
 
In the pursuit of synthesizing new multinuclear dendritic ruthenium(II) arene 
complexes, a series of air-stable monodentate N- donor and chelating, bidentate 
N,N- and N,O- donor ruthenium(II) arene metallodendrimers were prepared. These 
new dendritic complexes were fully characterized using spectroscopic and analytical 
techniques, namely 1H-NMR, 13C{1H}-NMR, IR spectroscopy, and elemental analysis 
and mass spectrometry. X-ray crystallography experiments were employed on the 
mononuclear complexes to further confirm the mode of coordination of the 
ruthenium-arene moiety and proposed structures. 
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Chapter 4 
In Vitro Biological Evaluation of Multinuclear Ruthenium(II) Arene  
Complexes of Pyridyl-imine and Salicylaldimine Dendritic Ligands 
 
4.1 Introduction 
 
It is believed that organometallic complexes are known for their toxicity and 
instability, decomposing when exposed to air and/or water. This observation has 
been misinterpreted, as there are an increasing number of air-stable and water-
soluble complexes in the literature, and ruthenium(II) arene complexes are such 
examples.1 Despite the fact that ruthenium(II) arene compounds have a low general 
toxicity and have a high selectivity for cancer cells, the main reason for their design 
are the amphiphilic properties of the arene-ruthenium unit, in the form of the 
hydrophobic arene ligand and the hydrophilic ruthenium metal centre. The arene ring 
is said to stabilize the metal oxidation state and gives the complex a lipophilic 
property, whilst the halide ligand is labile and undergoes hydrolysis in aqueous 
media. Aquation is believed to be the key aspect in the biological activity of the  
[(η6-arene)Ru(en)Cl]+ (en = ethylenediamine) complex (Fig. 4.1).2 
 
 
Figure 4.1: Hydrolysis of [(η6-p-PriC6H4Me)Ru(en)Cl]+ (en = ethylenediamine) in 
water at a 10 µM concentration. 
 
The mechanism of action of arene-ruthenium complexes is generally thought to 
involve hydrolysis of the Ru-X bond resulting in an active Ru-OH2 species.3 
Ruthenium(II) arene complexes provide an excellent substrate for the coupling of 
organic drugs to the ruthenium moiety in targeted chemotherapy. 
 
Chapter 4  Biological Evaluation 
 94 
The development of multinuclear complexes as anticancer agents has recently also 
generated tremendous interest. The platinum-based trinuclear complex [trans, trans, 
trans-(NH3)2Pt(Cl)NH2(CH2)6NH2Pt(NH3)2NH2(CH2)6NH2Pt-(NH3)2(Cl)][NO3]4 
(BBR3464, Fig. 4.2) showed higher in vitro cytotoxicity than its mononuclear 
analogue and cisplatin.4 Though phase II trials of BBR3464 were not pursued 
further,5 the concept that multinuclearity could assist in the improvement of the 
potency of potential anticancer drugs was established. 
 
 
Figure 4.2: The trans-platinum(II)-based trinuclear complex (BBR3464). 
 
Compared to multinuclear platinum complexes, analogous multinuclear 
organometallic ruthenium compounds have been less studied for their anticancer 
properties, with just a few examples to be found in the literature.6-9 
 
More recently, the in vitro anticancer activity of a series of mono-, di- and trinuclear 
ruthenium(II) p-cymene complexes has been investigated on SW480 and A2780 cell 
lines, with the dinuclear complex proving to be the most active, probably by cross-
linking biomacromolecules (Fig. 4.3).10,11 
 
4+ 
BBR3464 
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Figure 4.3: Dinuclear, mononuclear and trinuclear ruthenium(II) arene anticancer 
compounds. 
 
The relative size of metallodendrimers implies that they may exploit the ‘enhanced 
permeability and retention’ (EPR) effect, a phenomenon in which macromolecules 
accumulate at the tumour site due to an increase in blood vessel permeability within 
diseased tissues compared to normal tissues.12 The increase in the local 
concentration of transition metals in the metallodendrimer endows them with several 
advantages in the field of catalysis such as, enhanced catalytic activity compared to 
their mononuclear analogues.13-15 With these two aspects in mind, the in vitro 
biological activity of the synthesized ruthenium(II) arene complexes (1 - 18) (Fig. 4.4) 
in the A2780 cell line were investigated, and selected complexes were tested in the 
cisplatin resistant (A2780cisR) cell line. 
 
This chapter describes the biological activity, of the synthesized mononuclear and 
multinuclear ruthenium(II) arene complexes, against the cisplatin sensitive (A2780) 
and cisplatin resistant (A2780cisR) human ovarian cancer cells. Interactions of the 
two most highly cytotoxic ruthenium(II) arene complexes with DNA were also 
investigated, in the form of DNA binding experiments. 
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Figure 4.4: Synthesized ruthenium(II) arene complexes (1 - 18
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4.2 Influence of the number of ruthenium centres: mono- vs. tetra- vs. 
octanuclear 
 
The poly(propyleneimine) dendritic scaffolds (L3 - L6, L8, L9) were chosen to exploit 
the number of metal sites, on one substrate, entering the cancerous cell.  The 1st and 
2nd generation derivatives (3 - 6) and their mononuclear analogues (1, 2) of the 
monodentate 4-pyridyl-imine series were compared, following their biological 
evaluation in the A2780 cell line (Table 4.1). These findings have been recently 
published.16 
 
Table 4.1: IC50 values of synthesized monodentate 4-pyridyl-imine ruthenium(II) 
complexes tested against A2780 human ovarian cancer cells. 
 
(IC50, µM) Compound na Arene 
A2780 
4-Pyridyl-imine   
 
1 1 p-CYE 98 ± 5.0 
2 1 HMB 94 ± 5.0 
3 4 p-CYE 43 ± 5.0 
4 4 HMB 40 ± 5.0 
5 8 p-CYE 21 ± 5.0 
6 8 HMB 20 ± 5.0 
    
Cisplatin 1 - 1.5 
a
 Number of metals within the compound 
 
The second generation derivatives (5, 6) with 8 arene-ruthenium moieties within the 
complex show the greatest activity (IC50 ~ 20 µM), followed by the first generation 
derivatives (3, 4) with 4 arene-ruthenium moieties (IC50 ~ 41 µM). The mononuclear 
derivatives (1, 2) with only 1 arene-ruthenium moiety showed no remarkable activity 
(IC50 > 90 µM). The trend seen within the 4-pyridyl series confirms the hypothesis 
that functionalization with the ruthenium-arene moiety and increasing the metal 
content of higher dendritic generations will lead to an increase in the biological 
activity of the complexes. 
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The bidentate chelating ruthenium(II) arene  N,N- series (12) and N,O- series (17, 18) 
show the best activity of the ruthenium(II) dendritic series (Table 4.2). The biological 
activity of the mononuclear ruthenium(II) arene analogues (1, 2, 7, 8, 13, 14) are 
lower and drop further with the tetranuclear derivatives (3, 4, 9, 10, 15, 16), when 
comparing them to the activity of the octanuclear complexes (5, 6, 11, 12, 17, 18) 
(Table 4.2). 
 
Table 4.2: IC50 values of synthesized bidentate 2-pyridyl-imine and salicylaldimine 
ruthenium(II) complexes on A2780 human ovarian cancer cells. 
 
(IC50, µM) Ru(II) 
Compound n
a Arene 
A2780 A2780cisR 
2-Pyridyl-imine (N,N-) 
  
7 1 p-CYE > 200 > 200 
8
 
1 HMB > 200 > 200 
9
 
4 p-CYE > 200 > 200 
10 4 HMB 32 ± 1.6 42 ± 5.1 
11 8 p-CYE 23 ± 2.1 76 ± 9.4 
12 8 HMB 4 ± 1.3 4 ± 0.3 
Salicylaldimine (N,O-) 
  
13 1 p-CYE 49 ± 2.3 47 ± 0.8 
14 1 HMB 19 ± 1.8 18 ± 0.8 
15 4 p-CYE 50 ± 1.4 52 ± 0.8 
16 4 HMB 27 ± 1.3 25 ± 1.3 
17 8 p-CYE 22 ± 1.2 15 ± 1.4 
18 8 HMB 10 ± 0.3 9 ± 0.3 
   
  
Cisplatin 1 - 1.5 25 
a
 Number of metals within the compound 
 
The IC50 values of the bidentate chelating N,N- and N,O- ruthenium(II) arene 
complexes were also evaluated against the cisplatin resistant cell line (Table 4.2). A 
similar trend is seen to the non-cisplatin resistant cell line, however, the higher 
generations (8 arene-ruthenium metal centres) displayed the greatest activity. A 
more interesting observation are the results of the octanuclear complexes (11, 12, 
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17, 18) when comparing them to cisplatin, a platinum based drug currently used to 
fight most carcinomas. In the A2780 cell line, the second generation ruthenium(II) 
arene complexes (12: IC50 = 4 µM, 18: IC50 = 10 µM) were approximately 3 folds 
lower in biological activity compared to that of cisplatin (IC50 = 1.5 µM). However, the 
biological activity of the second generation ruthenium(II) arene complexes  
(12: IC50 = 4 µM, 17: IC50 = 15 µM, 18: IC50 = 9 µM) against the A2780cisR cell line, 
showed more potency than cisplatin (IC50 = 25 µM). The octanuclear N,O- bidentate 
complexes (17, 18) were found to show high cytotoxicity compared to similar 
mononuclear N,O- bidentate complexes reported by Grgurić-Šipka et al.17 
 
Analysis of the biological results obtained for each cell line (A2780 vs. A2780cisR) 
showed another trend. Comparing the biological values of the synthesized 
ruthenium(II) arene complexes (7 - 18) for each cell line (A2780 & A2780cisR), It was 
found that very similar values were obtained. This suggests that the mechanism of 
action followed by the mononuclear (7, 8, 13, 14) and dendritic  
(9 - 12, 15 - 18) ruthenium(II) arene complexes is different to that of the mechanism 
of action followed by cisplatin. 
 
4.3 Influence of the arene ring: p-cymene vs. hexamethylbenzene 
 
In the synthesis of the ruthenium(II) arene complexes, two types of arene ring 
systems, p-cymene and hexamethylbenzene, were used. Their antiproliferative 
activity as a function of the arene ring was investigated (Table 4.3).  
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Table 4.3: IC50 values of synthesized ruthenium(II) complexes against the A2780 
human ovarian cancer cell line. 
 
(IC50, µM) Ru(II) 
Compound n
a Arene 
A2780 
4-Pyridyl-imine   
 
1 1 p-CYE 98 ± 5.0 
2 1 HMB 94 ± 5.0 
3 4 p-CYE 43 ± 5.0 
4 4 HMB 40 ± 5.0 
5 8 p-CYE 21 ± 5.0 
6 8 HMB 20 ± 5.0 
2-Pyridyl-imine (N,N-) 
7 1 p-CYE > 200 
8
 
1 HMB > 200 
9
 
4 p-CYE > 200 
10 4 HMB 32 ± 1.6 
11 8 p-CYE 23 ± 2.1 
12 8 HMB 4 ± 1.3 
Salicylaldimine (N,O-) 
13 1 p-CYE 49 ± 2.3 
14 1 HMB 19 ± 1.8 
15 4 p-CYE 50 ± 1.4 
16 4 HMB 27 ± 1.3 
17 8 p-CYE 22 ± 1.2 
18 8 HMB 10 ± 0.3 
   
 
Cisplatin 1 - 1.5 
a
 Number of metals within the compound 
 
The arene ring system is another structural feature that is suggested to play an 
important role in the mode of action of ruthenium(II) arene complexes.2,18 In order to 
increase the π- electron density of the ring system of the arene ligand, the p-cymene 
ligand was replaced with hexamethylbenzene, which in turn results in a more 
lipophilic complex.  
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All synthesized ruthenium(II) complexes showed a moderate to high biological 
activity. In the ligand systems (N,N- & N,O-) the ruthenium(II) complexes containing 
the hexamethylbenzene arene ring exhibit a lower IC50 value than their p-cymene 
analogues. Literature suggests that the higher activity observed in 
hexamethylbenzene derivatives are due to the increased uptake of the 
hexamethylbenzene complexes due to the greater lipophilicity of the arene ring. 
 
Such an effect is also seen with the metallarectangles synthesized by Therrien and 
co-workers (Fig. 4.5).19 The p-cymene metallarectangles showed a higher IC50 value 
(A2780 cell line) than their hexamethylbenzene metallarectangles, suggesting 
greater lipophilicity of the hexamethylbenzene derivatives.1 
 
 
Figure 4.5: Molecular structure and IC50 values of ruthenium(II) arene 
metallarectangles. 
 
A similar effect was seen with their ruthenium(II) arene complexes containing the  
2-(pyridine-2-yl)thiazole N,N- chelating ligand (Fig. 4.6), with the hexamethylbenzene 
derivatives showing high antiproliferative activity against the A2780 cell line.20 
IC50 = 66 µM 
IC50 = 27 µM 
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Figure 4.6: Molecular structure and IC50 values of ruthenium(II) arene complexes 
containing the 2-(pyridine-2-yl)thiazole N,N- chelating ligand. 
 
4.4 Influence of the ligand: monodentate vs. bidentate ligand system 
 
Currently there are a few structure-activity relationship studies with ruthenium(II) 
arene complexes. Dyson and co-workers have shown that variation in the arene 
ligand system and/or the monodentate or bidentate ligand does influence the 
antiproliferative activity of these complexes.21 In comparing the two systems, the  
4-pyridyl-imine (monodentate) and the N,N- and N,O- (bidentate) systems, the 
bidentate systems show higher biological activity (Table 4.3). The second generation 
bidentate derivatives (12: IC50 = 4 µM, 18: IC50 = 10 µM) show a higher activity over 
the second generation monodentate derivatives (6: IC50 = 20 µM, 5: IC50 = 21 µM). 
  
Variation on the bidentate chelating (N,N- vs. N,O-) system generated cationic  
(7 - 12) and neutral (13 - 18) complexes. The effects on the biological activity of the 
complexes were evaluated on the A2780 and A2780cisR cell lines (Table 4.6). The 
mononuclear cationic salts (7, 8: IC50 > 200 µM) show no activity in comparison to 
the mononuclear N,O- complexes (13: IC50 = 49 µM, 14: IC50 = 19 µM). The cationic 
dendritic salts (10, 11) show moderate antiproliferative activity compared to the 
salicylaldimine dendritic complexes (15 - 17), however the octanuclear cationic salt 
(12: IC50 = 4 µM) showed a much lower IC50 value than the neutral octanuclear 
complex (18: IC50 = 10 µM) for both cell lines.  
IC50 > 300 µM 
IC50 = 258 µM 
IC50 = 182 µM 
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The low activity of the mono- (7, 8) and tetranuclear (9, 10) complexes, could be due 
to the poor solubility of the cationic complexes (7 - 12). The PF6 counterion of these 
cationic complexes is believed to give these compounds very poor solubility in the 
aqueous medium, for both the mononuclear (7, 8) and dendritic complexes (9 - 12). 
 
Table 4.6: IC50 values of synthesized N,N- (cationic) and N,O- (neutral) complexes 
on A2780 and A2780cisR human ovarian cancer cells. 
 
(IC50, µM) Ru(II) 
Compound n
a Arene 
A2780 A2780cisR 
2-Pyridyl-imine (N,N-) 
  
7 1 p-CYE > 200 > 200 
8
 
1 HMB > 200 > 200 
9
 
4 p-CYE > 200 > 200 
10 4 HMB 32 ± 1.6 42 ± 5.1 
11 8 p-CYE 23 ± 2.1 76 ± 9.4 
12 8 HMB 4 ± 1.3 4 ± 0.3 
Salicylaldimine (N,O-) 
  
13 1 p-CYE 49 ± 2.3 47 ± 0.8 
14 1 HMB 19 ± 1.8 18 ± 0.8 
15 4 p-CYE 50 ± 1.4 52 ± 0.8 
16 4 HMB 27 ± 1.3 25 ± 1.3 
17 8 p-CYE 22 ± 1.2 15 ± 1.4 
18 8 HMB 10 ± 0.3 9 ± 0.3 
   
  
Cisplatin 1 - 1.5 25 
a
 Number of metals within the compound 
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4.5 DNA binding studies 
 
The second generation, cationic octanuclear N,N- bidentate complex (12: IC50 = 4 
µM) and the second generation neutral octanuclear N,O- complex (18: IC50 = 10 µM) 
showed the highest biological activity of all the synthesized complexes against the 
A2780 human ovarian cancer cell line. As DNA is suggested to be a potential target 
for arene-ruthenium drugs, the interactions of these two highly cytotoxic octanuclear 
complexes 12 and 18 with DNA were investigated.   
 
Gel electrophoresis was employed for the DNA binding studies. It is a technique used 
to separate DNA based on its mobility in an electric field. Mobility of the DNA is 
primarily based on size. Thus, the larger the DNA fragment, the smaller the migration 
band down the gel matrix (agarose gel). Typically, the metal complex is incubated 
with the plasmid DNA and then separated by electrophoresis (Fig. 4.7). The process 
involved the connection of opposite ends of the gel plate to a power source whish is 
used to initiate migration of the DNA. Following electrophoresis, the gel is stained 
with a staining agent (ethidium bromide) and the bands analysed with an ultraviolet 
gel scanner. Incubation of the DNA with the metal complex may result in DNA 
damage which will alter the pattern of migration (i.e. retardation of the band).  
 
 
Figure 4.7: Illustration showing a general setup of gel electrophoresis  
 
Chapter 4  Biological Evaluation 
 105 
DNA binding studies were performed by incubating plasmid DNA in the presence of 
the ruthenium (II) arene complexes (12, 18) and cisplatin for 24 hours at 37°C at 
different metal center/DNA base pair ratios (r = 0.5, 0.25 and 0.125). The 
mononuclear ruthenium(II) arene complexes (8, 14) were also investigated for a 
comparison between the mononuclear and octanuclear analogues. The resulting 
mixtures were separated by gel electrophoresis and the resulting gels are shown in 
Fig. 4.8. 
 
 
 
 
 
 
 
Figure 4.8: Gel electrophoresis of pBR322 plasmid DNA incubated in presence of 
(from left to right on each gel) the N,N-  cationic mononuclear complex 
8 and octanuclear equivalent 12, the N,O- neutral mononuclear 
complex 14 and the octanuclear equivalent 18 and cisplatin (cisPt) for 
24 h at different metal cente to :DNA base pair ratios (r = 0.5, 0.25 and 
0.125). 
 
Using a metal centre to DNA base pair ratio allows the effect of metallodendrimer on 
DNA binding to be compared directly (i.e. the octanuclear complexes (12, 18) are 8 
times less concentrated than their mononuclear analogues (8, 14) and cisplatin). The 
control lane (no metal complex present) shows the migration of unmodified free 
plasmid DNA, which consist of about 5 % open circular (OC) DNA and 95 % 
supercoiled (SC) DNA. The darker the band, the more plasmid DNA present at that 
particular band.  
 
The mononuclear analogues (8, 14) show no visible movement of the DNA species, 
as the plasmid DNA migrates to the same point as the control, suggesting that there 
is no interaction under these conditions. These findings correlate with the low 
biological activity of the mononuclear complexes (8, 14). At r = 0.125 concentration 
(i.e. the metal centre to DNA base pair ratio), the bands were very dark for the 
mononuclear complexes (8, 14), suggesting that the plasmid DNA is binding more 
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readily with the staining agent over the mononuclear complexes (8, 14). Hence, there 
is no interaction between the mononuclear complexes (8, 14) and the plasmid DNA. 
  
At r = 0.5, no bands were visible for both the octanuclear complexes (12, 18). It could 
be that at this concentration and above, the octanuclear complexes (12, 18) are 
competing with the staining agent. For all concentrations (r = 0.5, 0.25 and 0.125), 
the octanuclear complexes (12, 18) show a smaller migration of the plasmid DNA 
relative to the control, which suggests some interaction between the complex (12, 18) 
and DNA species. The cationic N,N- octanuclear complex 12 shows a greater 
interaction with the plasmid DNA over the neutral N,O- octanuclear complex (18). 
These findings further correlate with the IC50 values of these two complexes (12: IC50 
= 4 µM, 18: IC50 = 10 µM). Cisplatin is known to interact with DNA readily, so the 
retarded migrations of cisplatin bands are expected. The cationic octanuclear 
complex (12) at r = 0.125 shows a smaller migration than cisplatin at r = 0.25. 
Therefore, the cationic octanuclear complex (12), the most cytotoxic complex of the 
series, interacts more efficiently with the plasmid DNA than cisplatin, while the neutral 
octanuclear complex (18) exhibits a moderate DNA binding activity. 
 
The reason for ready interaction of the cationic N,N- chelating bidentate octanuclear 
complex (12) with the plasmid DNA is not known. Two possible reasons for this 
interaction is therefore proposed; firstly there exists negatively charged phosphate 
groups on the surface of the DNA helix, which in turn allows electrostatic interactions 
between these groups and the cationic octanuclear complex (12). Secondly, the 
dendritic scaffold of the cationic octanuclear complex (12) resembles that of naturally 
occurring polyamines, which are known for their biological activity.22 Naturally 
occurring polyamines such as spermidine and putrescine have the ability to interact 
with nucleic acids of DNA and inhibit DNA replication.23 Moreover, there could be a 
cooperative effect between these two possible suggestions, resulting in the high 
cytotoxicity and DNA binding of the cationic N,N- octanuclear complex (12). 
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4.6 Conclusions 
 
Following the synthesis of a series of new dendritic ruthenium(II) arene complexes  
(1 -18), their cytotoxicities against A2780 and A2780cisR human ovarian cell lines 
were evaluated. As proposed the second generation cationic N,N- chelating 
bidentate octanuclear complex (12) and neutral N,O- chelating bidentate octanuclear 
complex (18) showed the highest antiproliferative activity against both cell lines. In 
the human ovarian cisplatin resistant cell line (A2780cisR), the cationic N,N- 
chelating bidentate octanuclear complex (12) showed encouraging results as this 
compound displayed higher cytotoxicity than the mononuclear platinum based drug, 
cisplatin.  
 
As a result of an increased lipophilicity of the hexamethylbenzene ruthenium(II) arene 
derivatives, these showed lower IC50 values in comparison with their p-cymene 
analogues. The chelating bidentate complexes displayed a higher biological activity 
over the monodentate derivatives. Nevertheless, some ruthenium compounds were 
shown to have low in vitro activity, but have shown in a number of cases to have 
good antitumor properties against animal models (in vivo studies).24 
 
The interaction of plasmid DNA and the two most cytotoxic octanuclear complexes 
(12, 18), their mononuclear analogues (8, 14) and cisplatin were investigated in the 
form of DNA binding experiments. The cationic N,N- chelating bidentate octanuclear 
complex (12) was found to interact more efficiently with plasmid DNA than cisplatin, 
with the neutral N,O- chelating bidentate octanuclear complex (18) displaying 
moderate interaction. Furthermore, the findings from the DNA binding experiments 
supplement the high cytotoxic data found for these complexes. In addition, these 
experiments showed that the new metallodendrimers appear to operate via a 
different mechanism to that of cisplatin.  
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Chapter 5 
Overall Summary and Future Outlook 
 
5.1 Overall summary 
 
A series of first- and second- generation end-group modified monodentate and 
chelating bidentate poly(pyridylimine) dendritic ligands were prepared. These 
dendritic ligands were fully characterized using a range of spectroscopic and 
analytical techniques. 
 
The synthesized dendritic ligands were coupled with ruthenium(II) arene precursors 
to afford air-stable monodentate N- donor and chelating, bidentate N,N- and N,O- 
donor ruthenium(II) arene multinuclear metallodendrimers, which were characterised 
using analytical and spectroscopic methods. 
 
Mononuclear analogues of the ruthenium(II) arene metallodendrimers were 
synthesized and characterized. The molecular structures of the mononuclear 
ruthenium(II) arene complexes were determined using single crystal X-ray 
crystallography. 
 
Subsequent to the synthesis of the ruthenium(II) arene metallodendrimers, their 
cytotoxicities against A2780 and A2780cisR human ovarian cell lines were evaluated. 
The second generation cationic N,N- and neutral N,O- chelating bidentate 
octanuclear hexamethylbenzene complexes showed the highest antiproliferative 
activity against both cell lines.  The cationic N,N- chelating bidentate octanuclear 
hexamethylbenzene metallodendrimer displayed higher cytotoxicity than cisplatin in 
the cisplatin resistant cell line (A2780cisR). 
 
The two most cytotoxic octanuclear metallodendrimers, their mononuclear analogues 
and cisplatin were further investigated in the form of DNA binding experiments. The 
cationic N,N- chelating bidentate octanuclear hexamethylbenzene metallodendrimer 
was found to interact well with plasmid DNA over cisplatin. Additionally, the DNA 
binding experiments have supplemented the high antiproliferative data shown for 
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these metallodendrimers and that these new metallodendrimers operate via a 
different mechanism to that of cisplatin. Hence, this study has shown a definite 
correlation between the size of the metallodendrimer, DNA damage and cytotoxicity. 
 
5.2 Future outlook 
 
The project has shown great scope in the field of ruthenium-arene metallodendrimers 
as biological agents. Functionalizing higher generations of the poly(pyridylimine) 
dendritic scaffold with the ruthenium(II) arene moiety may in turn show enhanced 
biological activity. Moreover, the introduction of a water soluble dendritic scaffold may 
play a role in increasing the antiproliferative activity of these complexes, such as 
replacing the DAB dendritic scaffold with the PAMAM dendritic scaffold.1 
 
Introducing water soluble ligands to the ruthenium-arene moiety, such as replacing 
the chlorido ligand with a water soluble phosphine ligand (e.g. PPh3 or PTA), may 
increase the water solubility of these complexes which in turn may result in lower IC50 
values.2 One of the more obvious alterations to the ruthenium-arene moiety is 
changing the arene ring to a more extended ring, such as introducing the 
tetrahydroanthracene ring which has shown to have good antiproliferative activity,3 or 
the biphenyl ring which has shown to improve lipophilicity.3 
 
Further biological experiments need to be achieved to clearly confirm possible drug 
targets for these ruthenium(II) arene metallodendrimers. Such biological experiments 
may include cell uptake studies, cell fractionation or imaging studies (ruthenium 
distribution).4 
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Chapter 6 
Experimental Details 
 
6.1 General remarks 
 
All reactions were performed under an inert atmosphere using a dual 
vacuum/nitrogen line and standard Schlenk-line techniques. All reaction solvents 
were dried by refluxing under an inert atmosphere over the appropriate drying agent 
and all samples were dried under vacuum.  
 
2-pyridinecarboxaldehyde, 4-pyridinecarboxaldehyde, salicylaldehyde,  
n-propylamine, 1,4-diaminobutane poly(propyleneimine) tetraamine (DAB-dendr-
(NH2)4-G1) and hexamethylbenzene were purchased from Aldrich; α-Phellandrene 
was purchased from Fluka; 1,4-diaminobutane poly(propyleneimine) octaamine 
(DAB-dendr-(NH2)8-G2) was purchased from SyMO Chem and used without further 
purification. Ruthenium(III) trichloride trihydrate was obtained as a generous donation 
from Johnson Matthey/Anglo Platinum. [(p-cymene)RuCl2]2,1 and 
[(hexamethylbenzene)RuCl2]2,2 were prepared according to literature methods. 
Deuterated solvents were purchased from Aldrich.  
 
Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Unity XR400 
spectrometer (1H: 399.95 MHz, 13C{1H}: 100.58 MHz) or Varian Mercury XR300 
spectrometer (1H: 300.08 MHz, 13C{1H}: 75.46 MHz) or Bruker Ultrashield 400 Plus 
spectrometer (1H: 400.20 MHz, 13C{1H}: 100.60 MHz) at ambient temperature with 
tetramethylsilane as an internal standard.  
 
Infrared (IR) absorptions were measured on a Perkin-Elmer Spectrum One FT-IR 
spectrometer as KBr pellets or in NaCl solution cells in dichloromethane. 
Microanalysis for carbon, hydrogen and nitrogen were carried out using a Fisions EA 
1108 CHNS elemental analyser. For certain metallodendrimers, the analyses are 
outside acceptable limits, and are ascribed to the encapsulation of solvent molecules 
and other inorganic salts by dendritic compounds. Melting points were determined 
using a Kofler hot stage microscope (Riechart Thermover) and are corrected.  
Chapter 6  Experimental 
 
 114 
Mass spectrometry was carried out at the University of Stellenbosch on a Waters API 
Quattro Micro triple quadrupole mass spectrometer. Data were recorded using 
Electrospray Ionisation (ESI) mass spectrometry in the positive-ion mode. Fast Atom 
Bombardment (FAB) and Matrix-Assisted Laser Desorption/Ionization-Time Of Flight 
(MALDI-TOF) mass spectrometry experiments were obtained from the Tokyo Institute 
of Technology. FAB data were obtained on the JEOL JMS-700 (3-nitrobenzyl 
alcohol) and MALDI-TOF analyses were carried out on a Bruker Ultraflex TOF/TOF 
mass spectrometer (Fluka 87884 trans-2-[3-(4-tert-Butylphenyl)-2-methyl-2-
propenylidene]malonitrile, DCTB), equipped with a nitrogen laser and operated at an 
accelerating voltage of 25 kV.  
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6.2. Synthesis and experimental data of pyridyl-imine ligands (L1 - L6) 
6.2.1 Preparation of monomeric ligand L13 
 
 
 
 
 
n-Propylamine (1.69 mL, 22.0 mmol) was added dropwise to an ice-cooled, solution 
of 4-pyridinecarboxaldehyde (2.00 mL, 21.0 mmol) in dry diethyl ether (50.0 mL) with 
stirring. Anhydrous MgSO4 (~ 10 g) was added and the reaction mixture was allowed 
to stir for 24 hours at room temperature. The solution was filtered by gravity and the 
solvent removed under reduced pressure, resulting in a crude residue (L1). The 
residue was dissolved in hexane (20.0 mL) and washed with distilled H2O (3 x 20.0 
mL). The organic layer was dried over anhydrous MgSO4 (~10 g), filtered by gravity 
and the solvent evaporated, yielding a pale-yellow oil (2.20 g, 70.7 %), which was 
dried in vacuo. 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1647 (s, imine, C═N) and 1599 (s, pyridyl, C=N).  
1H NMR (400 MHz, CDCl3): δ (ppm) = 0.94 (t, 3J = 7.4 Hz, 3H, H1), 1.56 (m, 2H, H2), 
3.73 (t, 2H, H3), 7.45 (d, 3J = 6.0 Hz, 2H, H6, H9), 8.09 (s, 1H, H4), 8.66 (d, 3J = 6.0 
Hz, 2H, H7, H8). 13C{1H} NMR (100 MHz, CDCl3): δ (ppm) = 11.8 (CH3); 23.8, 63.6 
(CH2); 121.9, 150.4 (CH pyr); 143.1 (C pyr); 158.8 (CH imine). Elemental Analysis (%): 
Calc. For C9H12N2: C, 72.94; H, 8.16; N, 18.90; Found: C, 71.43; H, 7.19; N, 18.47. 
MS (ESI, m/z): 149 [M+H]+. 
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6.2.2 Preparation of monomeric ligand L24 
 
 
 
 
 
 
 
A solution of n-propylamine (1.82 mL, 22.0 mmol) in dry diethyl ether (20.0 mL) was 
added dropwise to an ice-cooled solution of 2-pyridinecarboxaldehyde (2.00 mL, 21.0 
mmol) in dry diethyl ether (20.0 mL). To the reaction mixture anhydrous MgSO4 (~ 10 
g) was added and stirred at room temperature for 24 hours. The drying agent was 
filtered by gravity and the solvent removed under reduced pressure. The remaining 
yellow residue (L2) was dissolved in dichloromethane (20.0 mL) and washed 
copiously with distilled H2O (3 x 20 mL). The organic layer was collected, dried over 
MgSO4 (~10 g), filtered by gravity and the solvent removed by rotary evaporation, 
yielding a yellow oil (1.08 g, 34.8 %), which was dried in vacuo.  
IR: NaCl cells, CH2Cl2, ν/cm-1: 1650 (s, imine, C═N) and 1589 (s, pyridyl, C=N).  
1H NMR (400 MHz, (CD3)2CO): δ (ppm) = 0.96 (t, 3J = 7.4 Hz, 3H, H1), 1.75 (m, 2H, 
H2), 3.63 (t, 3J = 6.9 Hz, 2H, H3), 7.28 (m, 1H, H7), 7.72 (t, 3J = 7.7 Hz, 1H, H8), 7.98 
(d, 3J
 
= 7.9 Hz, 1H, H6), 8.36 (s, 1H, H4), 8.63 (d, 3J = 4.8 Hz, 1H, H9). 13C{1H} NMR 
(100 MHz, (CD3)2CO): δ (ppm) = 11.7 (CH3); 23.8, 63.2 (CH2); 121.1, 124.4, 136.4, 
149.3 (CH pyr); 154.8 (C pyr); 161.7 (CH imine). Elemental Analysis (%): Calc. For 
C9H12N2: C, 72.93; H, 8.16; N, 18.90; Found: C, 71.76; H, 10.97; N, 18.59. MS (ESI, 
m/z): 119 [M–CH3CH2]+. 
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6.2.3 Preparation of dendritic ligand L35 
 
 
 
 
 
 
 
4-pyridinecarboxaldehyde (1.23 mL, 12.9 mmol) in dry toluene (5.00 mL) was added 
dropwise to an ice-cooled solution of DAB-dendr-(NH2)4 (1.01 g, 3.18 mmol) in dry 
toluene (50.0 mL). Anhydrous MgSO4 (~ 10 g) was added and the resulting slurry 
was allowed to stir at room temperature for 24 hours. The MgSO4 was filtered off and 
the solvent removed by rotary evaporation leaving behind a dark-brown crude 
product. The crude product (L3) was dissolved in dichloromethane (20.0 mL), and 
washed copiously with H2O (6 x 20.0 mL). The organic layer was collected and dried 
over anhydrous MgSO4 (~10 g). The MgSO4 was filtered and the solvent removed 
from the filtrate by rotary evaporation and dried in vacuo, yielding a dark-orange oil 
(1.48 g, 67.9 %). 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1648 (s, imine, C═N) and 1699 (s, pyridyl, C=N).  
1H NMR (400 MHz, CDCl3): δ (ppm) = 1.42 (m, 4H, H1), 1.83 (m, 8H, H4), 2.38 (br t, 
4H, H2), 2.52 (m, 8H, H3), 3.63 (t, 3J = 7.5 Hz, 8H,  H5), 7.52 (d, 3J = 6.0 Hz, 8H, H8, 
H11 ), 8.23 (s, 4H, H6), 8.63 (d, 3J = 6.0 Hz, 8H, H9, H10). 13C{1H} NMR (100 MHz, 
CDCl3): δ (ppm) = 25.3, 28.3, 51.7, 54.1, 59.8 (CH2); 121.8, 150.4 (CH pyr); 143.0  
(C pyr); 159.0 (CH imine).  Elemental Analysis (%): Calc. For C40H52N10.1CH2Cl2:  
C, 68.00; H, 7.47; N, 19.58; Found: C, 68.52; H, 7.50; N, 20.82. MS (ESI, m/z):  
673 [M]+.  
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6.2.4 Preparation of dendritic ligand L45 
 
 
 
 
 
 
 
 
 
To a stirring solution of DAB-dendr-(NH2)8 (1.01 g, 1.30 mmol) in dry toluene  
(50.0 mL), 4-pyridinecarboxaldehyde (1.00 mL, 10.4 mmol) was added dropwise. The 
reaction mixture was cooled in ice and anhydrous MgSO4 (~ 10 g) was added. The 
reaction mixture was allowed to stir for 24 hours at room temperature. The MgSO4 
was filtered by gravity and the solvent removed from the filtrate by rotary evaporation, 
resulting in a yellow residue (L4). The residue was dissolved in dichloromethane 
(20.0 mL) and washed with distilled H2O (8 x 20.0 mL). The organic layer was dried 
over anhydrous MgSO4 (~10 g), filtered by gravity and the solvent from the filtrate 
removed by rotary evaporation, yielding an orange-yellow oil (1.62 g, 84.0 %), which 
was dried in vacuo. 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1648 (s, imine, C═N) and 1599 (s, pyridyl, C=N). 1H 
NMR (300 MHz, CDCl3): δ (ppm) = 1.39 (br m, 4H, H1), 1.47 (br m, 8H, H4), 1.72 (m, 
16H, H7), 1.94-2.44 (overlapping m, 36H, H2, H3, H5, H6), 3.56 (br t, 3J = 6,5 Hz, 16H, 
H8), 7.48 (d, 3J = 6.0 Hz, 16H, H11, H14 ), 8.17 (s, 8H, H9), 8.57 (d, 3J = 6.0 Hz, 16H, 
H12, H13). 13C{1H} NMR (75 MHz, CDCl3): δ (ppm) = 24.8, 25.2, 28.3, 51.7, 52.2, 52.3, 
54.3, 59.8 (CH2); 121.8, 150.4 (CH pyr); 142.9 (C pyr); 159.0 (CH imine). Elemental 
Analysis (%): Calc. For C88H120N22.1/2CH2Cl2: C, 69.54; H, 7.98; N, 20.16; Found: C, 
68.93; H, 8.18; N, 20.69. MS (ESI, m/z): 1485 [M]+. 
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6.2.5 Preparation of dendritic ligand L56 
 
 
 
 
 
 
 
 
A solution of 2-pyridinecarboxaldehyde (1.24 mL, 13.0 mmol) in dry toluene  
(5 mL) was added dropwise to an ice-cooled solution of DAB-dendr-(NH2)4  
(1.02 g, 3.21 mmol) in dry toluene (50.0 mL). Anhydrous MgSO4 (~ 10 g) was added 
to the reaction mixture and the resulting slurry was stirred at room temperature for 24 
hours. The solution was filtered by gravity and the solvent removed by rotary 
evaporation yielding a brown residue (L5). The residue was dissolved in 
dichloromethane (20.0 mL), and washed copiously with H2O (6 x 20.0 mL). The 
organic layer was dried over anhydrous MgSO4 (~10 g) and filtered by gravity, with 
the solvent removed by rotary evaporation and dried in vacuo, yielding a yellow-
brown oil (1.54 g, 73.5 %). 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1649 (s, imine, C═N) and 1588 (s, pyridyl, C=N). 1H 
NMR (300 MHz, (CD3)2CO): δ (ppm) = 1.47 (br s, 4H, H1), 1.87 (m, 8H, H4), 2.46 (m, 
4H, H2), 2.56 (br t, 8H, H3), 3.69 (br t, 8H, H5), 7.42 (br t, 4H, H9), 7.85 (br t, 4H, H10) 
7.96 (d, 3J
 
= 6.9 Hz, 4H, H8), 8.35 (s, 4H, H6), 8.58 (br d, 4H, H11). 13C{1H} NMR (100 
MHz, (CD3)2CO): δ (ppm) = 22.4, 27.6, 51.4, 53.9, 59.0 (CH2); 121.4, 125.3, 137.4, 
149.1 (CH pyr); 154.1 (C pyr); 162.1 (CH imine). Elemental Analysis (%): Calc. For 
C40H52N10.1/2CH2Cl2: C, 68.00; H, 7.47; N, 19.58; Found: C, 69.01; H, 8.60; N, 19.32. 
MS (FAB, m/z): 673 [M]+.
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6.2.6 Preparation of dendritic ligand L67 
 
 
 
 
 
 
 
 
 
A slight excess of 2-pyridinecarboxaldehyde (1.00 mL, 10.5 mmol) in a solution of dry 
toluene (5.00 mL) was added dropwise to a stirring ice-cooled solution of DAB-dendr-
(NH2)8 (1.01 g, 1.30 mmol) in dry toluene (50.0 mL). To the reaction mixture 
anhydrous MgSO4 (~ 10 g) was added and the resulting slurry was stirred at room 
temperature for 24 hours. The solution was filtered by gravity to remove the drying 
agent and the solvent removed from the resulting filtrate by rotary evaporation 
resulting in a yellow residue (L6). The residue was taken up in dichloromethane  
(20.0 mL), and washed copiously with H2O (8 x 20.0 mL). The organic layer was 
dried over anhydrous MgSO4 (~10 g) and filtered by gravity, the solvent removed by 
rotary evaporation and dried in vacuo, yielding an orange-yellow oil (1.34 g, 69.2 %). 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1649 (s, imine, C═N) and 1588 (s, pyridyl, C=N).  
1H NMR (400 MHz, (CD3)2CO): δ (ppm) = 1.40 (br m, 4H, H1), 1.59 (br m, 8H, H4), 
1.84 (br qn, 16H, H7), 2.43-2.53 (overlapping m, 36H, H2, H3, H5, H6), 3.66 (br t, 16H, 
H8), 7.39 (br t, 8H, H12), 7.82 (t, 3J = 7.7 Hz, 8H, H13) 7.95 (d, 3J = 7.9 Hz, 8H, H11), 
8.33 (s, 8H, H9), 8.55 (d, 3J = 4.9 Hz, 8H, H14).13C{1H} NMR (75 MHz, (CD3)2CO): 
δ (ppm) = 25.0, 25.8, 29.0, 52.7, 53.1, 53.3, 55.1, 60.2 (CH2); 122.6, 126.5, 138.5, 
150.3 (CH pyr); 155.3 (C pyr); 163.2 (CH imine). Elemental Analysis (%): Calc. For 
C88H120N22.1/2CH2Cl2: C, 69.54; H, 7.98; N, 20.16; Found: C, 69.51; H, 7.18; N, 21.16. 
MS (FAB, m/z): 1485 [M]+. 
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6.3 Synthesis and experimental data of salicyldimine ligands (L7 - L9)
 
6.3.1 Preparation of monomeric ligand L78 
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n-Propylamine (0.810 mL, 9.85 mmol) was added dropwise to a solution of 
salicyldehyde (1.00 mL, 9.38 mmol) in dry ethanol (20.0 mL). The reaction solution 
was gently heated (~ 40 oC) and stirred for 5 hours. The solvent was removed under 
reduced pressure, resulting in a crude yellow residue (L7). The residue was 
dissolved in dichloromethane (20.0 mL) and washed with distilled H2O (10 x 50.0 
mL). The organic layer was dried over anhydrous MgSO4 (~10 g), filtered by gravity 
and the solvent evaporated, yielding an orange-yellow oil (1.10 g, 71.7 %), which was 
dried in vacuo. 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1635 (s, imine, C═N). 1H NMR (400 MHz, CDCl3):  
δ (ppm) = 1.00 (t, 3J
 
= 7.4 Hz, 3H, H1), 1.74 (m, 2H, H2), 3.56 (t, 3J = 6.8 Hz, 2H, H3), 
6.88 (t, 3J
 
= 7.4 Hz, 1H, H7), 6.97 (d, 3J = 7.9 Hz, 1H, H9), 7.25 (d, 3J = 7.6 Hz, 1H, 
H6), 7.31 (t, 3J = 7.3 Hz, 1H, H8), 8.32 (s, 1H, H4), 13.66 (br s, 1H, OH). 13C{1H} NMR 
(100 MHz, CDCl3): δ (ppm) = 11.5 (CH3); 23.9, 61.0 (CH2); 116.9, 118.1, 130.9, 131.9 
(CH Ar); 118.6, 161.3 (C Ar); 164.4 (CH imine). Elemental Analysis (%): Calc. For 
C10H13NO: C, 73.59; H, 8.03; N, 8.58; Found: C, 73.48; H, 7.90; N, 8.55. MS (ESI, 
m/z): 164 [M+H]+
. 
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6.3.2 Preparation of dendritic ligand L89 
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Salicyldehyde (1.37 mL, 12.9 mmol) was added dropwise to a solution of DAB-dendr-
(NH2)4 (1.01 g, 3.18 mmol) in dry ethanol (20.0 mL). The reaction was allowed to stir 
overnight at 40 oC. The following day the reaction was allowed to cool to room 
temperature and the solvent was then removed by rotary evaporation leaving behind 
a yellow crude oil. The crude oil was dissolved in dichloromethane (10.0 mL), 
followed by the addition of hexane (30.0 mL) and placed in the freezer for 72 hours, 
to promote crystallisation. A yellow solid (L8) precipitated out of solution. This was 
isolated and dried in vacuo, yielding a yellow solid (1.19 g, 51.1 %). 
IR: KBr pellets,
 
ν/cm-1: 1631 (s, imine, C═N). 1H NMR (300 MHz, CDCl3): δ (ppm)  
= 1.40 (m, 4H, H1), 1.80 (m, 8H, H4), 2.39 (m, 4H, H2), 2.50 (t, 3J = 7.2 Hz, 8H, H3), 
3.60 (t, 3J
 
= 6.8 Hz, 8H, H5), 6.83 (t, 3J = 7.5 Hz, 4H, H9), 6.93 (d, 3J = 8.2 Hz, 4H, 
H11), 7.20 (d, 3J = 7.7 Hz, 4H, H8), 7.27 (t, 3J = 7.3 Hz, 4H, H10), 8.31 (s, 4H, H6), 
13.54 (br s, 4H, OH). 13C{1H} NMR (75 MHz, CDCl3): δ (ppm) = 25.1, 28.5, 51.4, 
54.0, 57.3 (CH2); 117.0, 118.4, 131.1, 132.0 (CH Ar); 118.8, 161.3 (C Ar); 164.8  
(C imine). Elemental Analysis (%): Calc. For C44H56N6O4: C, 72.10; H, 7.70; N, 11.47; 
Found: C, 71.66; H, 7.30; N, 10.89. MS (FAB, m/z): 733 [M]+. Melting Point: 58-60 
oC (Lit. M.p.: 66-68 oC)9.
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6.3.3 Preparation of dendritic ligand L99 
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To a stirring solution of DAB-dendr-(NH2)8 (0.504 g, 0.652 mmol) in dry ethanol  
(30.0 mL), salicyldehyde (0.559 mL, 5.25 mmol) was added dropwise. The reaction 
mixture was allowed to stir for 48 hours at 40 oC. The solvent was removed by rotary 
evaporation, resulting in a orange residue (L9). The residue was dissolved in 
dichloromethane (20.0 mL) and washed with distilled H2O (8 x 50.0 mL). The organic 
layer was dried over anhydrous MgSO4 (~10 g), filtered by gravity and the solvent 
removed by rotary evaporation, yielding an orange oil (0.97 g, 92.2 %), which was 
dried in vacuo. 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1635 (s, imine, C═N).  1H NMR (300 MHz, CDCl3):  
δ (ppm) =  1.38 (br m, 4H, H1), 1.54 (br m, 8H, H4), 1.79 (m, 16H, H7), 2.35-2.40 
(overlapping m, 20H, H2, H3, H5,), 2.49 (m, 16H, H6), 3.58 (t, 3J = 6,6 Hz, 16H, H8), 
6.82 (br t, 3J
 
= 7.3 Hz, 8H, H12), 6.92 (br d, 3J = 8.3 Hz, 8H, H14), 7.19 (br d, 3J = 7.7 
Hz, 8H, H11), 7.26 (br t, 3J = 6.7 Hz, 8H, H13), 8.29 (s, 8H, H9), 13.49 (br s, 8H, OH). 
13C{1H} NMR (100 MHz, CDCl3): δ (ppm) = 24.6, 25.2, 28.6, 51.5, 52.2, 52.3, 54.2, 
57.4 (CH2); 117.0, 118.4, 131.1, 132.0 (CH Ar); 118.7, 161.3 (C Ar); 164.8 (CH imine). 
Elemental Analysis (%): Calc. For. C96H128N14O8: C, 71.79; H, 8.03; N, 12.21; 
Found: C, 71.66; H, 8.35; N, 12.05. MS (FAB, m/z): 1607 [M+H]+. Melting Point: 188 
oC (decompose, without melting). 
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6.4 Synthesis and experimental data of ruthenium precursors
 
6.4.1 Synthesis of [Ru(η6-p-PriC6H4Me)Cl2]21 
 
 
 
 
 
 
 
 
The procedure outlined by Bennett and Smith4 was followed closely to synthesize the 
ruthenium dimer. To a Schlenk flask ruthenium(III) trichloride trihydrate (5.45 g, 20.4 
mmol) was dissolved in dry ethanol (100 mL). α-Phellandrene (20.0 mL, 122.2 mmol) 
was added dropwise to this solution and the solution heated under reflux for  
12 hours. The mixture was reduced and cooled on ice. The solution mixture was 
filtered and diethyl ether added to a reduced volume of the filtrate, to precipitate out 
the product.  The precipitate was filtered on a Büchner filter funnel, washed with cold 
diethyl ether (3 x 20.0 mL) and dried under vacuum, yielding a dark red solid. 
1H NMR (300 MHz, CDCl3): δ (ppm) = 1.27 (d, 3J = 6.93 Hz, 12H, CH(CH3)2), 1.64  
(s, 6H, CH3), 2.91 (m, 2H, CH(CH3)2), 5.32 (d, 3J = 6.03 Hz, 4H, Ar p-cye), 5.46 (d,  
3J
 
= 6.03 Hz, 4H, Ar p-cye). Melting Point: 201 - 204 oC (Lit. M.p.: 200 oC).1 
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6.4.2 Synthesis of [Ru(η6-C6Me6)Cl2]22 
Ru Cl
Cl
Ru
Cl
Cl
 
The [Ru(η6-p-PriC6H4Me)Cl2]2 dimer (1.50 g, 2.45 mmol) was stirred with molten 
hexamethylbenzene (ca. 7.00 g) for 3 days at 185 oC. The reaction vessel was 
allowed to cool to room temperature. Diethyl ether was added to extract any 
unreacted hexamethylbenzene. The reaction vessel was placed in an ultrasound 
bath to break up the large particles. The solution was filtered over Celite® and 
washed with excess ether. The red solid was extracted with chloroform and the 
solvent removed under vacuum to yield the product as a red crystalline solid. 
1H NMR (400 MHz, CDCl3): δ (ppm) = 2.04 (s, 36H, CH3). Melting Point: 268-271 oC 
(Lit. M.p.: 270 oC).2 
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6.5 Synthesis and experimental data of neutral 4-pyridyl-imine mononuclear  
(1, 2) and multinuclear complexes (3 - 6) 
6.5.1 Preparation of 15 
 
 
 
 
 
 
 
 
[Ru(η6-p-PriC6H4Me)Cl2]2 (0.223 g, 0.362 mmol) was dissolved in stirring 
dichloromethane (30.0 mL) and L1 (0.107 g, 0.723 mmol) was added dropwise, the 
reaction mixture was stirred for 5 hours. The solvent was reduced to approximately 
3.00 mL, and the product was precipitated with petroleum ether. This resulted in the 
formation of yellow precipitate, which was allowed to settle and the supernatant liquid 
removed. The precipitate was washed with petroleum ether (3 x 10.0 mL) and the 
mother liquor syringed off after each washing. The mustard-yellow solid 1  
(0.15 g, 45.7 %) was dried in vacuo. 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1647 (s, imine, C═N), 1615 (s, pyridyl, C═N). 1H NMR 
(400 MHz, CDCl3): δ (ppm) = 0.97 (t, 3J = 7.4 Hz, 3H, H1), 1.32 (d, 3J = 7.0 Hz, 6H, 
CH(CH3)2), 1.75 (m, 2H, H2),  2.11 (s, 3H, CH3), 3.00 (m, 1H, CH(CH3)2),  3.66 (t,  3J 
= 6.5 Hz, 2H, H3), 5.23 (d, 3J = 5.9 Hz, 2H, Arp-cye), 5.45 (d, 3J = 5.9 Hz, 2H, Arp-cye), 
7.60  (d, 3J
 
= 6.5 Hz, 2H, H6, H9), 8.27 (s, 1H, H4), 9.10 (d,  3J = 6.4 Hz, 2H, H7, H8). 
13C{1H} NMR (100 MHz, CDCl3): δ (ppm) = 11.8 (CH3); 18.2, 22.3 (CH3 p-cye); 23.8, 
63.6 (CH2); 30.7, 82.2, 83.1 (CH p-cye); 97.3, 103.6 (C p-cye); 122.5, 155.3 (CH pyr); 
144.6 (C pyr); 157.3 (CH imine). Elemental Analysis (%): Calc. For C19H26N2RuCl:  
C, 50.22; H, 5.77; N, 6.16; Found: C, 49.96; H, 5.38; N, 5.99. MS (ESI, m/z): 419.1 
[M-Cl]+. Melting Point: 163 oC – 166 oC. 
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6.5.2 Preparation of 25 
 
 
 
 
 
 
 
[Ru(η6-C6Me6)Cl2]2 (0.069 g, 0.100 mmol) was dissolved in a stirring solution of dry 
dichloromethane (30.0 mL) in a Schlenk tube. A solution of ligand L1 
(0.0300 g, 0.200 mmol) in dry dichloromethane (5.00 mL) was added dropwise and 
the reaction mixture was allowed to stir for 2 hours. The solvent was reduced to 
approximately 3.00 mL, and the product (2) was precipitated after the addition of 
petroleum ether. This resulted in the formation of yellow-orange precipitate, which 
was allowed to settle and the supernatant liquid removed. The precipitate was further 
washed with petroleum ether (3 x 10.0 mL) and the mother liquor syringed after each 
washing. The yellow-orange solid (0.05 g, 50.1 %) was crystallized with slow diffusion 
of petroleum ether into dichloromethane and dried in vacuo, to yield orange crystals. 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1646 (s, imine, C═N) and 1614 (s, pyridyl, C=N).  
1H NMR (400 MHz, CDCl3): δ (ppm) = 0.96 (t, 3J = 7.4 Hz, 3H, H1), 1.74  (m, 2H, H2), 
2.03 (s, 18H, CH3), 3.66 (t, 3J = 6.9 Hz, 2H, H3), 7.57 (d, 3J = 6.4 Hz, 2H, H6, H9), 8.26 
(s, 1H, H4), 8.86 (d, 3J = 6.2 Hz, 2H, H7, H8). 13C{1H} NMR (100 MHz, CDCl3): δ (ppm) 
= 11.8 (CH3); 15.4 (CH3 HMB); 23.8, 63.6 (CH2); 91.4 (C HMB); 122.5, 155.1 (CH pyr); 
144.2 (C pyr); 157.5 (CH imine). Elemental Analysis (%): Calc. For C21H30N2RuCl2:  
C, 52.28; H, 6.27; N, 5.81; Found: C, 51.84; H, 5.94, N, 5.47. MS (ESI, m/z): 447  
[M-Cl]+. Melting Point: 139 oC (decompose, without melting). 
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 6.5.3 Preparation of 35 
 
 
 
 
 
 
 
 
 
The dimer [Ru(η6-p-PriC6H4Me)Cl2]2  (0.213 g, 0.346 mmol) and L3 (0.117 g,  
0.173 mmol) were dissolved together in dichloromethane (35.0 mL) and the mixture 
was then stirred at room temperature for 24 hours, with the red solution becoming 
darker over the stirring period. The solvent was reduced to 3.00 mL and the mustard-
yellow product (3) was precipitated by the addition of an excess of petroleum ether. 
The solid (0.26 g, 79.1 %) was washed further with petroleum ether (6 x 10.0 mL) 
and then dried in vacuo. 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1646 (s, imine, C═N), 1615 (s, pyridyl, C=N). 1H NMR  
(300 MHz, CDCl3): δ (ppm) = 1.30 (d, 3J = 6.9 Hz, 24H, CH(CH3)2), 1.83 (br m, 4H, 
H1), 2.09 (s, 12H, CH3), 2.44 - 2.97 (overlapping m, 12H, H2, H3), 2.97 (m, 4H, 
CH(CH3)2), 3.67 (br m, 4H, H5), 5.28 (d, 3J = 5.7 Hz,  8H, Arp-cye), 5.70 (d, 3J = 5.7 Hz,  
8H, Arp-cye), 7.49 (d, 3J = 6.2 Hz, 4H, H8, H11), 8.20 (s, 4H, H6), 9.06 (d, 3J = 5.4 Hz,  
4H, H9, H10). 13C{1H} NMR (75 MHz, CDCl3): δ (ppm) = 18.3, 22.3 (CH3 p-cye); 27.1, 
31.5, 51.2, 53.7, 58.8 (CH2); 30.7, 82.1, 83.3 (CH p-cye); 97.5, 103.3 (C p-cye); 122.5, 
155.3 (CH pyr); 139.8 (C pyr), 158.4 (CH imine). Elemental Analysis (%): Calc. For 
C80H108N10Ru4Cl8.11/2CH2Cl2: C, 48.34; H, 5.52; N, 6.92; Found: C, 48.22; H, 5.15; N, 
6.74. MS (ESI, m/z): 565 [[M+4H+4CH2Cl2+H2O]4+. Melting Point: 165 oC 
(decompose, without melting). 
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6.5.4 Preparation of 45 
 
 
 
 
 
 
 
 
 
 
[Ru(η6-C6Me6)Cl2]2 (0.056 g, 0.081 mmol) was dissolved in a stirring solution of dry 
dichloromethane (30.0 mL) in a Schlenk tube. A solution of ligand L3  
(0.027 g, 0.041 mmol) in dry dichloromethane (5.00 mL) was added dropwise and the 
reaction mixture was allowed to stir for 24 hours. The solvent was reduced to 
approximately 3.00 mL, and the product was precipitated with petroleum ether. This 
resulted in the formation of yellow-orange precipitate (4), which was allowed to settle 
and the supernatant liquid removed. The precipitate was further washed with 
petroleum ether (6 x 10.0 mL) and the mother liquor syringed after each washing. 
The yellow solid (0.05 g, 86.5 %) was dried in vacuo. 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1646 (s, imine, C═N) and 1614 (s, pyridyl, C=N).   
1H NMR (300 MHz, CDCl3): δ (ppm) =  1.44 (br m, 4H, H1), 1.85 (br m, 8H, H4), 1.97 
(s, 72H, CH3), 2.49-2.58 (overlapping m, 12H, H2, H3), 3.67 (m, 8H, H5), 7.51 (d,  
3J
 
= 6.4 Hz, 8H, H8, H11), 8.23 (s, 4H, H6), 8.78 (d, 3J = 6.3 Hz, 8H, H9, H10). 13C{1H} 
NMR (75 MHz, CDCl3): δ (ppm) = 15.4 (CH3 HMB); 24.2, 26.2, 51.0, 53.4, 58.2 (CH2); 
91.4 (C HMB); 122.5, 155.0 (CH pyr); 143.9 (C pyr); 158.9 (CH imine). Elemental 
Analysis (%): Calc. For C88H124N10Ru4Cl8.CH2Cl2: C, 51.03; H, 6.06; N, 6.69; Found: 
C, 51.01; H, 5.85; N, 6.19. MS (ESI, m/z): 635 [M-3Cl]3+. Melting Point: 188 oC 
(decompose, without melting). 
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6.5.5 Preparation of 55 
 
 
 
 
 
 
 
 
 
 
 
 
The dimer [Ru(η6-p-PriC6H4Me)Cl2]2  (0.199 g, 0.307 mmol) and L4 (0.114 g, 0.077 
mmol) were dissolved together in dichloromethane (35.0 mL) and the reaction 
mixture was stirred at room temperature for 24 hours. The red solution turned darker 
in colour. The solvent was reduced to 3.00 mL, and the product precipitated with 
petroleum ether. This resulted in the formation of yellow-brown precipitate (5), which 
was allowed to settle and the supernatant liquid syringed off. The precipitate was 
further washed with petroleum ether (8 x 10.0 mL) and the supernatant syringed off 
after each washing. The mustard-yellow solid (0.30 g, 98.1 %) was dried in vacuo. 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1646 (s, imine, C═N), 1614 (s, pyridyl, C═N). 1H NMR 
(300 MHz, CDCl3): δ (ppm) = 1.32 (d, 48H, 3J = 6.9 Hz, CH(CH3)2), 1.35 – 1.48 
(overlapping m, 12H, H1, H4), 1.78 (m, 16H, H7) 2.09 (s, 24H, CH3), 2.30 – 2.53 
(overlapping m, 36H, H2, H3, H5, H6), 2.97 (br m, 8H, CH(CH3)2), 3.67 (m, 16H, H8), 
5.28 (d, 3J = 6.0 Hz, 16H, Arp-cye), 5.49 (d, 3J = 6.0 Hz, 16H, Arp-cye), 7.49 (d, 16H, 
3J
 
= 6.6 Hz, H11, H14), 8.19 (s, 8H, H9), 9.05 (d, 16H, 3J = 6.5 Hz, H12, H13). 13C{1H} 
NMR (75 MHz, CDCl3): δ (ppm) = 18.2, 22.2 (CH3 p-cye); 26.8, 27.1, 30.8, 38.8, 50.9, 
51.4, 55.2, 58.8 (CH2); 30.6, 82.0, 83.0 (CH p-cye); 97.4, 103.2 (C p-cye); 122.5, 155.3 
(CH pyr); 144.2 (C pyr); 158.3 (CH imine). Elemental Analysis (%): Calc. For 
C168H232N22Ru8Cl16.4CH2Cl2: C, 48.32; H, 5.66; N, 7.21; Found: C, 48.37; H, 6.03;  
N, 6.61. MS (ESI, m/z): 569.0 [M-7Cl+3CH2Cl2+CH3CN]7+. Melting Point: 214 oC 
(decompose without melting). 
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6.5.6 Preparation of 65 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Ru(η6-C6Me6)Cl2]2 (0.168 g, 0.248 mmol) was dissolved in a stirring solution of dry 
dichloromethane (30.0 mL) in a Schlenk tube. A solution of ligand L4  
(0.062 g, 0.041 mmol) in dry dichloromethane (5.00 mL) was added dropwise and the 
reaction mixture was allowed to stir for 48 hours. The solvent was reduced to 
approximately 3.00 mL, and the product was precipitated with petroleum ether. This 
resulted in the formation of yellow-orange precipitate (6), which was allowed to settle 
and the supernatant liquid removed. The precipitate was further washed with 
petroleum ether (6 x 10.0 mL) and the mother liquor syringed after each washing. 
The yellow solid (0.23 g, 91.7 %) was dried in vacuo. 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1646 (s, imine, C═N) and 1613 (s, pyridyl, C=N).  
1H NMR (400 MHz, CDCl3): δ (ppm) = 1.31 (br m, 4H, H1), 1.63 (br m, 8H, H4), 1.87 
(m, 8H, H5), 1.99 (s, 144H, CH3), 2.15-2.38 (overlapping m, 24H, H3, H7), 2.50  
(m, 4H, H2,), 2.60 (m, 16H, H6), 3.69 (m, 16H, H8), 7.54 (d, 3J = 6.0 Hz, 16H, H11, 
H14), 8.23 (s, 8H, H9), 8.78 (d, 3J = 5.6 Hz, 16H,  H12, H13). 13C{1H} NMR (100 MHz, 
CDCl3): δ (ppm) = 15.4 (CH3 HMB); 25.3 – 58.9 (CH2); 91.4 (C HMB); 122.5, 155.0  
(CH pyr); 143.9 (C pyr); 158.9 (C imine). Elemental Analysis (%): Calc. For 
C184H264N22Ru8Cl16.2CH2Cl2: C, 51.60; H, 6.24; N, 7.12; Found: C, 51.69; H, 6.43,  
N, 6.82. MS (ESI, m/z): 631 [M-7Cl+5CH2Cl2+2CH3CN]7+. Melting Point: 194 oC 
(decompose, without melting). 
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6.6 Synthesis and experimental data of cationic 2-pyridyl-imine mononuclear 
(7, 8) and multinuclear complexes (9 - 12) 
6.6.1 Preparation of 7 
N
4
5
6
7
8
9
NRu
Cl
+
PF6-
3
2
1
 
[Ru(η6-p-PriC6H4Me)Cl2]2 (0.230 g, 0.375 mmol) was added to a stirring solution of 
methanol (25.0 mL). The ligand L2 (0.111 g, 0.750 mmol) was dissolved in methanol 
(5.0 mL) and added dropwise to the stirred solution. The solution was allowed to stir 
for 1 h at room temperature. The resulting solution was then filtered by gravity and 
the filtrate reduced to about 5 mL, where NaPF6 (0.063 g, 0.375 mmol) was added 
and the reaction was allowed to stir at 0 oC for 3 h. This resulted in the formation of a 
yellow-orange precipitate (7), which was collected using a Hirsch filter funnel and 
dried under vacuum, to yield a yellow solid (0.16 g, 37.8 %).  
IR: KBr pellets,
 
ν/cm-1: 1623 (s, imine, C═N), 1599 (s, pyridyl, C=N), 844 (s, P-F).  
1H NMR (400 MHz, (CD3)2CO): δ (ppm) = 1.00 (t, 3J = 7.4 Hz, 3H, H1), 1.09 & 1.16 (d, 
3J
 
= 6.9 Hz, 6H, CH(CH3)2), 1.99 & 2.05 (m, 2H, H2), 2.30 (s, 3H, CH3), 2.79 (sep, 1H, 
CH(CH3)2), 4.40 & 4.66 (m, 2H, H3), 5.94 (t, 2H, 3J = 6.3 Hz, Arp-cye), 6.23 (dd, 3J = 6.3 
Hz, 2H, Arp-cye), 7.82 (t, 3J = 5.7 Hz, 1H,  H7), 8.23 (d, 3J = 7.7 Hz, 1H,  H6), 8.29 (t,  
3J
 
= 7.7 Hz, 1H,  H8), 8.79 (s, 1H, H4), 9.57 (d, 3J = 5.6 Hz, 1H,  H9). 13C{1H} NMR 
(100 MHz, (CD3)2CO): δ (ppm) = 10.8 (CH3); 21.3, 22.0, 23.0 (CH3 p-cye); 18.2, 68.9 
(CH2); 31.2, 84.8, 85.3, 85.7, 87.5 (CH p-cye); 103.7, 106.1 (C p-cye), 128.5, 128.9, 
140.0, 156.0 (CH pyr); 155.2 (C pyr); 167.0 (CH imine). Elemental Analysis (%): Calc. 
For C19H26N2RuClPF6: C, 40.47; H, 4.65; N, 4.97; Found: C, 40.40; H, 4.68; N, 4.87. 
MS (ESI, m/z): 419 [M-PF6]+. Melting Point: 186 oC – 187 oC. 
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6.6.2 Preparation of 8 
N
4
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[Ru(η6-C6Me6)Cl2]2 (0.248 g, 0.366 mmol) was added to stirring methanol (25.0 mL), 
resulting in a suspension of the dimer. The ligand L2 (0.108 g, 0.731 mmol) was 
dissolved in methanol (5.0 mL) and added dropwise to the stirring solution. This 
solution was allowed to stir for 1.5 h at room temperature. This was filtered by gravity 
and the filtrate reduced to about 5 mL, followed by the addition of NaPF6 (0.062 g, 
0.366 mmol). The reaction was then stirred at 0 oC for a further 2 h, resulting in the 
formation of a yellow-orange precipitate.  The solid was filtered using a Hirsch filter 
funnel and dried under vacuum, to yield the product (8) as an orange solid (0.22 g, 
50.8 %). 
IR: KBr pellets,
 
ν/cm-1: 1625 (s, imine, C═N), 1600 (s, pyridyl, C=N), 835 (s, P-F).  
1H NMR (300 MHz, (CD3)2CO): δ (ppm) = 0.93 (t, 3J = 7.4 Hz, 3H, H1), 1.82 & 1.98  
(m, 2H, H2), 2.24 (s, 18H, CH3), 4.20 & 4.45 (m, 2H, H3), 7.84 (t, 3J = 5.7 Hz, 1H, H7), 
8.17 (d, 3J
 
= 7.8 Hz, 1H, H6), 8.22 (t, 3J = 7.6 Hz, 1H, H8), 8.70 (s, 1H, H4), 9.07 (d,  
3J
 
= 5.7 Hz, 1H, H9). 13C{1H} NMR (75 MHz, (CD3)2CO): δ (ppm) = 10.8 (CH3); 15.2 
(CH3 HMB); 22.5, 65.7 (CH2); 96.6 (C HMB); 128.3, 128.4, 139.4, 153.6 (CH pyr); 155.2 
(C pyr); 166.6 (CH imine). Elemental Analysis (%): Calc. For 
C21H30N2RuClPF6.1/2CH3OH: C, 42.47; H, 5.31; N, 4.61; Found: C, 42.47; H, 5.35;  
N, 4.58. MS (ESI, m/z): 447 [M-PF6]+. Melting Point: 239 oC – 241 oC. 
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6.6.3 Preparation of 9 
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[Ru(η6-p-PriC6H4Me)Cl2]2 (0.191 g, 0.312 mmol) was added to a stirring solution of 
ethanol (25.0 mL). The ligand L5 (0.103 g, 0.152 mmol) was dissolved in ethanol (5.0 
mL) and added dropwise to the stirring solution. The solution was allowed to stir for 
12 h at room temperature. The resulting solution was then filtered by gravity and the 
filtrate transferred into a round bottom flask. The filtrate was reduced to about 5 mL 
and was transferred to a round bottom flask, where NaPF6 (0.061 g, 0.312 mmol) 
was added and the reaction was allowed to stir at 0 oC for 15 min. This resulted in the 
formation of a dark yellow precipitate (9), which was filtered using a Hirsch filter 
funnel and dried under vacuum, to yield a yellow-brown solid (0.17 g, 48.4 %). 
IR: KBr pellets,
 
ν/cm-1: 1625 (s, imine, C═N), 1599 (s, pyridyl, C=N), 851 (s, P-F).  
1H NMR (400 MHz, (CD3)2CO): δ (ppm) = 1.07 & 1.12 (br d, 24H, CH(CH3)2), 1.29 (br 
m, 4H, H1), 1.81 (br m, 8H, H4), 2.30 (s, 12H, CH3), 2.46 (br m, 4H, H2), 2.76 (br s, 
4H, CH(CH3)2), 2.95 (br m, 8H, H3), 4.59 & 4.73 (br m, 8H, H5), 5.97 (br d, 8H, Arp-
cye), 6.25 (br d, 8H, Arp-cye), 7.81 (br t, 4H, H9), 8.24 (br m, 8H, H8, H10), 8.98 (br s, 4H, 
H6), 9.57 (br d, 4H, H11). 13C{1H} NMR (100 MHz, (CD3)2CO): δ (ppm) = 18.5, 21.4, 
22.1 (CH3 p-cye); 24.2, 26.1, 51.3, 53.5, 64.9 (CH2); 31.2, 84.8, 85.4, 85.8, 87.6 (CH p-
cye); 104.1, 106.1 (C p-cye); 128.7, 129.4, 140.1, 156.1 (CH pyr); 155.1 (C pyr), 166.3 
(CH imine). Elemental Analysis (%): Calc. For C80H108N10Ru4Cl4P4F24: C, 41.14; H, 
4.66; N, 6.00; Found: C, 41.21; H, 4.70; N, 5.71. MS (MALDI-TOF, m/z): 2192 [M-
PF6]+. Melting Point: 169 oC – 172 oC. 
 
 
Chapter 6  Experimental 
 
 135 
6.6.4 Preparation of 10 
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[Ru(η6-C6Me6)Cl2]2 (0.211 g, 0.311 mmol) was added to a stirring solution of ethanol 
(25.0 mL). The ligand L5 (0.102 g, 0.152 mmol) was dissolved in ethanol (5.0 mL) 
and added dropwise to the stirring solution. The solution was allowed to stir for 12 h 
at room temperature. The resulting solution was then filtered by gravity and the 
filtrate transferred into a round bottom flask. The filtrate was reduced to about 5 mL 
and was transferred to a round bottom flask, where NaPF6 (0.053 g, 0.311 mmol) 
was added and the reaction was allowed to stir at 0 oC for 3 h. The flask was left in 
the freezer for 12 h. This resulted in the formation of a red-brown precipitate (10), 
which was filtered using a Hirsch filter funnel and first washed with ethanol and then 
further with diethyl ether. The product was dried under vacuum, to yield a red-brown 
solid (0.24 g, 65.9 %). 
IR: KBr pellets,
 
ν/cm-1: 1624 (s, imine, C═N), 1598 (s, pyridyl, C=N), 839 (s, P-F).  
1H NMR (300 MHz, (CD3)2CO): δ (ppm) = 1.28 (br m, 4H, H1), 1.50 (br m, 8H, H4), 
2.21 (br s, 72H, CH3), 2.54 (br m, 4H, H2), 2.89 (br m, 8H, H3), 4.38 (br m, 8H, H5), 
7.84 (br m, 4H, H9), 8.19 (br m, 8H, H8, H10), 8.76 (br s, 4H, H6), 9.08 (br m, 4H, H11). 
13C{1H} NMR (75 MHz, (CD3)2CO): δ (ppm) = 15.4 (CH3 HMB); 24.9, 26.5, 51.0, 53.6, 
62.1 (CH2); 96.6 (C HMB); 128.4, 128.7, 139.5, 153.6 (CH pyr); 155.1 (C pyr); 167.3  
(CH imine). Elemental Analysis (%): Calc. For C88H124N10Ru4Cl4P4F24: C, 43.18; H, 
5.11; N, 5.72; Found: C, 42.92; H, 4.89; N, 5.44. MS (MALDI-TOF, m/z): 2304  
[M-PF6]+. Melting Point: 232 oC – 236 oC. 
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6.6.5 Preparation of 11 
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[Ru(η6-p-PriC6H4Me)Cl2]2 (0.169 g, 0.276 mmol) was added to a stirring solution of 
ethanol (25.0 mL). The ligand L6 (0.101 g, 0.068 mmol) was dissolved in ethanol (5.0 
mL) and added dropwise to the stirring solution. The solution was allowed to stir for 
12 h at room temperature. The resulting solution was then filtered by gravity and the 
filtrate transferred into a round bottom flask. The filtrate was reduced to about 5 mL 
and was transferred to a round bottom flask, where NaPF6 (0.048 g, 0.276 mmol) 
was added and the reaction was allowed to stir at 0 oC for 2 h. This resulted in the 
formation of a dark yellow precipitate (11), which was filtered using a Hirsch filter 
funnel and washed with ethanol. The product was dried under vacuum, to yield a 
yellow-brown solid (0.13 g, 39.8 %).  
IR: KBr pellets,
 
ν/cm-1: 1623 (s, imine, C═N), 1598 (s, pyridyl, C=N), 847 (s, P-F).  
1H NMR (400 MHz, (CD3)2CO): δ (ppm) = 1.06 & 1.11 (br d, 96H, CH(CH3)2), 1.32  
(br m, 4H, H1), 1.61 – 3.36 (overlapping m, 60H, H2, H3, H4, H5, H6, H7), 2.30 (s, 24H, 
CH3), 2.77 (br m, 8H, CH(CH3)2), 4.75 (br m, 16H, H8), 5.97 (br m, 16H, Arp-cye), 6.29 
(br m, 16H, Arp-cye), 7.80 (br m, 8H, H12), 8.28 (br m, 16H, H11, H13), 9.13 (br s, 8H, 
H9), 9.58 (br m, 8H, H14). 13C{1H} NMR (100 MHz, (CD3)2CO): δ (ppm) = 18.7, 21.6, 
22.3 (CH3 p-cye); 25.5-27.2, 50.5-52.0, 64.9 (CH2); 31.3, 84.8, 85.6, 85.8, 87.7 (CH p-
cye); 104.3, 106.0 (C p-cye); 128.7, 129.6, 140.1, 156.1 (CH pyr); 155.1 (C p-cye); 168.9 
(CH imine). Elemental Analysis (%): Calc. For C168H232N22Ru8Cl8P8F48: C, 41.94; H, 
4.86; N, 6.40; Found: C, 41.82; H, 5.02; N, 6.19. MS (MALDI-TOF, m/z): 4811 [M]+. 
Melting Point: 175 oC – 179 oC. 
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6.6.6 Preparation of 12 
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[Ru(η6-C6Me6)Cl2]2 (0.200 g, 0.296 mmol) was added to a stirring solution of ethanol 
(25.0 mL). The ligand L6 (0.109 g, 0.073 mmol) was dissolved in ethanol (5.0 mL) 
and added dropwise to the stirring solution. The solution was allowed to stir for 12 h 
at room temperature. The resulting solution was then filtered by gravity and the 
filtrate transferred into a round bottom flask. The filtrate was reduced to about 5 mL 
and was transferred to a round bottom flask, where NaPF6 (0.055 g, 0.296 mmol) 
was added and the reaction was allowed to stir at 0 oC for 2 h. This resulted in the 
formation of a dark red precipitate (12), which was filtered using a Hirsch filter funnel 
and dried under vacuum, to yield a red-brown solid (0.18 g, 48.4 %).  
IR: KBr pellets,
 
ν/cm-1: 1621 (s, imine, C═N), 1597 (s, pyridyl, C=N), 843 (s, P-F).  
1H NMR (300 MHz, (CD3)2CO): δ (ppm) = 1.48 – 3.24 (overlapping m, 64H, H1, H2, 
H3, H4, H5, H6, H7), 2.20 (s, 144H, CH3), 4.39 (br m, 16H, H8), 7.83 (br m, 8H, H12), 
8.18 (br m, 16H, H11, H13), 8.70 (br s, 8H, H9), 9.07 (br m, 8H, H14). 13C{1H} NMR (75 
MHz, (CD3)2CO): δ (ppm) = 15.4 (CH3 HMB); 24.0-24.8, 50.0-51.0, 51.1, 68.2 (CH2); 
96.6 (C HMB); 128.4, 128.5, 139.4, 153.6 (CH pyr); 155.1 (C pyr); 167.0 (CH imine). 
Elemental Analysis (%): Calc. For C184H264N22Ru8Cl8P8F48: C, 43.88; H, 5.28;  
N, 6.12; Found: 43.57; H, 5.38; N, 6.22. MS (MALDI-TOF, m/z): 4891 [M-PF6]+. 
Melting Point: 210 oC – 212 oC. 
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6.7 Synthesis and experimental data of neutral salicylaldimine mononuclear 
(13, 14) and multinuclear complexes (15 - 18) 
6.7.1 Preparation of 13 
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To a stirring solution of L7 (0.105 g, 0.640 mmol), in dry ethanol, triethylamine (0.094 
mL, 0.672 mmol) was added dropwise. The yellow suspension was allowed to stir at 
room temperature for 30 minutes. [Ru(η6-p-PriC6H4Me)Cl2]2 (0.196 g, 0.320 mmol) 
was dissolved in dry ethanol (10.0 mL) and added drop wise to the reaction mixture. 
The reaction mixture was allowed to stir for 6 hours at room temperature. The 
reaction mixture was filtered by gravity and the solvent from the filtrate removed 
under reduced pressure, this resulted in an orange solid (13). The orange solid was 
dissolved in a minimum amount of toluene and placed in the freezer for 2 days. This 
resulted in the precipitation of a red-brown solid (0.12 g, 43.3 %) which was filtered 
and dried in vacuo. 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1624 (s, imine, C═N). 1H NMR (300 MHz, CDCl3): 
δ (ppm) = 1.01 (t, 3J
 
= 7.4 Hz, 3H, H1), 1.12 & 1.22 (d, 3J = 6.9 Hz, 6H, CH(CH3)2), 
1.96 & 2.07 (m, 2H, H2),  1.88 (s, 3H, CH3), 2.76 (m, 1H, CH(CH3)2), 3.97 & 4.19 (m, 
2H, H3), 5.03 (d, 3J = 5.6 Hz, 2H, Arp-cye), 5.39 (m, 2H, Arp-cye), 6.40 (t, 3J = 6.9 Hz, 
1H, H7), 6.91 (m, 2H, H6, H9), 7.14 (t,  3J = 6.9 Hz, 1H, H8), 7.67 (s, 1H, H4). 13C{1H} 
NMR (75 MHz, CDCl3): δ (ppm) = 11.5 (CH3); 18.5, 21.6, 22.7 (CH3 p-cye); 24.3, 71.1 
(CH2); 30.5, 80.2, 81.9, 83.1, 85.8 (CH p-cye); 97.3, 101.5 (C p-cye); 114.0, 122.3, 
134.3, 134.5 (CH Ar); 119.3, 165.0 (C Ar); 163.5 (CH imine). Elemental Analysis (%): 
Calc. For C20H26NRuClO: C, 55.48; H, 6.05; N, 3.24; Found: C, 55.40; H, 6.28,  
N, 3.03. MS (ESI, m/z): 430 [C20H23NRuClO]+. Melting Point: 150 oC – 152 oC. 
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6.7.2 Preparation of 14 
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To a stirring solution of L7 (0.109 g, 0.669 mmol), in dry ethanol, triethylamine (0.098 
mL, 0.703 mmol) was added dropwise. The yellow suspension was allowed to stir at 
room temperature for 30 minutes. [Ru(η6-C6Me6)Cl2]2 (0.226 g, 0.335 mmol) was 
added to the reaction mixture. The reaction mixture was allowed to stir for 6 hours at 
room temperature. The reaction mixture was filtered by gravity and the solvent from 
the filtrate removed under reduced pressure, this resulted in a red solid. The red solid 
was dissolved in a minimum amount of tetrahydrofuran and filtered by gravity. The 
solvent was removed from the filtrate and the resulting residue dissolved in a 
minimum amount of toluene and placed in the freezer for 2 days. This resulted in the 
precipitation of a red-orange solid 14 (0.23 g, 74.4 %) which was filtered and dried in 
vacuo.  
IR: NaCl cells, CH2Cl2, ν/cm-1: 1624 (s, imine, C═N). 1H NMR (300 MHz, CDCl3):  
δ (ppm) = 0.93 (t, 3J
 
= 7.4 Hz, 3H,  H1), 1.70 (m, 1H, H2), 2.01 (m, 1H, H2), 1.96  
(s, 18H, CH3), 3.96 (m, 1H, H3), 3.73 (m, 1H, H3), 6.38 (t, 3J = 7.0 Hz, 1H, H7), 6.92 
(m, 2H, H6, H9), 7.09 (t, 3J = 6.9 Hz, 1H, H8), 7.70 (s, 1H, H4). 13C{1H} NMR (100 
MHz, CDCl3): δ (ppm) = 11.4 (CH3); 15.6 (CH3 HMB); 24.1, 66.4 (CH2); 91.2 (C HMB); 
113.9, 124.0, 133.5, 133.6 (CH Ar); 121.5, 166.3 (C Ar); 161.8 (CH imine). Elemental 
Analysis (%): Calc. For C23H30NRuClO: C, 57.32; H, 6.56; N, 3.04; Found: C, 57.19; 
H, 6.59; N, 2.94. MS (ESI, m/z): 426 [M-Cl]+. Melting Point: 205 oC – 208 oC. 
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6.7.3 Preparation of 15 
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To a stirring solution of L8 (0.205 g, 0.279 mmol) in dry ethanol, triethylamine (0.156 
mL, 1.12 mmol) was added dropwise. The yellow suspension was allowed to stir at 
room temperature for 30 minutes. [Ru(η6-p-PriC6H4Me)Cl2]2 (0.342 g, 0.558 mmol) 
was dissolved in dry ethanol (10.0 mL) and added dropwise to the reaction mixture. 
The reaction mixture was allowed to stir for 15 hours at room temperature. The 
reaction mixture was filtered by gravity and the solvent from the filtrate removed 
under reduced pressure, this resulted in an orange solid (15). The orange solid was 
dissolved in a minimum amount of dichloromethane and placed in the freezer for  
2 days. This resulted in the precipitation of a orange-brown solid (0.12 g, 88.3 %) 
which was filtered and dried in vacuo. 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1621 (s, imine, C═N). 1H NMR (400 MHz, CDCl3):  
δ (ppm) = 1.06 & 1.16 (br m, 24H, CH(CH3)2), 1.94 – 2.12 (overlapping m, 12H, H1, 
H4), 2.22 (s, 12H, CH3), 2.40 (m, 4H, H2), 2.64 (br m, 8H, H3), 3.19 (br m, 4H, 
CH(CH3)2), 4.06 & 4.45 (br m, 4H, H5), 5.23 (br d, 8H, Arp-cye), 5.41 (br d, 8H, Arp-cye), 
6.38 (br t, 4H, H9), 6.87 (br m, 4H, H8), 7.12 (br m, 8H, H10, H11), 7.96 (br m, 4H, H6). 
13C{1H} NMR (100 MHz, CDCl3): δ (ppm) = 18.9, 21.7, 22.8 (CH3 p-cye); 21.1, 25.4, 
51.4, 52.5, 67.2 (CH2); 30.6, 46.0, 81.0, 81.5, 83.1, 87.8 (CH p-cye); 99.1, 100.2  
(C p-cye); 114.1, 121.9, 134.8, 135.5 (CH Ar); 118.9, 165.0 (C Ar), 164.8 (CH imine). 
Elemental Analysis (%): Calc. For C84H108N6Ru4Cl4O4.41/2CH2Cl2: C, 48.45; H, 5.37; 
N, 3.83; Found: C, 48.15; H, 6.48; N, 3.99. MS (FAB, m/z): 1777 [M-Cl]+. Melting 
Point: 161 oC – 164 oC. 
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To a stirring solution of L8 (0.203 g, 0.278 mmol), in dry ethanol, triethylamine (0.155 
mL, 1.11 mmol) was added dropwise. The yellow suspension was allowed to stir at 
room temperature for 30 minutes. [Ru(η6-C6Me6)Cl2]2 (0.376 g, 0.555 mmol) was 
added to the reaction mixture. The reaction mixture was allowed to stir for 15 hours 
at room temperature. The reaction mixture was filtered by gravity and the solvent 
from the filtrate removed under reduced pressure, this resulted in a dark orange 
solid. The dark orange solid was dissolved in a minimum amount of tetrahydrofuran 
and filtered by gravity. The solvent was removed from the filtrate and the resulting 
residue dissolved in a minimum amount of dichloromethane. Diethyl ether was added 
to the dichloromethane solution, resulting in the precipitation of a solid. The 
precipitate was isolated by filtration and dried under reduced vacuum, to yield a dark 
orange solid 16 (0.46 g, 86.5 %). 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1618 (s, imine, C═N). 1H NMR (400 MHz, CDCl3):  
δ (ppm) = 1.28 (br m, 4H, H1), 1.71 (overlapping br s, 80H, H4, CH3), 2.23 (br m, 4H, 
H2), 2.93 (br m, 8H, H3), 4.03 (br m, 8H, H5), 6.44 (br m, 4H, H9), 6.89 (br m, 4H, H8), 
7.11 (br s, 8H, H10, H11), 8.06 (br m, 4H, H6). 13C{1H} NMR (100 MHz, CDCl3): δ (ppm) 
= 15.7 (CH3 HMB); 21.7, 25.5, 50.2, 52.4, 62.7 (CH2); 91.4 (C HMB); 114.4, 123.7, 
134.0, 134.7 (CH Ar); 121.5, 166.1 (C Ar); 164.8 (CH imine). Elemental Analysis (%): 
Calc. For C92H124N6Ru4O4Cl4.31/2CH2Cl2: C, 51.64; H, 5.94; N, 3.78; Found: C, 51.41; 
H, 6.36; N, 4.07. MS (FAB, m/z): 1888 [M-Cl]+. Melting Point: 186 oC – 188 oC. 
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To a stirring solution of L9 (0.136 g, 0.085 mmol) in dry tetrahydrofuran, triethylamine 
(0.100 mL, 0.715 mmol) was added dropwise. The yellow suspension was allowed to 
stir at room temperature for 30 minutes. [Ru(η6-p-PriC6H4Me)Cl2]2 (0.208 g, 0.340 
mmol) was dissolved in dry tetrahydrofuran (10.0 mL) and added dropwise to the 
reaction mixture. The reaction mixture was allowed to stir overnight at room 
temperature. The solvent was removed from the reaction mixture, resulting in a 
orange-red residue. The residue was dissolved in a minimal volume of 
dichloromethane. Diethyl ether was added to the dichloromethane solution, resulting 
in the precipitation of a red-orange solid (17). The solid (0.19 g, 60.3 %) was isolated 
by filtration and dried under reduced vacuum.  
IR: NaCl cells, CH2Cl2, ν/cm-1: 1621 (s, imine, C═N). 1H NMR (400 MHz, CDCl3):  
δ (ppm) = 1.04 & 1.15 (br m, 48H, CH(CH3)2), 1.84 – 2.76 (overlapping m, 64H, H1, 
H2, H3, H4, H5, H6, H7), 2.24 (s, 24H, CH3), 3.26 (br m, 8H, CH(CH3)2), 4.20 & 4.48 (br 
m, 16H, H8), 5.26 (br d, 16H, Arp-cye), 5.45 (br d, 16H, Arp-cye), 6.39 (br m, 8H, H12), 
6.81 (br m, 8H, H11), 7.11 (br m, 8H, H14), 7.18 (br m, 8H, H13), 8.10 (br m, 8H, H9). 
13C{1H} NMR (100 MHz, CDCl3): δ (ppm) = 19.0, 21.7, 22.9 (CH3 p-cye); 22.3, 25.2, 
30.8, 49.9, 51.1, 51.5, 53.2, 67.4 (CH2); 30.5, 46.0, 80.6, 81.1, 83.4, 87.9 (CH p-cye); 
98.9, 99.8 (C
 p-cye); 114.2, 121.8, 134.8, 135.7 (CH Ar); 119.1, 165.1 (C Ar); 164.5  
(CH imine). Elemental Analysis (%): Calc. For C176H232N14Ru8Cl8O8.1/2CH2Cl2:  
C, 55.69; H, 6.17; N, 5.15; Found: C, 55.59; H, 6.34; N, 4.89. MS (MALDI-TOF, m/z): 
3765 [M-Cl]+. Melting Point: 172 oC (decompose without melting). 
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To a stirring solution of L9 (0.121 g, 0.075 mmol) in dry tetrahydrofuran, triethylamine 
(0.084 mL, 0.603 mmol) was added dropwise. The yellow suspension was allowed to 
stir at room temperature for 30 minutes. [Ru(η6-C6Me6)Cl2]2 (0.204 g, 0.302 mmol) 
was dissolved in dry tetrahydrofuran (10.0 mL) and added drop wise to the reaction 
mixture. The reaction mixture was allowed to stir overnight at room temperature. The 
solvent was removed from the reaction mixture, resulting in an orange-red residue. 
The residue was dissolved in a minimal volume of dichloromethane. Diethyl ether 
was added to the solution, resulting in the precipitation of a solid (18). The precipitate 
was isolated by filtration and dried under reduced vacuum, to yield a mustard yellow 
solid (0.20 g, 65. 5 %). 
IR: NaCl cells, CH2Cl2, ν/cm-1: 1618 (s, imine, C═N). 1H NMR (400 MHz, CDCl3):  
δ (ppm) = 1.60 – 3.00 (overlapping m, 64H, H1, H2, H3, H4, H5, H6, H7), 1.94 (s, 144H, 
CH3), 4.00 (br m, 8H, H8), 4.10 (br m, 8H, H8), 6.43 (br m, 8H, H12), 6.89 (br m, 8H, 
H11), 7.12 (overlapping m, 16H, H13, H14), 8.12 (br m, 8H, H9). 13C{1H} NMR (100 
MHz, CDCl3): δ (ppm) = 15.8 (CH3 HMB); 21.2, 22.5, 25.6, 38.0, 50.6, 53.2, 56.3, 62.5 
(CH2); 91.3 (C HMB); 114.2, 121.7, 134.0, 134.7 (CH Ar); 121.7, 166.2 (C Ar); 164.7 
(CH imine). Elemental Analysis (%): Calc. For C192H264N14Ru8Cl8O81/2.CH2Cl2:  
C, 57.36; H, 6.63; N, 4.86; Found: C, 57.19; H, 7.03; N, 4.16. MS (ESI, m/z): 3955 
[M-Cl]+. Melting Point: 177 oC (decompose without melting). 
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6.8 X-ray crystallography 
 
The crystal structures were solved by direct methods using the program SHELXS-
97.10 Refinement and all further calculations were carried out using SHELXL-97.10 In 
all cases, the H-atoms were included in calculated positions and treated as riding 
atoms using the SHELXL default parameters. In all cases, the non-H atoms were 
refined anisotropically, using weighted full-matrix least-square on F2. Crystallographic 
details of complexes were drawn with ORTEP11 and/or MERCURY.12 
 
6.9 Cell culture and inhibition of cell growth 
 
The human A2780 and A2780cisR human ovarian cancer cell lines were obtained 
from the European Collection of Cell Cultures (Salisbury, UK). Cells were grown 
routinely in RPMI-1640 medium with 10 % foetal calf serum (FCS) and antibiotics 
at 37 °C and 5 % CO 2. Cytotoxicity was determined using the MTT assay  
(MTT = 3(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide). Cells 
were seeded in 96-well plates as monolayers with 100 µL of cell solution 
(approximately 20,000 cells) per well and pre-incubated for 24 hours in medium 
supplemented with 10 % FCS. Compounds were prepared as DMSO solution then 
dissolved in the culture medium and serially diluted to the appropriate 
concentration, to give a final DMSO concentration of 1 %. 100 µL of drug solution 
was added to each well and the plates were incubated for another 72 hours. 
Subsequently, MTT (5 mg/mL solution) was added to the cells and the plates were 
incubated for a further 2 hours. The culture medium was aspirated, and the purple 
formazan crystals formed by the mitochondrial dehydrogenase activity of vital cells 
were dissolved in DMSO. The optical density, directly proportional to the number 
of surviving cells, was quantified at 540 nm using a multiwell plate reader and the 
fraction of surviving cells was calculated from the absorbance of untreated control 
cells. Evaluation is based on means from three independent experiments, each 
comprising three microcultures per concentration level. 
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6.10 DNA binding study 
 
Samples were prepared by mixing a solution of 75 ng/µL pBR322 plasmid DNA with 
the appropriate complex at the appropriate concentration to give the required r value 
(0.5, 0.25 and 0.125, r being the ratio of the metal center to DNA base pairs). The 
samples were incubated for 24 hours at 37 °C. The m obility of the plasmid DNA was 
analyzed by gel electrophoresis on 0.8% agarose gels, at a constant voltage of 100 V 
for 1 hour in Tris-acetate-EDTA buffer. The gel was stained for 30 min in 0.5 µg/mL 
(w/v) ethidium bromide and the bands were then analyzed with an UVP gel scanner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6  Experimental 
 
 146 
6.11 References 
 
1) M. A.  Bennett and A. K. Smith, J. Chem. Soc. Dalton Trans., 1974, 2, 233. 
2) M. A. Bennett, T. W. Matheson, G. B. Robertson, A. K. Smith and  
P. A. Tucker, Inorg. Chem., 1980, 19, 1014. 
3) P. Di Bernardo, P. L. Zanonato, S. Tamburini and P. A. Vigato, Inorg. Chim. 
Acta, 2007, 360, 1083.  
4) J. Cloete and S. F. Mapolie, J. Mol. Catal. A: Chem., 2006, 243, 221. 
5) P. Govender, N. C. Antonels, J. Mattsson, A. K. Renfrew, P. J. Dyson,  
J. R. Moss, B. Therrien and G. S. Smith, J. Organomet. Chem., 2009, 694, 
3470.   
6) G. Smith, R. Chen and S. Mapolie, J. Organomet. Chem., 2003, 673, 111. 
7) G. S. Smith and S. F. Mapolie, J. Mol. Catal. A: Chem., 2004, 213, 187. 
8) M. A. Torzilli, S. Colquhoun, D. Doucet and R. H. Beer, Polyhedron, 2002, 21, 
697. 
9) R. Malgas, S. F. Mapolie, S. O. Ojwach, G. S. Smith and J. Darkwa, Cat. 
Comm., 2008, 9, 1612. 
10) G. M. Sheldrick, Acta Cryst., 2008, A64, 112. 
11) L. J. Farrugia, J. Appl. Cryst., 1997, 30, 565. 
12) I. J. Bruno, J. C. Cole, P. R. Edgington, M. Kessler, C. F. Macrae, P. McCabe, 
J. Pearson and R. Taylor, Acta Cryst., 2002, B58, 389. 
 
 
